Malaria control dynamics in rural Tanzania : evaluation of implementation of artemisinin based anti-malarial combination therapy by Khatib, Rashid Ali
  
 
Malaria control dynamics in rural Tanzania: Evaluation 
of implementation of Artemisinin based Anti-malarial 
Combination Therapy 
 
 
 
 
 
INAUGURAL- DISSERTATION 
 
 
 
zur 
 
Erlangung der Würde eines Doktors der Philosophie 
 
 
vorgelegt der 
 
Philosophisch-Naturwissenschaftlichen Fakultät der 
Universität Basel 
 
 
von 
 
Rashid Ali Khatib 
 
aus  Ole, Pemba, Tanzania 
 
 
 
 
 
 
 
 
 
 
Basel, July 2010 
  
Genehmigt von der Philosophisch-Naturwissenchaftlichen Fakultät auf Antrag 
von Prof. Dr. M. Tanner, Prof. Dr. D. Schellenberg.
 
 
Basel, den 10. November, 2009 
 
 
 
    Prof. Dr. Eberhard. Parlow 
    Dekan 
 
 
 
 
 
 
  - i - 
Table of Contents 
 
MALARIA CONTROL DYNAMICS IN RURAL TANZANIA: EVALUATION OF 
IMPLEMENTATION OF ARTEMISININ BASED ANTI-MALARIAL 
COMBINATION THERAPY ..................................................................................1 
TABLE OF CONTENTS ........................................................................................I 
ACKNOWLEDGEMENTS .................................................................................. IV 
SUMMARY ......................................................................................................... IX 
ZUSAMMENFASSUNG.................................................................................... XIII 
MUHTASARI ...................................................................................................XVII 
PART I: BACKGROUND......................................................................................1 
CHAPTER 1: INTRODUCTION............................................................................2 
MALARIA TRANSMISSION .......................................................................................2 
MALARIA BURDEN IN AFRICA .................................................................................6 
GLOBAL PUBLIC HEALTH INITIATIVES IN THE FIGHT AGAINST MALARIA.......................11 
KEY MALARIA CONTROL INTERVENTIONS...............................................................12 
Prompt diagnosis and early treatment with effective medicines...................12 
Vector Control measures .............................................................................15 
Intermittent Treatment of malaria in pregnancy ...........................................18 
Intermittent Treatment of malaria in infants..................................................19 
Malaria control in Tanzania..........................................................................19 
ARTEMISININ-BASED ANTI-MALARIAL COMBINATION THERAPY: POTENTIAL AND 
CHALLENGES .....................................................................................................23 
Implementation and evaluation of ACT in rural Tanzania ............................26 
PART II: OBJECTIVES AND METHODS...........................................................33 
CHAPTER 2: GOAL AND METHODOLOGY.....................................................34 
GOAL OF THE STUDY ..........................................................................................34 
Objectives of the study ................................................................................34 
STUDY AREA......................................................................................................34 
MALARIA ENDEMNICITY .......................................................................................38 
INTERVENTIONS OTHER THAN IMPACT THAT WOULD HAVE AFFECTED MALARIA 
SITUATION IN THE STUDY AREA ............................................................................38 
Tanzania Essential Health Interventions Project (TEHIP)............................38 
ACCESS......................................................................................................39 
Integrated Management of Childhood Illnesses (IMCI)................................40 
Kilombero Insecticide Treated Nets program (KINET).................................40 
METHODOLOGY .................................................................................................41 
Household surveys ......................................................................................41 
Adherence study..........................................................................................42 
PART III:  ARTICLES .........................................................................................45 
  - ii - 
CHAPTER 3: ADHERENCE TO ANTIMALARIAL COMBINATION THERAPY 
WITH SULFADOXINE/ PYRIMETHAMINE AND ARTESUNATE IN RURAL 
TANZANIA..........................................................................................................46 
ABSTRACT .....................................................................................................47 
INTRODUCTION.............................................................................................47 
MATERIALS AND METHODS.........................................................................49 
RESULTS........................................................................................................54 
DISCUSSION..................................................................................................61 
CHAPTER 4: MARKETS, VOUCHER SUBSIDIES AND FREE NETS COMBINE 
TO ACHIEVE HIGH BED NET COVERAGE IN RURAL TANZANIA.................71 
ABSTRACT.........................................................................................................72 
BACKGROUND ...................................................................................................73 
METHODS .........................................................................................................75 
Study area and population...........................................................................75 
Study design and data collection .................................................................77 
Data management and analysis ..................................................................78 
RESULTS...........................................................................................................79 
DISCUSSION AND CONCLUSIONS..........................................................................86 
CHAPTER 5: ARTEMISININE-BASED COMBINATION DEPLOYMENT AND 
HIGH BED NET COVERAGE BOTH CONTRIBUTE TO DECLINE OF MALARIA 
TRANSMISSION IN RURAL COMMUNITIES OF TANZANIA...........................94 
ABSTRACT.........................................................................................................95 
BACKGROUND ...................................................................................................96 
APPROACHES & METHODS .................................................................................97 
Study area and population...........................................................................97 
Study design and procedures ......................................................................98 
ETHICAL APPROVAL............................................................................................99 
DATA ANALYSIS..................................................................................................99 
RESULTS.........................................................................................................100 
DISCUSSION ....................................................................................................107 
CHAPTER 6: EFFECTS OF INTRODUCTION OF ANTIMALARIAL 
COMBINATION THERAPY FOR MALARIA ON HEALTH FACILITY 
UTILIZATION FOR FEBRILE ILLNESS IN RURAL TANZANIA .....................114 
ABSTRACT.......................................................................................................115 
INTRODUCTION ................................................................................................116 
METHODS ....................................................................................................117 
Study area and population.........................................................................117 
Study design and data collection ...............................................................118 
DATA MANAGEMENT AND ANALYSIS....................................................................119 
RESULTS.........................................................................................................119 
DISCUSSION ....................................................................................................121 
PART IV: DISCUSSION AND CONCLUSIONS ...............................................127 
CHAPTER 7: DISCUSSION AND CONCLUSIONS.........................................128 
  - iii - 
METHODOLOGICAL ISSUES................................................................................128 
MALARIA PARASITAEMIA BEFORE AND AFTER THE INTRODUCTION OF ACT.............129 
TREATMENT SEEKING PRACTICES FOR MALARIA EPISODES BEFORE AND AFTER THE 
INTRODUCTION OF ACT....................................................................................132 
MALARIA PATIENTS’ ADHERENCE TO ACT PROVIDED AT THE HEALTH FACILITIES ....134 
FACTORS OTHER THAN ACT THAT COULD INFLUENCE MALARIA TRANSMISSION ......136 
THE WAY FORWARD FOR MALARIA CONTROL IN TANZANIA AND ELSEWHERE...........137 
FURTHER KEY RESEARCH AREAS .......................................................................139 
CONCLUSION ...................................................................................................140 
CURRICULUM VITAE ......................................................................................157 
 
 
  - iv - 
Acknowledgements 
I have reached a point that reminds me a swahili song hayawi hayawi sasa 
yamekuwa that I used to overhear at wedding festivals more than twenty years 
ago when I was a small village boy. This song literally means that hopes of 
success that used to be ridiculed as mere daydream have finally materialized. I 
have ultimately reached what even three years ago I perceived to be the climax 
of academic ladder. However, I always believe that the world is too big to be 
conquered by whatever level of a single skill or whatever volume of a single 
thesis. That aside, finalizing a PhD program is a long journey that does not start 
when one joins the University that provides that program. The chapter begins on 
day one of beginning ones education. To me, it was in 1973 at a school within the 
walking distance from our home at a remote village in Africa. It comes at its last 
end this year in 2009 at the University of Basel in Switzerland at the heart of 
Europe. It is obvious that it has taken many healthy life years for me up to the 
point of writing this acknowledgement. This could not be possible was it not for 
the almighty God who has given me life and good health for the whole that period.  
 
This academic achievement for me has entailed hard work and commitment of 
many people who would need more than two books of the size of this thesis if I 
mention them one by one. It is because of this constraint that those individuals- 
from then Ole primary school, Utaani secondary school, Institute of languages, 
Zanzibar and the University of Dar es Salaam- will bear with me if I express a 
general heart-felt gratitude to all of them for their contribution towards this end.  
However, as it is in relay race, the final leg runner is the one who is mentioned 
most when the trophy is finally snatched. They are the shining stars of the day 
that every spectator would wish to catch a sight. Hence, I think I will do 
inexcusable injustice not only to people who have helped make the thesis as it is, 
but surely to most of the potential readers. First and foremost, I would mention 
Professor Marcel Tanner, Professor and Director of Swiss Tropical Institute (STI). 
I have seen this name being generously mentioned in every acknowledgement of 
every PhD thesis from STI that I had time to read.  It gave me an impression that 
  - v - 
people were using this big name as marketing gimmick for their thesis.  I have 
now proven the true test of the pudding. Speaking from heart of my heart was it 
not for Marcel I would not even have started my PhD program. He was the one 
who identified me the source of funding for my study at Basel and spontaneously 
offered to supervise my thesis. Despite being a busy man, he was able to find 
time to guide my thesis to reach the right standard for acquisition of a PhD. He 
was so meticulous and timely to every chapter that I sent it to him far away from 
Basel. Someone unfamiliar with his schedule would conclude that he was only 
working on my thesis. I can not be that person because I have now seen him how 
speedy he is and efficient in doing many things at a time.  
 
I would also thank Dr Hassan Mshinda, the former Ifakara Health Institute 
Director and currently Director General of Tanzania Commission of Science and 
Technology for his encouragement and efforts that convinced me that it was the 
right time to pursue a PhD. Every long journey has ups and downs especially 
when you follow an unpaved road. Every time I reached to cross the bamboo 
bridge and my legs felt hesitant, Hassan showed up and told me “move forward” 
“yes, you can”.  
 
This thesis is based on a research work conducted by IMPACT-Tz. So, I feel 
obliged to thank the most important individuals who developed this program and 
made it a success. My thanks should go to Dr Peter Bloland and Dr Patrick 
Kachur from United States Centers of Disease Control and Prevention (CDC). 
Peter was the American’s Project’s Principal Investigator. Patrick had been 
appointed by the United States government to be the director for the program. I 
was very privileged to work with Patrick during the whole project’s period as he 
kept the doors of his treasure of research skills open to me. I actually consider 
Patrick to be one of my important mentors. I would also thank Dr Salim Abdulla 
who was another Project’s Principal Investigator from Tanzanian side and the 
now IHI director. I am very grateful to both Patrick and Salim for giving me the 
rare opportunity of being the coordinator of all household and health facility 
  - vi - 
surveys together with the patients’ adherence studies which were the biggest part 
of the project. I was privileged to get all kinds of support from the duo that made 
IMPACT exemplarily successful.   
 
I also had the privilege to work with Catherine Goodman then a PhD student from 
London School of Hygiene and Tropical Medicine attached to IMPACT-Tz. I must 
admit that Catherine pioneered most data quality enforcement mechanisms of 
the study. I was also able to learn some of the research skills from her. Catherine 
was actually part of my inspiration for this PhD as she similarly used IMPACT’s 
research findings to write her PhD work.  
 
IMPACT-Tz was a so collaborative that it involved many individuals and 
institutions. I would thank all of them, in particular the Ministry of Health of the 
United Republic of Tanzania, Tanzania’s National Malaria Control Program 
especially its astute Manager Dr Alex Mwita,  CDC and London School of 
hygiene and Tropical Medicine. My thanks should also go to villagers in Rufiji and 
Ifakara DSS sites who for more than 5 years volunteered there time to participate 
in our interviews and blood collection.  Our data were collected by a hardworking, 
committed, inspired and disciplined team. I feel comfortable with them and would 
wish to always work with them. Even if I do not mention each one here but should 
similarly all of them take pride for this achievement. However, I am sure each one 
of them will not be comfortable if I do not mention even some as their 
representatives. Let me begin with their Overall managers who are Dr Honorati 
Masanja (Rufiji) and Dr Rose Nathan (Ifakara). Dr Masanja deserves my 
particular mention because of his readiness to provide me with his data 
management and statistical support during the project period no matter what time 
I approached him. The frontline field, data and laboratory staff were: Chrisostome 
Mahutanga (DSS supervisor, Ifakara), Jensen Charles (DSS supervisor, Ifakara), 
Mathew Alexender (DSS field manager, Ifakara), Yahya Mkilindi (DSS field 
Manager, Rufiji), David Magonyozi (IMPACT field supervisor (Ifakara), Benard 
Mumba (IMPACT supervisor, Rufiji), Amaniel (data manager, Ifakara), Francis 
  - vii - 
Lavira (data manager, Rufiji), John Wigayi (Lab technologist, Ifakara), John 
Malugu, Mahundi and Bakari Kissa and Mzee Kobero (lab technicians, Ifakara) 
and Tabia (lab attendant, Ifakara). 
 
I would be ungrateful if I do not thank IMPACT drivers especially James Temba, 
the late Hashim Mdemu, Saidi Mtimi, Edward and Rajabu Andemile for the hard 
work they did in moving people and supplies during the field period. I would also 
thank Naiman Mchomvu, John Mkondya, Safina Juaeli, Bakari Ali and Hamza for 
an excellent managerial and logistical support during the entire project’s life. May 
I also thank my other colleagues in the project; Joseph Njau, Rene Gerrets, 
Emmy Metta, Dr Irene Masanja , Dr Abdunoor Mulokozi, Dr Lymo, Debora 
Sumari, Frida Ettling, Dr E Kahigwa, Dr Julu and Angela Kimweri. I am equally 
specially grateful to Dr. Baraka Amuri and Dr. Fatma Manzi for coordinating 
INESS activities while proceeding with my PhD program. 
 
I am also dearly grateful To Dr Gerry Killeen and Dr Blaise Genton for their 
crucial support during the preparations of my study. I equally owe many thanks to 
my co-supervisor, Prof. David Schellenberg from London School and Tropical 
Medicine together with my PhD defence committee chairman Prof. Christian 
Lengeler 
 
Back at STI I benefited from lectures and seminars presented by many 
outstanding academic staff. My acknowledgement will not complete if I do not 
mention Professors Christian Lengeler, Tom Smith, Penelope Vounatsou, Don de 
Savigny, Christian Buri, Allan Shapira, Mitchelle Weiss, Marcel Tanner and Jürg 
Utzinger. I am also grateful to Thomas Fürst for his German Translation and to 
Diggory Hardy for his language editing. I also enjoyed the warm company of my 
fellow Tazanians similarly doing their studies at IHI. They are Angel Dillip, Dr. 
Mulokozi, Susan Rumisha, Henry Mwanyika, Angelina Lutambi, Judith Kahama, 
Benadeta Huho and Pax Masimba. 
 
  - viii - 
The days that I spent on my own to fulfill the necessary formalities for my trips, 
my accommodation and my per diems during the period I have been in Basel 
were numbered. I do not believe that this happened because everything was 
automatic as in heaven. I am convinced that my nice stay was the results of very 
hard and efficient work of Christine Mensch, Magret Selouis and Christine 
Walliser. I normally do not feel confident in foreign territories, but when I came 
across the faces of Marcel and Christine Mensch I felt as if I was in Tanzania.  
 
I would also thank my parents for understanding the importance of education and 
sending me to school, their prayers and for providing me with every support they 
could have during the whole period that I had gone through my educational 
process. I wish also to thank my bothers, sisters, relatives and friends whose 
prayers and moral support gave me joy and see the world as a place of hope.  
 
I am heartedly indebted to my children and my beloved wife, Husna, for their love, 
patience, understating and encouragement during the whole period of my studies. 
Husna endured the hard work of staying with the family while I was away from 
home for my field activities and study work. 
 
The work described here was funded by he U.S. Agency for International 
Development, US centres for disease Control and Prevention, Ifakara Health 
Institute and Swiss Tropical Institute 
 
  - ix - 
SUMMARY 
 
Malaria is the most important parasitic disease caused by protozoans of the 
genus plasmodia that are transmitted by female anophelene mosquitoes. 
Plasmodium falciparum is the most important species owing to its distribution, 
virulence and pathogenicity. World-wide some 500 million infections, 200-300 
million episodes and about 1 million malaria-related deaths occur every year 
amounting to a burden of some 45 million DALYs (Disability Adjusted Life Years) 
[1]. At least 80% of this intolerable burden is concentrated in Sub-Saharan Africa 
with young children bearing the biggest share. In Tanzania, malaria accounts for 
not less than 30% of the country’s burden of disease [2].  
 
Malaria can be cured if it is diagnosed and treated rapidly with effective drugs. 
Delay in diagnosis and treatment leads to the progression of disease and 
eventually death. Chloroquine and salfudoxine-pyremethamine (SP) had for a 
long time been the first-line treatment of choice for most endemic African 
countries but these drugs are no longer effective for treating patients in many 
parts owing to the development of resistance [3]. Artemisinin based Combination 
Therapy (ACT) is now widely recommended as the first-line treatment of choice 
owing to its efficacy, safety profile and the fact that no resistance has, so far, 
been described.  
 
Regarding prevention of malaria infections, Insecticide Treated Nets (ITNs) play 
the key role, while Indoor Residual Spraying (IRS) and elimination of mosquito 
breeding sites using larvicides are additional tools for integrated malaria control 
that can be applied dependant on local conditions.  
 
As a reaction to the growing resistance of malaria parasites to Chloroquine and 
SP, and when ACTs were being considered for first-line treatment, the 
Interdisciplinary Monitoring Project for Anti-malarial Combination Therapy for 
Tanzania (IMPACT-Tz) was designed to evaluate the effectiveness of ACT 
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introduction and application in the Rufiji, Kilombero and Ulanga districts within the 
Coast and Morogoro Regions of Southern Tanzania.  
 
The present thesis was undertaken within the frame of IMPACT-Tz from 2001-
2006 with the following aims:  
(i) Describing patients’ adherence to ACT 
(ii) Following the dynamics of parasite prevalence during ACT 
promotion and use 
(iii) Analyzing the project’s impact on health facility use, and ITN 
coverage and its concomitant delivery strategies within the study areas of 
IMPACT-Tz . 
 
The present studies were based on the demographic surveillance systems which 
have been well established within the studied districts for many years.  We 
conducted the study assessments using questionnaires to members of sampled 
households, key informant interviews and analyzed blood specimens that we 
concurrently collected during the interviews.  Follow up visits to the homes of 
patients who had been treated with ACT at health facilities was the main method 
that we used to analyze patients’ adherence.  
 
Patients’ adherence to ACT showed very promising results with 75% reaching 
complete adherence as established by self-reporting and tablet counts. These 
results were substantially better than reported elsewhere and compared 
favorably with former intervention studies to optimize adherence to chloroquine.  
 
ITN coverage continuously increased through mixed delivery strategies involving 
free distribution during an immunization campaign combined with social 
marketing and a voucher system. All delivery mechanisms, especially sale of 
nets at full market price, tended to under-serve the poorest. Voucher-subsidized 
and freely distributed nets did not appear to create inequalities. In 2005, overall 
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net use reached 62.7% and that among infants 87.2%. Thirty percent of all nets 
had been treated six months prior to the interview.  
 
The parasite prevalence declined over the study period and was clearly related to 
the interventions. In 2001, parasite prevalence was 26% in the general 
population of Rufiji and 18% in Ifakara. Following the deployment of ACT in 2003, 
there was a sharp decline of malaria prevalence from 29% in 2002 to 19% in 
2004 in Rufiji. It remained the same in 2005 and decreased to 15% in 2006. The 
respective estimates for Ifakara were 22% in 2002, 25% in 2004, 11% in 2005 
and 14% in 2006. The prevalence of anaemia (Hb<8g/dl) measured from 2004 to 
2006 showed a drop from 23% in 2004 to 16% in 2005 and 2006 in Rufiji. 
Respective values for Ifakara were 12%, 18% and 10%. Use of any nets 
increased from 18% in 2001 to 63% in 2006 in Rufiji and from 69% to 86% in 
Ifakara. 
 
Treatment-seeking also changed with the introduction of AC. Starting with 31-
35% of febrile episodes seen at health facility level at the beginning of the study, 
an increase to up to 45% was observed as a consequence of ACT introduction. 
Treatment seeking in the comparison district where SP was still used as first-line 
treatment as stipulated in the national policy, treatment-seeking showed 
fluctuations but remained basically unchanged. Young children were those most 
seen with febrile episodes. The least poor showed higher health facility usage 
than the poorest segments of the population.  
 
 Our study suggests that ACT first-line therapy is an accepted and feasible 
approach that can reduce both the burden of disease and transmission when 
ACT is offered at health facility level. ACT was effective as part of an integrated 
approach that also entailed the promotion of ITNs. The study further 
demonstrated that high levels of adherence to ACT can be reached provided 
treatment is preceded by sufficient health worker training together with innovative 
information, education and communication. Provision of ACT at health facilities 
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improves the use of health facilities in a broad sense.  Achieving and sustaining 
broad access to ACTs will require other strategies for ACT delivery that include 
all providers of services and may include home-based management in order to 
reach all segments of a population and, thus, to achieve equitable access.  
 
There are additional other important issues that need to be investigated further 
such as how ACTs can be effectively made available to all possible health 
service providers in a given area, also including possible home management 
strategies to achieve broad and equitable access to rapid diagnosis and 
treatment. Finally we need to understand to what extent synergies are created 
when different sets of malaria control interventions are implemented 
concomitantly and/or sequentially with different time-space dynamics of coverage. 
Such information is critical for tailoring strategies to different endemic settings 
and for moving from control towards elimination. 
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Zusammenfassung 
 
Malaria ist die wichtigste parasitäre Erkrankung, welche durch die Protozoen der 
Gattung Plasmodia verursacht wird. Die Plasmodien werden durch die weiblichen 
Moskitos der Gattung Anopheles übertragen. Plasmodium falciparum ist die 
wichtigste Spezies aufgrund ihrer Verbreitung, Virulenz und Pathogenität. 
Weltweit gibt es geschätzte 500 Millionen Infizierte, wobei etwa 200-300 
Millionen Episoden und 1 Million Tote jedes Jahr durch Malaria verursacht 
werden, was 45 Millionen DALYs (Disability Adjusted Life Years) entspricht. 
Mindestens 80% von dieser Krankheitslast konzentriert sich auf Afrika südlich der 
Sahara und dort wiederum insbesondere auf junge Kinder. In Tansania ist 
Malaria für nicht weniger als 30% der gesamten nationalen Krankheitslast 
verantwortlich. 
 
Malaria kann geheilt werden, wenn die Krankheit rechtzeitig diagnostiziert und 
mit wirksamen Medikamenten behandelt wird. Verzögerungen in der Diagnose 
oder Behandlung können zu einem Fortschreiten der Krankheit und letztlich zum 
Tod führen. Chloroquine und Salfudoxine-Pyremethamine (SP) waren lange Zeit 
in den meisten endemischen Ländern in Afrika als Erstbehandlung vorgesehen, 
sind aber heute aufgrund von zunehmenden Resistenzen vielerorts nicht mehr 
wirksam. Wegen ihrer Wirksamkeit, ihres Sicherheitsprofils und bisher noch nicht 
aufgetretenen Resistenzbildungen wird deshalb heutzutage die so genannte 
Artemisinin-based Combination Therapy (ACT) als Erstbehandlung empfohlen. In 
Bezug auf die Prävention spielen Insecticide Treated Nets (ITN) eine 
Schlüsselrolle. Indoor Residual Spraying (IRS) sowie das Eliminieren von 
Moskitobrutstätten mit Larviziden sind zusätzliche Massnahmen für eine lokal 
angepasste, integrierte Malariakontrolle. 
 
Als Reaktion auf die zunehmende Resistenz der Malaria-Erreger gegenüber 
Chloroquine und SP wurde der Einsatz von ACT als neue Methode der 
Erstbehandlung in Betracht gezogen. Um die Wirksamkeit von ACT im Rufiji, 
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Kilombero und Ulanga Distrikt in der Küsten- und der Morogoro-Region im Süden 
von Tansania zu evaluieren, wurde das Interdisciplinary Monitoring Project for 
Anti-malarial Combination Therapy for Tanzania (IMPACT-Tz) konzipiert. 
 
Die vorliegende Doktorarbeit wurde im Rahmen von IMPACT-Tz zwischen 2001 
und 2006 durchgeführt und beabsichtigte innerhalb des IMPACT-Tz 
Studiengebietes (i) die Befolgung der ACT durch die Patienten zu beschreiben, (ii) 
die Dynamik der Parasiten-Prävalenz während der ACT Förderung und 
Anwendung zu beschreiben, (iii) den Einfluss des Projekts auf die Nutzung von 
Gesundheitseinrichtungen und ITNs unter Berücksichtigung von deren 
Verfügbarkeit und Belieferungsstrategien zu analysieren. Die Studien stützten 
sich auf die seit einigen Jahren in den Studiengebieten etablierten Demographic 
Surveillance Systems (DSS). Zur Durchführung der Studien befragten wir 
Mitglieder von ausgewählten Haushalten mit Hilfe von Fragebogen, führten 
Interviews mit Key Informants und analysierten Blutproben, welche gleichzeitig 
mit den Interviews eingesammelt wurden. Hausbesuche bei Patienten, welche in 
den Gesundheitseinrichtungen mit ACT behandelt wurden, waren die 
grundlegende Methode um die Befolgung der Therapie durch die Patienten zu 
beschreiben. 
 
Die Resultate zur Befolgung der ACT-Therapie durch die Patienten waren viel 
versprechend. Gemessen an den Aussagen der Patienten und dem Auszählen 
der Tabletten befolgten 75% der Patienten die Therapie vollständig. Diese 
Resultate waren deutlich besser als anderswo und auch besser als Resultate von 
früheren Interventionsstudien zur Optimierung der Befolgung von Chloroquine-
Behandlungen. 
 
Der Deckungsgrad mit ITNs stieg kontinuierlich dank einer gemischten 
Belieferungsstrategie, welche eine Gratis-Verteilung während Impfkampagnen 
mit Massnahmen des Social Marketing und einem Gutschein-System kombinierte. 
Alle Belieferungsmechanismen und insbesondere der Verkauf von ITNs zu 
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Marktpreisen tendierten dazu die Ärmsten unterzuversorgen. Durch Gutscheine 
subventionierte und gratis verteilte Netze schienen am wenigsten Ungleichheiten 
zu erzeugen. Gesamthaft erreichte der Anteil von Netzbenutzer im Jahr 2005 
62.7% und sogar 87.2% bei Kindern. Dreissig Prozent aller Netze wurde in den 
letzten sechs Monaten vor dem Interview mit Insektizid behandelt. 
 
Die Parasiten-Prävalenz war eindeutig mit den Interventionen verbunden und 
nahm im Verlauf der Studien ab. 2001 betrug die Prävalenz 26% in der 
allgemeinen Bevölkerung von Rufiji und 18% in Ifakara. Nach dem Start der 
ATC-Anwendung 2003 sank die Malaria-Prävalenz in Rufiji von 29% im Jahr 
2002 auf 19% im Jahr 2004 deutlich, blieb im Jahr 2005 konstant und sank 
schliesslich noch einmal auf 15% im Jahr 2006. Dieselben Schätzungen für 
Ifakara sind 22% 2002, 25% 2004, 11% 2005 und 14% 2006. Die Anaemie-
Prävalenz (Hb<8g/dl) in Rufiji sank von 23% 2004 auf 16% 2005 und 2006. 
Dieselben Werte für Ifakara liegen bei 12%, 18% und 10%. In Rufiji nahm die 
Anwendung von Moskitonetzen aller Art von 18% im Jahr 2001 auf 63% im Jahr 
2006 zu und in Ifakara von 69% auf 86%. 
 
Durch die Einführung von ACTs änderte sich auch das so genannte Treatment-
Seeking. Als Konsequenz der Einführung von ACTs stieg der Anteil 
Fieberepisoden, welche auch zu den Gesundheitseinrichtungen gelangten, von 
31-35% auf 45% im Verlauf der Studien. Treatment-Seeking in einem 
Vergleichsdistrikt, wo gemäss der nationalen Strategie immer noch SP als 
Erstbehandlung verwendet wurde, zeigte zwar Fluktuationen, blieb aber im 
Wesentlichen unverändert. Im Zusammenhang mit Fieberepisoden wurden am 
häufigsten junge Kinder festgestellt. Die reichsten Bevölkerungssegmente 
benützten die Gesundheitseinrichtungen häufiger als die ärmsten. 
 
Unsere Studien zeigen, dass ACT als Erstbehandlung in 
Gesundheitseinrichtungen ein akzeptierter und realisierbarer Ansatz ist, der 
sowohl die Krankheitslast als auch die Krankheitsübertragung einschränken kann. 
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ACT war wirksam als ein Teil eines integrierten Ansatzes, der auch die 
Förderung von ITNs beinhaltete. Die Studien zeigen auch, dass eine gute 
Befolgung der ACT erreicht werden kann, wenn den Behandlungen ein 
ausreichendes Training des Gesundheitspersonals und innovative Informations-, 
Aufklärungs- und Kommunikationsmassnahmen vorangehen. Die Bereitstellung 
von ACT in Gesundheitseinrichtungen verbessert die Nutzung dieser 
Einrichtungen in vielerlei Hinsicht. Zur Erreichung und Gewährleistung eines 
breiten Zugangs zu ACTs sind aber auch andere Abgabestrategien nötig, welche 
alle Anbieter von Gesundheitsleistungen mit einschliessen und für die bessere 
Erreichbarkeit und Zugangsgerechtigkeit auch heimbasierte Behandlungen 
zulassen. 
 
Dementsprechend gibt es wichtige Probleme, welche weitere 
Forschungsanstrengungen benötigen. Wie zum Beispiel können ACTs wirksam 
und unter Berücksichtigung sowohl aller Anbieter von Gesundheitsleistungen in 
einem bestimmten Gebiet als auch aller Möglichkeiten der heimbasierten 
Behandlung zur Verfügung gestellt werden, so dass ein möglichst breiter und 
gerechter Zugang zu schnellen Diagnosen und Behandlungen erreicht werden 
kann? Zudem sollten wir Synergien, welche entstehen, wenn verschiedene 
Malariakontrollinterventionen begleitend und/oder einander nachfolgend in 
unterschiedlichen Zeit-Raum-Dynamiken der Abdeckung implementiert werden, 
besser verstehen. Diese Informationen sind entscheidend um 
massgeschneiderte Strategien für verschiedene endemische Situationen zu 
entwerfen und um einen Schritt von der Malariakontrolle hin zur 
Malariaelimination zu machen. 
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MUHTASARI 
 
Ugonjwa wa malaria huambukizwa na vimelea vya aina ya P.Falciparum. 
Vimelea hivi huenezwa na mbu wa kike wa aina ya anophelene. Vimelea hivi vya 
P.Falciparum vina usumbufu wa kipekee kwa vile vipo maeneo mengi na 
vinazaliana haraka haraka na kuzaa ugonjwa mbaya. Kila mwaka wata wapatao 
millioni 500 humbukizwa vimelea ambapo wagonjwa baina ya millioni 200 mpaka 
300 huugua ugonjwa wa malaria na kiasi ya wagonjwa millioni moja hufa kote 
duniani. Jumla ya maisha ya binadamu inayopotea kutokana na vifo na kuugua 
ugonjwa huu inakadiriwa kufikia miaka millioni 45. Kiasi ya asilimia thamanini ya 
hasara hii hupatikana katika bara la Africa na wanaoathirika zaidi ni watoto 
wadogo wadogo. Nchini Tanzania kiasi ya asilimia thelathini ya hasara iletwayo 
na magonjwa husababishwa na malaria.  
 
Ugonjwa wa malaria unaweza kutambulika na kutibika kwa haraka kwa dawa 
imara. Ugonjwa huu hugeuka kuwa hatari sana na kusababisha vifo vingi ikiwa 
matibabu yake yatacheleweshwa. Dawa za Chloroquine na salfadoxine-
pyremethamine (SP) ambazo kwa muda mrefu zilikuwa zinatumika kutibia 
ugonjwa huu katika nchi za Africa zenye kuambukizwa zaidi, sasa hivi hazifanyi 
tena kazi kwa sababu ya usugu wa vimelea.  Dawa za mseto zenye 
mchanganyiko wa artemisinin (ACT) sasa hivi zinapendekezwa zaidi kutokana na 
kuthibitika uimara na usalama na kwa vile kwa sasa hakuna matokeo ya usugu 
wa vimelea uliotolewa taarifa. Pamoja na hayo, Ugonjwa wa malaria unakingika 
kwa kutumia vyandarua vyenye viatilifu (ITN), dawa za kunyunyiza majumbani na 
kuuwa mayai ya mbu kwa kutumia dawa katika mazalia ya mbu. 
 
Katika kipindi ambapo dawa za Chloroquine na SP zilikuwa zinashindwa kwa 
kasi kubwa kuponesha ugonjwa wa malaria, mradi wa kutathmini dawa mseto za 
malaria (IMPACT-TZ) ulibuniwa na ulifanya tathmini ya dawa mseto katika wilaya 
za Rufiji, Kilombero na Ulanga zilizopo mikoa ya Pwani na Morogoro nchini 
Tanzania. 
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Kitabu hiki cha uhitimu wangu wa shahada ya  udaktari wa falsafa katika fani ya 
epidemiology kinatokana na utafiti uliofanywa chini ya muavuli wa mradi wa 
IMPACT-Tz kati ya mwaka 2001 mpaka 2006. Madhumuni yake ni  (i)kutathmini  
jinsi wagonjwa wa malaria waliotibiwa kwa dawa mseto walivykuwa wakitumia 
dawa hizo kwa usahihi; (ii) kufuatilia uwepo wa vimelea vya malaria katika kipindi 
ambacho dawa mseto zilihamasishwa na kutumika; na (iii) kutafiti athari ya 
utekelezaji wa mradi huu kwa matumizi ya vituo vya tiba na pia matumizi ya 
vyandarua vyente viatilifu na mikakati mbali mbali ya kuvisambaza katika vijiji 
vilivyokuwa kwenye mradi. Tathmini hizi zilifanywa katika vijiji vilivyo kwenye 
mpango wa kufuatilia taarifa zinazohusu uhamiaji, uhamaji, vizazi na vifo (DSS 
sites) katiak sehemu za Rufiji na Ifaka zilizo chini ya Taasisi ya Utafiti wa afya ya 
binadamu ya Ifakara (IHI). Utaratibu huu wa DSS ulishakuwepo kwenye vijiji 
hivyo kwa muda mrefu. Tulifanya utafiti huu kwa njia ya mahojiano na wanakaya 
wa kaya ambazo zilichaguliwa kwa bahati nasibu na kwa kuhakiki matone ya 
damu yaliyokuwa yakichukuliwa wakati wa mahojiano. Katika kuangalia matumizi 
ya dawa mseto kwa usahihi, tulikuwa tunawazungukia wagonjwa waliokuwa 
walishatibiwa kwa dawa mseto katika vituo vya tiba majumbani mwao na 
kuwadodosa jinsi walivyokuwa wametumia dawa hizo. 
 
 Jumla ya wagonjwa 253 walifuatiliwa majumbani mwao kuulizwa maswali baada 
ya masaa 24 na 48 tokea kwenda kituoni kupata matibabu. Ilionekana kuwa 
asilimia 75 ya wagonjwa waliofuatiliwa baada ya masaa 48 walitumia dawa 
mseto kiusahihi. Haya yalipimwa kwa kukehasabu idadi ya vidonge vilivyokuwa 
vimebaki na taarifa za mgonjwa mwenyewe walipotembelewa majumbani mwao 
na kudodoswa na wahojaji. Kwa kweli majibu haya ya wagonjwa kutumia dawa 
mseto kiusahihi yalikuwa bora kuliko majibu yaliyokuya yamepatikana huko 
nyuma katika tathmini ya dawa za Chloroquine 
 
Matumizi ya vyandarua vyenye viatilifu yalikuwa yanaongezeka kutokana na 
vyandaraua hivyo kusambazwa kwa kutumia njia mseto ambazo zilijumuisha 
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ugawaji wa vyandarua vya bure siku ya chanjo na kwa njia ya soko na hati 
punguzo. Njia zote hizo hasa ile ya kuviuza vyandarua dukani haikuwanyanyua 
sana watu maskini sana. Vyandarau vilivyotolewa bure na vile vilivyouzwa kwa 
hati punguzo havikuonekana kuleta kutokuwepo na usawa. Katika mwaka 2005, 
matumizi ya kila aina ya chandarua yalifikia silimia 63 na kwa watoto wachanga 
peke yao yalifikia asilimia 87. Asilimia thelathini ya vyandarua vilikuwa 
vimewekwa viatilifu kipindi cha miezi 6 kabla ya mahojiano. 
  
Ama katika tathmini ya vimelea vya malaria katika jamii, tuliona kuwa mwaka 
2001 uwepo wa vimelea ulikuw asilimia 26 ya watu wote katika DSS upande wa 
Rufiji ikilinganishwa na asilimia 18 katika  upande wa Ifakara.  Uwepo wa vimelea 
ulipungua  hadi kufikia asilimia 19 mwaka 2004 kwa upande wa Rufiji baada ya 
kanzishwa matibabu ya dawa mseto mwaka 2003. Katika mwaka 2002 uwepo 
wa vimelea huko ulikuwa 29%. Baadae kiwango hicho cha mwaka 2004 huko 
Rufiji kilibaki hivyo kwa mwaka 2005 na kushuka  kufikia asilimia 15 mwaka 2006. 
Tathmini ya Ifakara ilionesha kuwa  uwepo wa vimelea ulikuwa 22% mwaka 2002, 
25% katika mwaka  2004, 11% mwaka 2005 na 14% mwaka 2006.  Kwa upande 
wa upungufu wa damu mwilini , tathmini yetu iliyofanywa mwaka 2004 mpaka 
2006 katika upande wa Rufiji ilionesha kuwa upungufu ulipungua kutoka asilimia 
23 mwaka 2004 hadi 16% mwaka 2005 na 2006.  Upande wa Ifakara hali ilikuwa 
12% mwaka 2004, 18% mwaka 2005 na 10% mwaka 2006. Matumizi ya 
vyandarua yaliongezeka huko Rufiji kutoka asilimia 18% mwaka 2001 na kufikia 
asilimia 63 mwaka 2006. Na huko Ifakara matumizi yalikuwa asilimia 69 mwaka 
2001 na kuongezeka kuwa asilimia 86 mwaka 2006. 
 
Katika tathmini yetu ya kujua matumizi ya vituo vya matibabu kwa wale 
waliosema waligua homa au malaria wiki mbili kabla ya mahojiano tuligundua 
kwamba matumizi ya chanzo hicho yalikuwa 31% na 35% kwa mika ya 2001 na 
2002 huko Rufiji. Hii ni miaka kabla ya kuanza kutibu malaria kwa kutumia dawa 
mseto katika vituo vya afya sehemu hiyo. Matumizi yaliongezeka kufikia 45% 
katika mwaka 2004, mwaka mmoja baada ya kuanza dawa hizo katika vituo vya 
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afya peke yake. Matumizi hayo yalipungua kidogo na kufikia 41% mwaka 2005. 
Yalianguka zaidi mwaka 2006 kwa kufikia 30% tu. Kwa upande wa Ifakara 
ambako wagonjwa waliendelea na sera ya serikali kwa nchi nzima ya matibabu 
ya dawa isiyo ya mseto ya SP wakati ule , wagonjwa waliopata matibabu yao  
kutoka vituo vya Afya yalikuwa 27% kunako mwaka 2001 na 33% katika mwaka 
2002. Hali ilishuka na kufikia 29% kunako mwaka 2004 na kuongezeka kufikia 
36% katika mwaka 2005 na kutokuwepo na mabadiliko katika mwaka 2006. 
Katika kuhusisha matumizi haya ya vituo vya afya na rika za watu, watoto chini 
ya miaka 5 walikuwa wanatumia vituo hivyo mara nyingi zaidi kuliko wenye umri 
zaidi yao kutoka zote za Rufiji na Ifakara.  Aidha, wale wenye unafuu wa maisha 
walikuwa na fursa zaidi ya kutumia vituo vya matibabu kwa zaidi ya 50% ya wale 
waliokuwa wanaishi maisha ya chini zaidi kutoka katika sehemu zote. 
 
Kwa ujumla, utafiti wetu umeonesha kuwa matumizi ya dawa mseto yanaweza 
kupunguza maambukizi ya vimelea vya malaria na mzigo wa maradhi katika jamii 
hata kama dawa hizo zitakuwa zinapatikana kutoka vituo vya afya peke yake.  
Dawa mseto zilikuwa na umadhubuti kama sehemu ya mkakati wa pamoja 
ambao pia ulihusisha uhamasishaji wa vyandarua vyenye viatilifu. Utafiti wetu pia 
umegundua kuwa kuna fursa nzuri kwa wagonjwa wa malaria kutumia dawa 
mseto kwa usahihi ikiwa wafanyakazi wa afya wataelimishwa na kutakuwa na 
elimu kwa wagonjwa kabla ya kuanzishwa mpango wowote wa dawa mseto.  
Matibabu ya dawa mseto kwenye vituo vya matibabu huboresha matumizi ya 
vituo hivyo kwa upana wa namna yake. Ufanikishaji wa kuongeza upatikanaji wa 
dawa mseto na udumishaji wake unahitaji mikakati mengine ya kutibu kwa dawa 
mseto kwa njia nyengine kama vile njia za upatikana ji dawa majumbani  ili 
wagonjwa wa kila uwezo azipate na kwa namna hiyo kufikia lengo la usawa wa 
upatikanaji wa dawa. 
 
Kuna mambo mengine muhimu ambayo inabidi yatafitiwe zaidi kama vile namna 
gani dawa mseto zinaweza kupatikana zaidi kwa kuwahusisha watowaji 
matibabu wengine katika eneo husika  ikiwemo mikakati ya kuzitowa dawa katika 
  - xxi - 
njia zisizo rasmi ili kuwafikishia wagonjwa dawa na vipimo karibu zaidi bila kuleta 
tofauti kati ya watu wa vipato mbali mbali. Mwisho inabidi tuelewe namna gani 
njia mbali mbali za kudhibiti malaria zinaweza kuchangishana matokeo bora 
zitakapotumika kwa pamoja.  
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PART I: BACKGROUND
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CHAPTER 1: Introduction 
Malaria transmission 
Malaria is a protozoan infection caused by four major species of Plasmodium. 
They are P. Falciparum, P. Vivax, P. Ovale and P. Malariae. The most virulent, 
most prolific, most unpredictable and most lethal is P. Falciparum. This work will 
focus on this species as it is one of the leading health risks in sub-Saharan Africa. 
The parasite is capable of reproducing both sexually in the mosquito and 
asexually in the human body. The life cycle of P. Falciparum begins when 
mosquitoes feed on human blood infected with gametocytes. When feasting on 
their blood meal, mosquitoes simultaneously ingest the parasites at this stage of 
their life cycle. Once reaching the mosquito’s body, gametocytes split into male 
and female gametes and glue themselves in the gut. They then fertilise to 
produce zygote that elongates to form ookinete. Ookinete penetrates the 
mosquitoes’ gut lining and multiply into oocysts. Oocysts grow up in the gut wall 
and ultimately rupture to release thousands of sporozoites that migrate to the 
salivary glands of mosquitoes. Each oocyst multiplies into 10,000 sporozoites.  
This process normally takes 9-30 days depending on ambient temperature. At 
30oC it can take exactly 9 days, 10 days if temperature falls to 25oC and 23 days 
at 20oC (Beier 1998). Evidence so far suggests that sporozoites can not be 
developed in the mosquito body below 16-18oC. 
 
Asexual reproduction of P. Falciparum in the human body begins when infected 
mosquitoes bite a human being for their blood requirement. While mosquitoes tap 
the human blood, they simultaneously inject the sporozoites into the human body. 
Within half an hour after reaching the human body, sporozoites move to the liver 
where they multiply into thousands of schizonts in the human liver cells. This 
development takes between 6-15 days. Each schizont divides itself into 30,000 
merozoites. The merozoites rupture their host cells in the liver and migrate into 
blood stream. They attach to specific erythrocyte surface receptors and penetrate 
into red blood cells. Upon entering red blood cells, each merozoite splits again 
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into trophozoites and back into schizonts. The invaded red blood cells swell and 
burst, releasing the next batch of merozoites. When in the blood, each schizont 
multiplies into 16-32 merozoites. Several such multiplications occur, giving rise to 
simultaneous waves of merozoites escaping and infecting red blood cells. The 
pathogenicity resulting from the parasite infection appears in different ways. First 
when red blood cells rupture due to pressure of increased merozoites, parasite 
toxin is released which precipitates a complex network of cytokines and effectors 
that causes fever. Second after red blood cells are destroyed they sequester into 
blood vessels, the combination of this sequestration and toxin cause tissue 
damage. Third when red blood cells are destroyed by different level of parasite 
multiplications, anaemia comes into being (Winstanley 2000). Some of the 
merozoites change themselves into male and female gametocytes and circulate 
freely in the human blood ready to be picked up by mosquitoes for another turn of 
sexual reproduction. However, parasite progression in the human body into a 
form that is disastrous to human health is influenced by a number of factors. For 
instance, it has been observed that sickle cell and other traits that alter red blood 
cell structure can limit parasite multiplication within red blood cells (Allison 1954). 
It has also been shown that hereditary ovalocytosis, glucose-6-phosphate 
dehydrogenase deficiency, spectrin, Lewis and Kid Is (a) red cell mutations in the 
gene for red blood cell membrane protein can also reduce parasite efficiency 
(Luzzatto 1979). Frequency of the class 1 major histocompatibility complex 
molecule HLA-B53 has equally been found to have an impact on immunity on 
liver stage of parasite (Hill et al. 1991)  
  
Mosquitoes are crucial in malaria parasite transmission cycle. Female anopheles 
gambiae complex sensu strictois mosquito species is the most effective in 
transmitting malaria in Africa. They are the predominant malaria vector in the 
continent. They badly need human blood for egg maturation. They prefer 
breeding in small and large collection of sun-exposed still water under very humid 
environments. These conditions are more likely to occur in tropical areas with 
heavy rainfall. Mosquitoes can not survive at temperature below 18oC. 
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Temperatures of above 32°C have been reported to cause high vector population 
turnover, weak individuals and high mortality (Craig 1999). A number of studies 
have demonstrated the association between An. gambiae s.l. abundance and 
rainfall (Charlwood et al. 1995; Molineaux and Gramiccia 1980). Anopheles 
gambiae s.l. is seen to breed more prolifically in temporary and turbid water 
bodies, such as ones formed by rain. It has been shown that the ideal climatic 
conditions for stable malaria transmission are temperatures between 22-32oC   
with monthly rainfall of about 80mm for not less than five months per year (Craig 
et al. 1999)   The vectors preferential biting time is midnight when most people in 
sub-Saharan Africa especially in rural areas are dead asleep. It has been 
recently observed that they can even feed in late afternoon or early morning. 
Some of these mosquitoes can bite throughout the day. They are exquisitely 
adapted to living around humans and adapt to changing human mosquito 
preventing habits. Just one bite from an infected mosquito can cause disease.  
Some studies have shown that mosquitoes do not just bite any human. They 
have preferences. Their biting choice is determined by some form of smell 
containing kairomone, a chemical substance that is secreted in certain parts of 
the body by individuals with certain characteristics. It is this odor that helps them 
detect their human preys. It has been observed that people with big bodies like 
pregnant women and smelly regions of the body like feet and ankles are very 
much associated with this odor and therefore are most attractive to mosquitoes 
(De Jong and Knols 1995; Dekker 1998; Haddow 1942). It has also been shown 
that A. gambiae becomes hungrier to multiple blood meals when infected by 
parasites than when they are not infected (Koella et al. 1998).  
 
Thus, the presence of sporozoite infected female mosquitoes is the necessary 
condition for malaria transmission. However, this process is so complex that it 
entails a dynamic causal web of factors related to humans, malaria parasites and 
mosquitoes.  
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Figure 1: The life cycle of malaria parasites in the human host and anopheline 
mosquito vector  
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Figure 1: Map showing distribution of malaria intensity in Africa 
 
Malaria burden in Africa 
It is obvious that such enormous resources invested for malaria control in Africa 
can be reasonably justified if we describe a brief assessment of the magnitude of 
health problems caused by this disease.  However, estimating malaria burden in 
Africa is a subject for discussion and in some ways may be controversial. This is 
the case due to the fact that these estimates are based on health facility records 
of malaria patients attending these facilities. It is argued that in areas that malaria 
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transmission is endemic; the majority of the infections are asymptomatic (Breman 
et al. 2001). But the fact is that substantial percentage of them have parasitaemia 
at any one time and children less than five years of age may have 4-9 or more 
febrile episodes each year (Breman et al. 2001). Different research studies have 
shown that above 70% of malaria illnesses in Africa are treated outside health 
facilities. Consistent to this, treatment seeking pattern and similar amount of 
deaths are suspected to occur at home. Poor documentation for health facility 
records makes reporting even for cases presented to health facilities unreliable. 
In their article published in Lancet on the scandal of invisibility, Setel and his co-
authors argue that most people in Africa and Asia are born and die without 
leaving a trace in any legal record or official statistic (Setel et al. 2007). 
 
Malaria burden estimates in Africa are also criticized for deriving their numbers 
from only malaria direct effects. They overlook such effects like malaria-induced 
acute and chronic anaemia, maternal pathology (including low birth weight babies 
that increases risk of death in the first month of life, hypoglycemia and long term 
neuropsychologic-development sequelae. It is urged that malaria-induced 
anaemia causes more deaths than any other manifestations of malaria infection 
(Murphy et al. 2001). The highest prevalence of anaemia occurs toward the end 
of the child’s first year (Crawley 2004). It has been shown that in areas with 
stable and intense malaria transmission, more than 80% of the infants 10 months 
of age are anaemic, and approximately one third have haemoglobin level <8g/dl 
(Crawley 2004). These numbers do not include malaria’s enhancement of the 
severeness of childhood illnesses (Breman et al. 2004). People infected with HIV 
are especially at risk of malaria. 
 
These weaknesses aside, available estimates suggest that there are 515 million 
clinical attacks due to P. falciparum worldwide. The majority of these events, 70%, 
are concentrated in Africa (Snow et al. 2005). Malaria kills between 1 and 3 
million people each year. Between 80-90% of these deaths occur in Africa 
(Guinovart et al. 2006). African children younger than five years have been 
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shown to be the biggest victims of malaria related deaths. They are responsible 
for 65-75% of all malaria deaths occurring on the continent (Breman et al. 2004; 
Snow et al. 1999).  Other effects include impaired growth and development for 
small children that have an effect on their learning capability, low birth weight for 
babies born to parasitimic mothers and anaemia. Malaria is responsible for 3% of 
worldwide life years lost due to just premature deaths and sufferings. Africa 
accounts for more than 10% of this burden (Hay et al. 2004). Table 1 shows 
estimates for 2008 of all deaths occurring globally, proportion of malaria deaths 
and their distribution by different geographic regions. Africa suffered lower all 
cause mortality than Southeast Asia or Western Pacific but was responsible for 
more than four fifths of all malaria specific mortality. Simple interpretation of 
these numbers is that when talking of deaths in Africa, you talk of malaria deaths. 
Measures designed to reduce mortality on the continent must target malaria. 
 
Table 1: Deaths and malaria-related deaths (,000s) 
    
  Population All deaths (%) Malaria deaths (%) 
World 6,436,826 58,772 889 
Africa  737,536 11,249(19.2) 806(90.6) 
Americas  874,380 6,158(10.5) 2.2(0.2) 
Eastern Mediterranean  519,688 4,307(7.3) 39(4.4) 
Europe  883,311 9,493(16.2) 0 
Southeast Asia  1,671,904 15,280(26.0) 36.5(4.1) 
Western Pacific 1,738,457 12,191(20.8) 5.5(0.6) 
WHO, 2008 report    
 
 
 
Table 2 has summarized global disability-adjusted life years lost due to illnesses 
and premature deaths from malaria parasites for the year 2008. Of 1523,259,000 
life years lost due to sufferings and premature deaths from all health problems, 
376,525,000 years were lost due to malaria.  
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Table 2: Disability-adjusted life years (DALYs, 000s), all cause and malaria-related 
 
  DALYs from all causes (%) 
DALYs from malaria deaths 
(%) 
World 1,523,259 33,976 
Africa  376,525(24.9) 30,928(91.1) 
Americas  143,232(9.5) 89(0.3) 
Eastern Mediterranean  141,993(9.4) 1,412(4.2) 
Europe  141461(9.4) 4(0.01) 
Southeast Asia  442,979(29.3) 1,341(4.0) 
Western Pacific 264,772(17.5) 169(0.5) 
WHO, 2008 report   
Table 3 presents under-five mortality in Africa distributed by each manifestation 
of malaria parasite infection. It is shown that total under-five deaths due to 
malaria represents 65% of all malaria related deaths on the continent. The 
majority of these deaths occur as a result of low birth weight babies during 
delivery. Many studies have shown that malaria in pregnancy is a very important 
factor for low birth weight deliveries in Africa which is an exposure to increasing 
infant mortality observed on the continent.  
Table 3: Deaths from malaria in Africa in children less than five years of age  
            
  Range of deaths in    
  Cause of death children <5 years old       
 Cerebral malaria  110,000 (no range)    
 Severe malarial anemia  190,000–974,000    
 Respiratory distress  110,000 (no range)    
 Hypoglycemia  153,000–267,000    
 Low birth weight  62,000–363,000    
 Deaths  625,000–1,824,000    
  All malaria deaths in Africa†  962,000–2,806,000       
 
†
 Children <5 years of age represent 65% of all deaths in Africa as per Snow and others (Breman et 
al. 2004) 
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Despite the sufferings and deaths that could be translated into billions of US 
dollars, malaria in Africa is similarly responsible for direct costs of expenditure on 
prevention and treatment. Households spend their money on preventive measure 
such as mosquito coils, aerosol sprays, bed nets and mosquito repellents. 
Malaria related treatment seeking expenses include out-of-pocket expenditures 
for consultation fees, drugs, transport and the cost of subsistence at a distant 
health facility. It has been demonstrated that a monthly per capita household 
expenditure on malaria prevention ranges between US$0.24 per household in 
rural Malawi and US$15 in urban Cameroon.  Associated costs related to 
treatment per month per household were US$1.88 in rural Malawi and US$26 in 
urban Cameroon (Mills 1998).  It is estimated that direct costs of malaria 
treatment amount to 28% of households’ income amongst very low income 
households, and 2% amongst the rest (Ettling et al. 1994). Around 20-40% of 
outpatient visits in sub-Saharan Africa are meant for fever (Chima et al. 2003). 
The average total cost per malaria outpatient ranges between US$1.54 and 
US$4.49, and per inpatient admission between US$3.05 and US$21.29 in 
Tanzania (1999). Inpatient treatment for severe paediatric malaria cost US$68 
per admission in the district hospital in Kenya (Kirigia et al. 1998). The 
opportunity cost of healthy household members’ time spent treating or attending 
to the malaria patients or accompanying them for treatment in Africa is enormous. 
It is estimated that the average time lost per malaria episode for a sick adult 
ranges from 1 to 5 days (Chima et al. 2003). In Ethiopia 71% of adult cases were 
attended by a carer who stopped performing his or her own work (Cropper 1999). 
In Malawi the indirect cost of malaria amounted to 2.6% of annual household 
income (Ettling et al. 1994). Total annual value of malaria related productivity loss 
was 2-6% of GDP in Kenya and 1-5% in Nigeria (Leighton and Foster 1993).  
Malaria treatment and prevention expenses directly shouldered by African 
governments account for 40% of all public expenditures on health  (Chima et al. 
2003). Malaria is estimated to cost African countries about US$12 billion each 
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year in lost GDP (RBM 2003). The disease could be controlled for a fraction of 
that sum.  
 
Global public health initiatives in the fight against malaria 
Growing evidence of malaria devastation in Africa inspired commitments and 
initiatives from African governments and their international development partners. 
Roll Back Malaria (RBM) was the first of these initiatives on which all other 
frameworks that followed have been built. RBM was adopted in 1998 under the 
leadership of World Health Organization. The momentum had been built by 
commitments shown by African heads of states and governments at their 
meeting one year earlier in Abuja, the capital of Nigeria. At its beginning RBM 
laid down target of halving morbidity and mortality from the disease between 
2005 and 2010 and reducing it by additional 15% by 2015. RBM’s long term 
aspiration is total worldwide elimination of the disease. This commitment is 
supported by other important malaria control partners such as Bill & Melinda 
Gates Foundation and WHO.  
 
Malaria control efforts are equally shared by the Millennium Development Goals 
(MDGs). This is the poverty eradication programme initiated by the United 
Nations at its millennium assembly in 2000. It calls for a halt in the 
growing incidence of malaria by 2015 and a reversal thereafter. Goal 6 of the 
programme specifically categorise malaria control as one of its priority. However, 
even achieving goals 4 and 5 on reduction of under-five and maternal mortality 
especially for Africa require substantial gains in malaria control. Malaria infection 
is the biggest risk for under-five mortality in Africa. Equally important, malaria in 
pregnancy significantly contributes to maternal mortality.  
 
Application of combination of all malaria control strategies has been identified by 
all malaria control initiatives to be the cornerstone of malaria control goals. These 
are prompt recognition of symptoms and early treatment with effective medicines, 
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Insecticide treated nets (ITN), Indoor residual spraying, Intermittent Presumptive 
treatment during pregnancy and other vector control strategies. For interventions 
providing individual protection such as ITN, prompt recognition and early 
treatment with effective medicines and IPTP RBM has set a target of 80% 
coverage to population groups most vulnerable to transmission. These initiatives 
are largely funded through grants from Global Fund to fight AIDS, Tuberculosis 
and Malaria, Bill and Melinda Gates Foundation, US President’s Malaria Initiative 
(PMI) and the World Bank Malaria Booster Program.  
 
Key malaria control interventions 
In the preceding section I have stated that global malaria control initiatives have 
identified a combination of malaria control interventions for achieving the targets 
and overall control of the disease. In this section I will introduce each of these 
strategies 
Prompt diagnosis and early treatment with effective medicines 
 This is the primary malaria control strategy. Therapeutic measures are the only 
way that can clear parasites from humans. There is little evidence showing that 
malaria can be transmitted in any way other than sporozoite infective bites of 
mosquitoes. Sexual reproduction of malaria parasites that result in the presence 
of sporozoites in the mosquito salivary glands can only happen when this 
mosquito ingests gametocyte infected blood of human. Hence the logic is simple. 
Anti-malarial drugs that are strong enough to eliminate parasites in human body 
will starve mosquitoes of gametocytes that they need for malaria transmission to 
humans. Effective implementation of this strategy is undermined by many and 
complex challenges.  
 
 In malaria endemic settings, transmission to most people other than under-five 
children and pregnant women is asymptomatic. People are infected but they do 
not become sick and they do not seek treatment. Hence the benefits of 
medicines, of whatever effectiveness, do not reach them. Some studies have 
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shown that untreated adults are significant sources of gametocytes in their 
community (Githeko et al. 1992). However, other approaches consider silent 
infection as an advantage in the fight against malaria. It is seen to be an 
immunity that inhibits parasite multiplication and hence prevents the progression 
to severe disease and leads to resolution of fever and other symptoms (Day et al. 
1996; White 2004). Like other medicines, anti-malarial drugs can only reach their 
potential of parasite clearance if its toxic concentration reaches its optimal blood 
levels (Bloland et al. 2000). Patients need to observe full recommended dosing 
regimen. However, the need for timely malaria treatment has encouraged African 
government to adopt policies that have led to widespread availability of anti-
malaria drugs. Because access to health facilities in Africa is not so good, a 
significant number of people who perceive their conditions to be malaria and 
warrant malaria treatment their preferred source of medicines are retail outlets 
and left over medicines from family members and nearby friends (Deming et al. 
1989; McCombie 1996; Ruebush et al. 1995). These retail outlets encompass 
pharmacists, drug shop staff with minimal medical qualifications, and 
shopkeepers and street vendors with no medical training (Deming et al. 1989; 
Ejezie et al. 1990; Hamel et al. 2001; Ndyomugyenyi and Magnussen 1999; 
Yeneneh et al. 1993) (Hamel et al. 2001; Molyneux et al. 2002; Ndyomugyenyi 
and Magnussen 1999).  Hence health facilities are visited as an alternative and 
not the preferred choice for malaria treatment. Some estimates suggest that 
more than 70% of malaria cases are initially treated through this string of retailers 
(Amexo et al. 2004; Bloland 1999b). Breman has equated this condition with 
showing up of hippopotamus’s ears with largest and most dangerous part resting 
below water (Breman et al. 2001). It has been observed that self treatment for 
malaria is an exposure to inappropriate use of medicines in Africa (McCombie 
1996; Ruebush et al. 1995; Slutsker et al. 1994). These observations justify the 
conclusion that self treatment of malaria in Africa reduces medicine ability to 
clear parasite even for symptomatic malaria cases and hence preventing malaria 
chemotherapy from reaching their potential. An improper practice to malaria 
management in Africa is not limited to malaria patients who treat themselves at 
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home. Again, many governments in sub-Saharan Africa are not able to equip 
most of their peripheral health facilities with diagnostic equipments and 
sufficiently trained personnel. Along this problem, presumptive treatment of 
malaria patients is very common at these clinics. As a result some illnesses that 
share similar clinical symptoms with malaria are treated as malaria cases (Amexo 
et al. 2004; Redd et al. 1992). Under this confusion the risks of mistreating both 
malaria and non malaria cases and subsequent treatment failure are high. Given 
the familiarity of malaria the most likely scenario seems to treat non-malaria 
cases as malaria. This scenario can pose three risks. First, patients whose 
problems do not warrant anti-malarial drugs are given these drugs. It is argued 
that this practice is dangerous as people are exposed to selective drug pressure 
unnecessarily. This is especially the case when they remain at high risk of 
subsequent exposure to malaria while their drug levels are declining (Bloland et 
al. 2000). Second, problems that are responsible for health facility attendance are 
not appropriately managed and they remain the same. Sometimes lives are lost 
or the illness is unnecessarily prolonged with subsequent loss of income or 
productivity (Amexo et al. 2004). When the illness is cured through non-
conventional means (such as traditional practices- which is a common option in 
Africa) trust in modern health practices is eroded. Third, unnecessary prescription 
of anti-malaria drugs is one of the factors contributing to persistent stock outs at 
health facilities, a factor mentioned to scare away malaria patients from this 
encouraged source of treatment (McCombie 1996a). This situation poses a big 
challenge to ending malaria in Africa for whatever medicines that will be deployed. 
 
Life threatening symptoms of malaria such as convulsions, severe anaemia, 
respiratory distress, splenomegaly, dehydration, coma and impaired 
consciousness in African communities are confused with illnesses that according 
to many customs require traditional management. These symptoms are most 
common among children below five years. They may arise due to many factors. 
They include delayed treatment, inappropriate management at home or at the 
health facilities, treated with parasite resistant or substandard drugs or 
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inadequate dosage. These symptoms have widely been shown to be an 
exposure to hospital based treatment (McCombie 1996a; Mwenesi et al. 1995). 
As I have stated it also occurs that the illness deteriorates into this condition after 
failure of treatment obtained from health facilities. A study in Ifakara, Kilombero 
district, found that 60% of mothers and guardians had to visit traditional healers 
after visiting the hospital (Muela et al. 1998).  Hence treatment seeking for 
malaria is a complex process, but poses a big challenge to control interventions. 
  
Loss of anti-malarial medicines to parasite resistance is another problem 
undermining the effectiveness of malaria control using case management as an 
intervention of choice. Inappropriate treatments of malaria due to reasons that 
have been reported are largely responsible for the development and spread of 
parasite resistance to important malaria medicines. Chloroquine was the first line 
treatment for uncomplicated falciparum malaria throughout Africa. It was safe, 
efficacious, simple and affordable. Widespread parasite resistance to 
Chloroquine forced many countries to replace it with sulfadoxine pyremethamine 
(SP). Apart from sharing all the advantages of Chloroquine, SP is given as a 
single doze treatment. It has now suffered the same fate of Chloroquine. The 
emergence of parasite resistance to every single drug has heralded a disaster for 
malaria control in Africa. Drug resistance is the single largest challenge facing 
malaria community. It is reported that resistance to drugs has contributed 
substantially to the resurgence of malaria over the past 30 years (Baird 2000)  
 
Vector Control measures 
I have shown that mosquitoes are the necessary exposure to malaria 
transmission. Malaria transmission intensity is measured in terms of average 
mosquito sporozoite infectious bites a person receives for a specified period of 
time (Winkler et al. 1999) . In entomological terms, this phenomenon is called 
entomological inoculation rate (EIR). Areas experiencing 1 average bite per year 
are considered to be low transmission settings and those with 100 average bites 
high transmission settings (Geissbuhler 2008)   Hence when measures are taken 
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to reduce or remove these bites, malaria can definitely be reduced or eliminated. 
Different strategies have been found to achieve this goal. They include 
environmental measures that deny mosquitoes of their habitat.  
 
There are many successes that have been documented arising from 
implementing this measure (Hay et al. 2004). Environmental management 
through draining of swampland combined with improved housing and modern 
infrastructures have eliminated malaria in rich developed countries (Kitron and 
Spielman 1989). Another strategy that has proven to reduce EIR is an indoor 
residual spraying of insecticides.  Widespread use of 
dichlorodiphenyltrichloroethane (DDT) following malaria eradication program in 
the 1950s towards the end of 1960s is associated with massive malaria reduction 
in those areas that the program was implemented (Kitron and Spielman 1989; 
Sharma 2003). Reported vectors resistance to DDT and its subsequent adverse 
outcome to environment resulted to its abandonment (UNEP).  Insecticide 
Treated Nets (ITN) is the latest and biggest technology that has revived hopes of 
malaria control initiatives. Its efficacy, safety and effectiveness have well been 
documented (Abdulla et al. 2001; Binka et al. 1996; Lengeler 2004; Schellenberg 
et al. 2001b). ITN reduces malaria transmission by preventing mosquito and 
human contact, repelling them from households that residents sleep under these 
nets and killing them if they at all dare to land on the nets (Abdulla et al. 2005; 
Binka et al. 1998 ; Gimnig et al. 2003; Hawley et al. 2003; Howard et al. 2000; 
Killeen and Smith 2007; Maxwell et al. 2003). These characteristics of ITN have 
been shown to provide individual, household and community protection against 
infective mosquito bites (Abdulla et al. 2005; Gimnig et al. 2003; Killeen et al. 
2007). These multiple benefits of ITN are the main reasons that this intervention 
has emerged as the popular malaria preventive tool for Africa (Schellenberg 
2001). The biggest challenge for ITN is on how it can be translated into a 
protection for those most at risk of malaria transmission. This issue has incited a 
hot debate among malaria control stakeholders on the continent. A large-scale 
social marketing program of ITNs in rural Tanzania demonstrated that promotion 
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and distribution of ITN and insecticides involving both public and private sectors 
with subsidies targeted to pregnant women and young children can achieve high 
and sustainable ITN coverage for these biologically vulnerable groups that can 
save them from malaria related morbidity and mortality (Abdulla et al. 2001; 
Mushi et al. 2003; Schellenberg et al. 2001b; Schellenberg et al. 2003). Some 
arguments encourage free distribution of ITNs and insecticides to all at risk of 
transmission as the only way that can realise quick benefits of the technology 
(Curtis et al. 2003; Teklehaimanot et al. 2007). These arguments are concerned 
by costs that will hinder the ITNs full potential. Other arguments counter that 
frees distribution may kill market for ITNs and insecticide (Lines et al. 2003). A 
study in another rural part of Tanzania has demonstrated that voucher subsidies, 
commercial market and free distribution can collectively achieve sufficient and 
equitable ITN coverage without endangering one another (Khatib et al. 2008). 
Insecticide re-treatment was another setback to realization of full potential of 
ITNs. Insecticide that was available could be effective only for a certain period. 
Users have to retreat the nets once the previous one expires. Many studies 
observed that net re-treatment was low in many places in Africa. Development of 
technology that will make nets pre-treated at source with insecticide that can be 
effective during net’s life time may ultimately provide a solution to this problem. 
Many net manufacturers now produce long lasting insecticide treated nets. 
Another potential challenge for ITN intervention is the reported threat of 
mosquitoes resistance to most insecticides developed to kill them. Some studies 
are concerned by the long-term effects of reducing malaria transmission in case 
ITN realize its full potential (Snow et al. 1997). If countries succeed to eliminate 
malaria through massive ITN use, they would find it impossible to sustain 
(Feachem and Sabot 2008). Reduced malaria transmission has been associated 
with a suppression of immunity in areas that malaria transmission is endemic. 
This condition called rebound effects of malaria elimination has been observed in 
several studies of malaria chemoprophylaxis in children (Coulibaly 2002; 
Greenwood et al. 1995; Menendez et al. 1997; Saarinen et al. 1988; von Seidlein 
and Greenwood 2003). 
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Intermittent Treatment of malaria in pregnancy 
 Pregnant mothers are at particular risks of malaria transmission. The acquired 
immunity resulting from persistent malaria attacks in endemic areas is 
suppressed during this period. Their condition is more worrying as their infections 
can endanger their health and the health of their babies. Parasitimic pregnant 
mothers are associated with abortion, still birth, severe anaemia and delivery of 
low weight babies. It has been shown that low birth weight is an important risk for 
infant mortality. Severe anaemia is an exposure to delivery complications 
including death of a mother or a baby. This is why Millennium Development 
Goals 4 and 5 of reducing under-5 and maternal mortality rates by two-thirds by 
2015 can only be achieved if malaria in pregnancy is properly addressed. 
Intermittent preventive treatment (IPT) of pregnant women with a therapeutic 
course of an anti-malarial drug has shown a potential of protecting them against 
the adverse consequences of malaria. It has been observed that IPT use during 
pregnancy in high transmission areas can reduce placental parasitaemia and 
anaemia (Eijk et al. 2004; Parise 1998; Rogerson et al. 2000; Schultz et al. 1994 ; 
Shulman 1999). Thus, this strategy has been identified as another priority 
intervention for malaria control in Africa (Greenwood and Mutabingwa 2002; 
Parise 1998; Shulman 1999; Verhoeff et al. 1998).  Pregnant mothers in endemic 
transmission areas are required to be administered with IPT during their 
antenatal (ANC) clinics during pregnancy. The treatment need to be administered 
during second and third trimesters of pregnancy to achieve the potential of the 
intervention. Poor attendance to ANC visits are widely reported in Africa 
(Nydomugyenyi et al. 1998; Okonofua et al. 1992). Plenty of reasons have been 
raised to explain this behavioral pattern. They range from persistent drug stock 
outs, user fees charged for the services, long distance to health facilities, delays 
in clinic openings, long waiting time, unwelcome behavior of health workers and 
adverse reactions of the medicines (Mubyazi and Gonzalez-Block 2005; 
Nydomugyenyi et al. 1998). Whatever the reasons, however, if pregnant women 
do not make regular visits to clinics during their pregnancy there is little chance 
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that they can benefit from the intervention. Some studies have shown that the 
effectiveness of this strategy is also compromised by late clinic attendance. It is 
estimated that 25% of women attend ANCs for the first time during third trimester 
(WHO/UNICEF 2003).  In this circumstance it is difficult for women to take all the 
required two doses of protection. Very high client to staff ratios and inadequate 
supervision have bee also cited as other  significant barriers to effective delivery 
of IPT in Africa (Hill and Kazembe 2006). In Malawi, providers in some clinics 
may attend up to 75 pregnant women daily, resulting in poor quality of care, 
minimal (if any) counseling and long waiting times (Hill and Kazembe 2006). 
Another important challenge facing this program is emerging threat of parasite 
resistance of the commonly used drugs. 
 
Intermittent Treatment of malaria in infants 
Randomized Controlled Trials have demonstrated that this intervention strategy 
is as effective as ITN in its ability to protect young children from malaria 
transmission (Chandramohan et al. 2005; Schellenberg et al. 2006; Schellenberg 
et al. 2001a). It has been shown that it can be delivered through integration with 
the existing child health programs with limited additional costs It has not yet 
promulgated as a policy, but has a strong appeal to large part of malaria control 
community and is seriously considered to be included in malaria control armoury. 
 
Malaria control in Tanzania 
Tanzania lies just south of the equator between the great lakes Victoria, 
Tanganyika and Nyasa on one hand and the Indian Ocean on the other. With 
land area of about 945,000 square kilometers, Tanzania is the biggest country in 
East Africa. Its size is the same as Nigeria, bigger than California and a little 
smaller than France and Spain combined. Except for a narrow belt along the 900 
kilometers coast, most of Tanzania’s land lies above 200 meters altitude and 
much of the country is higher than 1,000 meters above sea level. Woodland, 
bush land and wooden grasslands, are the predominant types of vegetation. The 
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main climatic feature is the long dry spell from May to October, followed by a 
period of low rainfall, which is often concentrated into relatively few days of heavy 
showers. The main rainy season on the coast of the country is from March to 
May but there is a second season from October to December. Total rainfall 
increases towards the north. Around Lake Victoria rainfall is well distributed 
throughout the year but there is a peak during March to May. 
 
By 2008 estimates Tanzania has a population of about 49.7 million. The 
population density is 39 people per square kilometre. The majority of the 
population are highly scattered in rural areas. Poor road network is a serious 
problem to access to public services including malaria treatment and ANC 
attendance for pregnant women.  The country has over 100 ethnic groups, each 
one with its unique ethnic language. However, Kiswahili is the country’s only 
national language. Tanzania has a per capita income of US$.428. Its economy is 
dominated by subsistence farming of food and cash crops.  
 
Tanzania is characterized by endemic malaria transmission across the country. 
The number one infectious agent is Plasmodium falciparum.  It accounts for 96% 
of all infections in the country  (PMI 2007). However, there are some variations in 
the degree of indemnicity. Unstable seasonal malaria transmission characterizes 
approximately 20% of the country, while stable malaria with seasonal variation 
occurs in another 20%. The remaining malaria endemic areas in Tanzania (60%) 
are characterized as stable perennial transmission. The principal transmission 
vector is Anopheles gambiae (PMI 2007). 
 
An estimated 100,000 malaria deaths occur annually in the country, of which 
80% are in children under five years of age. Approximately 14-18 million clinical 
malaria cases each year are reported by public health services. Over 40% of all 
outpatient attendances are attributable to malaria. Prevalence of very high 
malaria transmission intensity is the main reason that Tanzania has been an 
important research site for a plenty of important malaria intervention evaluation 
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studies in Africa (PMI 2007). However, results from HIV and Malaria indicator 
survey conducted in the country in 2008 suggest that point prevalence of malaria 
parasitaemia is low as 0.4% in regions with low indemnicity and as high as 49% 
in areas with perennial and stable transmission (NBS 2008). 
 
Malaria control activities in Tanzania are coordinated by National Malaria Control 
Program (NMCP). It is a vertical program under the department of preventive 
services in the ministry of health and social welfare. NMCP – Tanzania strategies 
for malaria control are those adopted from RBM.  The goal of medium-term 
strategic plan for malaria in Tanzania (2008-2012) is reduction of all mortality and 
morbidity due to the disease by 80% by 2012. Strategies outlined to achieve this 
goal are: 1) appropriate management of febrile episodes in homes and health 
facilities  2) protecting pregnant women against malaria by using IPT; 3) vector 
control which includes encouraging populations at risk to sleep under ITNs and 
efforts to implement indoor residual spraying (IRS) in epidemic-prone areas; and 
4) prompt recognition and response to epidemics.    
 
Over fifty years the key malaria control strategy in Tanzania had been 
management of cases with Chloroquine (Mshinda 2000). It was safe, effective 
affordable and acceptable. It succumbed to similar challenges that have been 
reported under malaria control strategies. Parasites responded to pressures of 
those challenges by developing resistance that was reported throughout the 
country. Widespread resistance to Chloroquine made it worthless and was 
abandoned in 2001. SP was officially adopted to replace ill fated Chloroquine in 
2001. All acute uncomplicated malaria cases were required to be treated with SP. 
This drug could not last long in Tanzania. Pockets of its resistance had already 
been reported in some parts of the country even before its official use (Ronn et al. 
1996; Warsame et al. 1999). Its introduction was like monitoring its increasing 
resistance. In 2007, the government replaced SP with anti-malarial combination 
(ACT) composed of co-formulated artemether-lumefantrine (Arlu). The new policy 
discourages availability of Arlu in informal retail outlets. It is a measure taken to 
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address the risks of development and spread of parasite resistance. The 
government is promoting Accredited Drug Dispensing Outlets (ADDOs) to make 
up for the shortfall arising from restricted availability measures. It has been 
observed that about 40% of malaria patients in Tanzania are getting their 
treatment from informal retail outlets. The government is also getting ready to 
introduce rapid diagnostic tests (RDT) as a popular parasitological examination 
intervention aimed at reducing unnecessary treatment with anti-malarial drugs. 
This technology will serve two purposes. One, it will reduce the use of Arlu which 
is very expensive. We have seen that due to the lack of microscopes in most 
primary health facilities in Africa, malaria treatment is treated presumptively. 
Treatment that depends on clinical symptoms has been shown to be an important 
factor of high use of anti-malarial drugs in Africa. For very expensive drugs like 
Arlu, syndromic treatment will increase the risks of persistent stock outs. Two, 
reduction of unnecessary prescription of ACT will inherently shrink anti-malarial 
drug pressure in the community which has been shown to be an important 
exposure to drug resistance. In all, RDT and ADDOs will help protect resources 
and life of ACT.    
 
The National Malaria Control Program is promoting ITNs as its key vector control 
strategy.  Apart from its compliance with RBM, the program’s adoption of ITN has 
been encouraged by the fact that Tanzania has been a testing ground for both 
efficacy and effectiveness of the technology (Magesa 1991; Schellenberg et al. 
2001b). Tanzania embrace of ITN is responsible for government’s removal of 
string of taxes on netting materials which has turned the country into a hub of 
mosquito net industry in Africa. The government has also been encouraged by 
huge financial support it is getting from Global Fund to fight AIDS, Tuberculosis 
and Malaria (GFATM), Unites States President’s Malaria Initiative (PMI) and 
other multilateral and bilateral donors. In response to observations that had 
shown that Tanzania was not on trek to achieve RBM or PMI targets, NMCP and 
other malaria control partners introduced  pregnant women and infant ITN 
vouchers and under-five catch-up campaigns. These strategies had worked 
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elsewhere in increasing and sustaining equitable high ITN coverage to malaria 
vulnerable groups in Africa. In 2008, NMCP will implement nation-wide free 
distribution of long lasting insecticide treated nets and insecticide treatments. 
This program will be financed by US$ 59.8 million grant from GFATM (NATnets 
2008). This implementation will target all sleeping sites used by under-five 
children and pregnant women. Concerns are lingering over this operation on 
future market, long-tern availability of ITNs and future control of malaria. 
 
We have seen that preventive malaria treatment in pregnancy is another 
intervention that has been identified for malaria control consistent with RBM 
strategies. As a policy, every expectant mother is required to be administered 
with one dose of SP during his second trimester and another one in the third 
semester when attending ANC visits. Tanzania Demographic and Health Survey 
(TDHS) has shown that IPTP coverage is still low in Tanzania  (Tanzania 2005). 
It has been observed that one third of women do not make ANC visits until their 
sixth month or later. These figures suggest that there is little chance that these 
women can complete the required dosage of IPTP. It is shown that only 22% of 
pregnant women complete the two dose regimen of SP in Tanzania.  
 
Artemisinin-based Anti-malarial Combination Therapy: Potential 
and challenges 
The increasing loss to parasite resistance of anti-malarial mono-therapeutic 
drugs is an important risk to malaria control. This is more serious to Africa which 
bears the brunt of malaria burden. An experience from South East Asia has 
demonstrated that an approach that combines artemisinin derivatives and 
another anti-malarial drug can offer the solution (Bloland et al. 2000; Nosten et al. 
2000; Winstanley 2001). This strategy is based on a theory that the two 
chemotherapeutic agents have independent mechanisms of action and hence the 
probability that the parasites could confer resistance to both medicines 
simultaneously is very low (White 1998). This theory had been validated in the 
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treatment of tuberculosis, cancer, and HIV (Bloland et al. 2000). A randomized 
clinical trial conducted in Gambia, a single dose of sulphudoxine-pyremethamine 
combined with six dose regimen of artesunate taken for three days showed to 
resolve clinical symptoms and gametocytaemia (von Seidlein et al. 2000a). 
Another one carried out in Uganda involving similar course regimen of artesunate 
and amodiaquine demonstrated high activity against parasitaemia (Yeka et al. 
2005). Evaluations being conducted in Zanzibar and KwaZulu-Natal, South Africa, 
following implementation of multiple malaria control interventions demonstrated a 
dramatic decline of malaria transmission partly associated with adoption of 
artemisinin based anti-malarial combination therapy (ACT) (Barnes et al. 2005; 
Bhattarai et al. 2007). The collateral benefit that has been widely reported for 
artemisinin based ACT to malaria control is its strong action on gametocytes 
(Hallett et al. 2004; Price et al. 1996; Targett et al. 2001). This treatment targets 
the malaria parasite at the stage that its risks to continued cycle of transmission 
begins. This means that even if a parasite has survived the double action of the 
drugs, the probability that it will be transmitted is low. This impact on gametocyte 
carriage has not been shown from administration of monotherapeutic agents 
(Gogtay et al. 1999). 
  
All these are good reasons for malaria control movement to recommend the 
rolling out of artemisinin based anti-malarial combination therapy in Africa. 
However, there are serious concerns that the benefits of combination treatment 
could not be extrapolated to the whole of the continent (Bloland et al. 2000). First, 
malaria transmission intensity in Africa is different from those reported success 
stories. South-East Asia is a low transmission setting and people infected by 
malaria in such environment become symptomatically ill with no difference across 
age groups and are therefore more likely to seek some form of treatment (Alles et 
al. 1998; Luxemburger et al. 1996; Price et al. 1996). This condition increases the 
probability of most infections being treated with combination treatment. In Africa, 
where malaria transmission is largely stable and intense, most falciparum 
infected people especially older children and adults are asymptomatic and hence 
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they have little reason to seek treatment (Bloland et al. 2000). The majority of 
treatment seekers are young children and pregnant women whose immunity to 
malaria transmission is comparable to low transmission areas of South-East Asia. 
Older children and non pregnant adults comprise the bulk of the population and 
hence they could not only contribute to the maintenance of intense malaria 
transmission by acting as reservoirs of gametocytes but could also perpetuate 
resistance through the inappropriate use of medicines (Githeko et al. 1992).  
 
  Second, in South-East Asia and even in South Africa, public health care delivery 
is very strong. Access to health care facilities is very high and treatment provision 
is strictly subject to microscopic examination (Bloland et al. 2000).  Malaria 
treatment in most parts of Africa is largely based on clinical signs and symptoms 
of the disease that have been found to overlap with other illnesses.  
Consequently, people visiting health facilities are over- diagnosed and as a rule 
fever is treated as malaria (Font et al. 2001; Reyburn et al. 2007). It has been 
demonstrated that laboratory based diagnosis can reduce the use of anti-malarial 
drugs. It has been explained that this weakness can be a risk factor for 
development and intensification drug resistance in any strategy of malaria 
therapy (Bloland et al. 2000).  Limited access to health facilities and cultural 
beliefs and practices about malaria in Africa encourage treatment seeking 
practices that create conditions that are also conducive to emergence, 
intensification and spread of drug resistance. It is argued that poor practices 
about drug use result in inappropriate dosing that provides increased opportunity 
for parasites to be exposed to sub-optimal blood levels of either drug in the 
combination (Bloland et al. 2000).  
 
This study reports some findings of the evaluation that was conducted in 
Southern Tanzania to address those concerns. 
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Implementation and evaluation of ACT in rural Tanzania 
We implemented ACT in one rural district in Southern Tanzania.  Our evaluation 
involved another rural district with similar conditions. All health facilities in this 
district replaced SP monotherapy with SP+Art combination for routine malaria 
treatment. We first of all, evaluated health workers and patients’ compliance with 
the treatment regimen.  This was even important for combination treatment and 
in the setting that we conducted our implementation. The implementation would 
replace the then ongoing SP monotherapy which was a single dose regimen with 
the combination of SP+Artesunate whose regimen was composed of two 
separate drugs with many tablets, to be taken twice per day for three days. 
Artemisinin derivatives had been shown to resolve fever symptoms more quickly 
than SP (Nosten et al. 1994; Williams et al. 1999). So, there was a concern that 
quick fever disappearance before a regimen was completed would prompt the 
perception of being cured on the part of the patient and treatment would be 
stopped and the remaining drug would be saved for later use (McCombie 1996a)  
Hence compliance with treatment regimen was a legitimate outcome measure of 
the evaluation. This evaluation could also help the implementers to identify the 
risks of poor compliance and they would take measures to address them.  
 
The project was implemented in a way that the appropriate use of the 
combination would be maximized and their potential benefits would be realized. 
In that case their availability was limited to health facilities. I have already dwelt 
on the risks of retailers on misuse of medicines and subsequent development 
and spread of parasite resistance. However, we have seen how manifestations of 
malaria are perceived in many endemic transmission settings in Africa. And how 
these perceptions translated into treatment seeking. There was an understanding 
between the project and all health facilities providing this treatment that malaria 
treatment would be provided for free. Therefore, direct costs were not a barrier to 
treatment. However, several studies have demonstrated an association between 
delays in seeking malaria treatment from health facilities and physical distance 
between one’s residence and the health facility (McCombie 1996a). It was 
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interesting for the project to investigate whether that availability for free of 
effective medicines in the midst of other factors that were beyond our subject 
area had affected the choice of sources of treatment. 
 
This evaluation has provided an opportunity to observe long term trend for 
malaria parasitaemia across the population and anaemia prevalence for under-
five children in the two study sites. We thought that in documenting this dynamic, 
malaria community would have an opportunity to see the changes for the 
important indicators for malaria morbidity as a result of implementation of SP+Art 
combination for malaria treatment and rolling out insecticide treated nets. Our 
data also provide an opportunity to report on the effects of the implementation of 
ACT on treatment seeking pattern. The report will better inform the delivery 
strategies for ACT at the time that most countries in Africa are looking for right 
ways to take this medicine to scale. When ACT implementation was in progress 
in Rufiji district in 2004, the Tanzanian Red Cross implemented an ITN catch-up 
campaign for under-fives during the child vaccination period. It is widely believed 
that this is very important for achieving ITN coverage targets in Africa 
(Grabowsky et al. 2005; Grabowsky M 2007). Since the campaign occurred 
during the time that ITN voucher subsidies for pregnant women and market 
operation were already in place in the district, it provided an opportunity for our 
subsequent surveys to evaluate the potential of multiple ITN distribution systems 
for achieving high and equitable ITN coverage. It has been argued that the 
promised impact of ACT in Africa can only be established through detailed 
evaluation that includes an evaluation of INT coverage (Kachur et al. 2001a).  
This is the case because persistent malaria transmission due to lack of ITN 
protection is a potential risk exposure to an evolution of drug resistance (Hastings 
and D'Alessandro 2000; Molyneux et al. 1999). The next chapter will present 
malaria transmission intensity in the two study sites and major malaria control 
interventions in existence in each one of them. This will include the introduction 
of ACCESS project which is implemented in Kilombero/Ulanga site in order to 
  - 28 - 
identify and address most important risks to prompt and appropriate malaria 
treatment in the area (Hetzel et al. 2007a; Hetzel et al. 2007b; Hetzel et al. 2006). 
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PART II: OBJECTIVES AND METHODS
  - 34 - 
Chapter 2: Goal and Methodology 
 
 
Goal of the study 
This study was conducted to measure the impact of introduction of artemisinin 
based combination therapy (ACT) in health facilities for routine treatment at a 
district scale on parasite resistance and malaria transmission in African 
communities.   
 
Objectives of the study 
1. Assess the changes in the prevalence of malaria parasitaemia before 
and after the introduction of ACT 
2. Describe and analyse the changes in treatment seeking practices for 
malaria episodes before and after the introduction of ACT 
3. Evaluate malaria patients’ adherence to ACT provided at the health 
facilities 
4. Describe and analyse the contextual factors other than ACT that could 
influence malaria transmission. 
 
Study area 
The basic evaluation for this study was conducted within the frame of the Rufiji 
and Ifakara Demographic Surveillance System sites (Mwageni E 2002; 
Schellenberg 2001) in southern Tanzania between 2001 and 2006. However, the 
district-wide implementation of SP and Artesunate was conducted only in Rufiji 
district between 2003 and 2006.  
 
The Rufiji DSS site operates in Rufiji District, Coast Region about 178 kilometres 
south of Dar es Salaam - Tanzania’s commercial centre. The site covers a land 
area of 1,813 square kilometers in the flood plain of Rufiji River. There are 
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80,842 people in the sites residing in 17,287 households in 31 registered villages. 
Ifakara DSS site covers Kilombero and Ulanga Districts in Morogoro Region. It 
covers the flood plain of Kilombero River which about 460 kilometres south west 
of Dar es Salaam. The Ifakara DSS site has a population of 74,200 individuals 
and 17,050 households in 25 registered villages.  Households in both sites are 
highly scattered with estimated population density of 25 people/km2. The area is 
characterized by a poor road network; there are no paved roads, and some 
villages are cut off for parts of the year as a result of flooding. There is limited 
opportunity for mixing of population between the two DSS sites due to the 
presence of the Selous Game Reserve along their common border.  Most local 
houses have mud walls and thatched roofs, but up to one-third have brick walls 
and corrugated iron roofs. Most families have a second house known as a 
shamba house (farmhouse), in Rufiji they call them Dungus (traditionally built 
shelters on stilts that suit the flooding conditions), where they stay during the 
planting and harvesting seasons. The most common sources of water are 
shallow wells, open wells, and rivers. During the time of our surveys the sites had 
no telephone service, and most houses had no electricity. The sites have an 
overall mean altitude of less than 500 meters. Their vegetation is mainly formed 
of tropical forests and grassland. They are characterized by hot weather 
throughout the year and two rainy seasons; short rains (October to December) 
and long rains (February to May). The average annual precipitation in the area is 
between 800 to 1000 millimeters. 
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Figure 2: A map of Tanzania showing the location of the study areas 
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Figure 3: DSS sites of Ifakara and Rufiji 
 
 
The population in the study area has a wide mix of ethnic groups. The largest 
ones are Wandamba, Wapogoro, Wabena, Wambunga, and Wahehe in Ifakara 
and Wandengereko, Wamatumbi, Wanyagatwa, and Wamakonde in Rufiji. 
Muslims constitute the majority of Rufiji population followed by Christians and the 
opposite is the case for Ifakara. Like the rest of Tanzania, Kiswahili is the lingua 
franca in the area. People are predominantly peasants who are largely growing 
rice, maize, bananas, vegetables and cassava. Some residents are involved in 
fishing while others in small-scale commercial activities such as selling wood 
products (e.g. timber, furniture and carvings). 
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Malaria endemnicity 
The study site is characterized by essential features for intense and perennial 
malaria transmission with some seasonal fluctuation. It reaches its peak during 
the season of long rains during the months of May and June. Malaria related 
mortality accounts for most deaths reported by the health system and in the 
community (De Savigny et al. 2008; Schellenberg et al. 1999). The main parasite 
specie is Plasmodium falciparum. An. gambiae complex and An. funestus are the 
prime vectors involved in the transmission cycle. The estimates in the area for 
1990s  suggest that there were 200 – 300 infective mosquito bites per person per 
year (Schellenberg et al. 1999).  Of late, there has been a sharp decline to 42 
and 120 bites thanks to increased ITN use (Smithson 2009).  However, like any 
area with stable endemnicity, young children and pregnant women have the 
highest risks of malaria transmission in the study site.  
 
Interventions other than IMPACT that would have affected 
malaria situation in the study area  
As outlined in chapter one there are other major interventions that had been and 
are still being implemented in the study area.  These interventions are outlined in 
the following sections.  
 
Tanzania Essential Health Interventions Project (TEHIP) 
It essentially strengthened the Council Management Team (CHMT) in Rufiji 
District to develop health plans that would respond to priority local health needs. 
The principle behind this intervention was that health status among poor 
communities could be improved by redirecting resources to cost effective 
programs that addressed health problems that matter most in those communities.  
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Based on health needs assessment conducted by the project, it was discovered 
that in the district malaria claimed virtually a third of life years lost due to 
premature deaths and disability.  Two thirds of the burden was shouldered by 
children less than five years. This evidence together with the tools developed by 
TEHIP, led to a more effective approach in health planning through an 
intervention addressable disease-burden based approach of priority setting and 
resource allocation. More specifically, it convinced the CHMT to subsequently 
increase financial allocation for malaria in their plans from 5 to 25% (De Savigny 
et al. 2008) . Furthermore, much more interventions that were implemented 
targeted to malaria and children less than five years such as IMCI (Schellenberg 
et al. 2004b).  This development could obviously make a difference in malaria 
control efforts in Rufiji district including the DSS area.  
 
ACCESS   
It is a program that was designed to identify and address factors that were 
important for malaria patients’ access to appropriate and effective treatment in 
Kilombero and Ulanga Districts. Previous studies had demonstrated that timely 
treatment seeking for malaria had been undermined by common local 
perceptions that associated symptoms of severe malaria with an illness not 
amenable to chemotherapy (Hetzel et al. 2007). In one of its surveys, ACCESS 
found out that more than three quarters of malaria cases in the community was 
being treated with recommended anti-malarial medicines (Hetzel et al. 2008b). 
An important challenge to malaria case management was poor adherence with 
the recommended dose by patients regardless of medicine delivery source 
(Hetzel et al. 2008b). The program was introduced during the time that malaria 
patients in the study area were being routinely treated with sulfadoxine-
pyrimethamine consistent with the national policy for malaria treatment in 
Tanzania that existed at the time.    
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Several research studies have associated informal drug outlets with the rising 
loss of malaria medicines to parasite resistance (Bloland et al. 2000). The 
government confronts this risk exposure by limiting drug availability to formal 
delivery points. ACCESS had observed that that restriction had denied access to 
appropriate treatment to the poorest of the poor and malaria patients from the 
remote hamlets of the villages (Hetzel et al. 2008a). Interventions carried out by 
ACCESS targeted these important risk factors to access to prompt and 
appropriate malaria treatment. Important elements of the intervention were a) 
strengthening knowledge and awareness of malaria and promote prompt and 
appropriate treatment seeking from reliable sources; b)capacity building on the 
part of health workers in order to be able and willing to deliver quality malaria 
treatment; and c) supporting efforts to introduce and build capacity for Accredited 
Drug Dispensing Outlets (ADDO) (Hetzel et al. 2007) . 
 
Integrated Management of Childhood Illnesses (IMCI)   
The IMCI strategy was initially implemented only in Rufiji and Morogoro rural 
districts (1997 – 1998) due to TEHIP. It was then extended to Ulanga and 
Kilombero districts (2002 onwards). The program was designed to improve child 
health and development through combined delivery of essential child health 
interventions by addressing leading causes of childhood mortality in the area 
such as pneumonia, diarrhea, malaria, measles, and malnutrition. These 
conditions were responsible for more than three quarters of post-perinatal deaths 
for under-fives (Schellenberg et al. 2004b).  Its elements were improvements in 
case management, improvement in health systems and improvements in family 
and community practices.  
 
Kilombero Insecticide Treated Nets program (KINET) 
KINET implemented a large-scale social marketing program of insecticide-treated 
nets in Ifakara DSS site between 1997 and 2000 (Schellenberg et al. 1999). The 
program identified and promoted Zuia Mbu (a Kiswahili name which means 
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preventing mosquitoes) for all treated bed nets and insecticide sachets that it 
supplied. Prices for Zuia Mbu products were subsidized by the program and they 
were targeted to under-five children and pregnant women. In parallel to 
distribution of subsidized insecticide treated nets and insecticide sachets, the 
program implemented an extensive information, education and communication 
campaign intended to create, expand and sustain community demand for this 
malaria control intervention. The commodities were supplied through both public 
and private sales agents. Following KINET and based on its impact and 
experience, a national program aimed at going to scale introduced voucher 
subsidies targeting pregnant women and their newly born babies in some areas 
of the country such as Rufiji district between 2004 and 2006. Free distribution to 
small children was also implemented during the vaccination campaign in 2005 by 
the Red Cross (Khatib et al. 2008). ITN use increased to 36% in Ifakara and 30% 
in Rufiji across all ages (chapter 5) 
 
Methodology 
The detailed description of data collection and analysis are described is found in 
each chapter. At this stage, only the broad approaches are outlined below:  
Household surveys  
The primary sampling units for the study were households. They were sampled 
from a database of households compiled and updated by each of Ifakara and 
Rufiji DSS sites. The questionnaires were administered to each individual who 
had been listed in the sampled households. The respondents were equally asked 
to provide drops of blood which was used for examining malaria parasitaemia 
status and hemoglobin level for children less than five years. Household socio-
economic status was estimated using indicator variables administered to heads 
of households or their substitutes. The interviews were conducted subject to 
informed consent obtained from the study participants or caretakers of small 
children.  
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The questionnaires were originally written in English but were translated in 
Kiswahili and then back translated in English. They were comprehensively 
pretested. The translation was necessary as all interviews were conducted in 
Kiswahili, the lingua franca in the study community. These same questionnaires 
were used for data collection in all survey years of the study. They were 2001, 
2002, 2004, 2005 and 2006.  
 
The interviewers were recruited from the local community. They were form four 
leavers at minimum and most of them had been involved in data collection 
activities conducted by DSS in the area. They were trained for seven days on 
how to administer the questionnaire and collecting blood specimens. After the 
training, they were initially asked to pilot among themselves. They were then sent 
to the field to practice the questionnaires for couple of days. Interviewers who 
could not pass all these tests were dropped. Most interviewers who participated 
in the initial survey were recruited again in the subsequent survey years. 
 
Adherence study 
Patients’ adherence with sulfadoxine-pyrimethamine combined with artesunate 
was assessed in 2003 in the Rufji DSS site. Consecutive outpatients diagnosed 
with uncomplicated malaria and prescribed SP plus AS were approached for 
enrollment at the under 5 clinic and the general outpatient clinic before arriving at 
the dispensing unit to receive treatment. Patients residing in a catchment area of 
nine census-enumerated villages surrounding the health facility were considered 
eligible and provided consent for enrollment.  
 
Two data collectors were recruited among form four leavers from the local 
community. They were identified from the team that the project used for 
household surveys. They were trained on all procedures to do this job. These ata 
collectors observed encounters between dispensing health workers and all study 
patients in the dispensing unit and recorded key health worker behaviors on a 
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structured observation checklist. This included noting the exact number of tablets 
delivered under direct observation for the 
first dose and the number dispensed to the patient for follow-up doses on the 
second and third days. In addition, they noted what counseling advice dispensing 
health workers provided. Data collectors also recorded demographic data and 
any additional diagnoses other than malaria. Before being discharged home, 
detailed information about the household location 
was obtained from all enrolled patients. Enrolled participants were randomly 
assigned to three study arms: observation of dispensing encounter with no 
follow- up; observation of dispensing encounter with follow-up at home after 24 
hours; and observation of dispensing encounter with follow-up at home after 48 
hours.  
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ABSTRACT 
Artemisinin-containing antimalarial combination therapies are recommended to 
confront drug resistant P. falciparum malaria. Among the questions surrounding 
whether these complex multi-dose treatments will be practical is to what extent 
patients complete the recommended doses. Combination therapy through 
coadministration of sulfadoxine/ pyrimethamine plus artesunate was introduced 
as first-line treatment for uncomplicated malaria in one district. Interventions to 
optimize correct use were implemented as well. We observed 453 patient 
encounters at one health facility and recorded key practices as health workers 
dispensed the combination. A total of 253 patients were followed up at 24 or 48 
hours. Complete adherence measured at 48 hours reached 75.0%, based on 
self-report and tablet counts. This is substantially better than reported elsewhere 
and compares favorably with intervention studies to optimize adherence to 
chloroquine. Counseling about what to do if a patient vomits appears to have 
been an independent risk factor for nonadherence. 
 
INTRODUCTION 
Antimalarial drug resistance undermines efforts to reduce the public health 
burden nearly everywhere malaria transmission occurs. Chloroquine, once highly 
effective against the parasites that cause the disease, has become compromised 
as drug-resistant P. falciparum parasites have become increasingly prevalent in 
recent decades (Bloland et al. 1998). Resistance to other drugs including 
sulfadoxine-pyrimethamine, mefloquine, and quinine, has followed closely behind. 
In 2 refugee camps in Thailand, the use of an artemisinin-containing combination 
treatment (ACT) with artesunate and mefloquine has been linked to halting the 
progression of antimalarial drug resistance(Price et al. 1997) and reducing 
malaria transmission (Nosten et al. 2000). Advocates of this approach(White et al. 
1999) and international organizations (World Health Organization 2001) have 
recently called for ACT strategies to  be deployed without delay across Africa, 
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where the greatest burden of malaria-related morbidity and mortality occurs. 
Although there are limited data and experience to guide the introduction of ACTs 
in Africa, there is consensus evolving that the threat of unchecked resistance to 
the currently used drugs is too urgent to delay their deployment. At least two 
large-scale evaluations are underway to document the effect of ACTs in African 
settings (Kachur et al. 2001b). However, these research outcomes may be years 
away and potential short-term advantages of ACTs are already evident from in 
vivo efficacy studies on the continent (Adjuik et al. 2002; International Artemisinin 
Study Group 2004; von Seidlein et al. 2000b). So far, the cost of artemisinin-
containing drugs, (Snow et al. 2003) their limited global supply, (Duffy and 
Mutabingwa 2004) and some lingering concerns about safety, (Bloland et al. 
2003b) have slowed their wide-spread deployment. As unprecedented resources 
for malaria control start to become available,(World Health Organization and 
UNICEF 2003) these barriers, too, are being lowered.  
 
When chloroquine was efficacious, patterns of drug use evolved that were often 
far from ideal. Because it was relatively affordable and safe, health officials 
widely recommended chloroquine for anyone who might have malaria (World 
Health Organization 1986). Over decades the drug became pervasive - used with 
or without diagnostic confirmation, obtained easily from formal health facilities as 
well as unregulated sources in the community, and taken with little or no attention 
to complete, appropriate dosing. As a result, a number of studies in Africa 
documented that health workers’ and consumers’ adherence to recommended 
indications and doses were poor, (McCombie 1996b) and may have contributed 
to the intensification and spread of resistant parasites (Basco 2004). More 
recently, efforts to improve the use of chloroquine have demonstrated promise. 
Providing the drug through trained community health workers, (Kidane and 
Morrow 2000; Pagnoni et al. 1997) training shopkeepers (Marsh et al. 1999b) 
and wholesalers, (Tavrow et al. 2003) and dispensing prepacked unit doses 
(Yeboah-Antwi et al. 2001) with improved labeling, (Agyepong et al. 2002) have 
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all been shown to enhance the proportion of patients who receive and complete 
the recommended dose.  
 
Before ACTs are widely deployed in Africa, it will be useful to revisit experiences 
gained with chloroquine and other monotherapies and carefully consider how the 
new treatments can be used judiciously. Health officials will have to balance the 
need to make ACTs widely accessible with concerns about minimizing their 
inappropriate use (Bloland et al. 2003b). In particular, it may be possible to adapt 
approaches used to improve complete adherence with chloroquine to the more 
complex combination regimens. As part of a multidisciplinary evaluation of ACT, 
the Rufiji District Council Health Management Team (CHMT) introduced 
sulfadoxine-pyrimethamine (SP) plus artesunate (AS) as first line treatment for 
confirmed or suspected malaria at all registered health facilities in the district. 
Shortly after introducing the new treatment, we undertook a follow-up study to 
assess patient adherence.   
 
MATERIALS AND METHODS 
This study was completed as part of the Interdisciplinary Monitoring Project for 
Antimalarial Combination Therapy in Tanzania.* The objective of this study was 
to measure adherence shortly after introduction of SP + AS for routine treatment 
of malaria and to assess factors that might influence this proportion. Informed 
consent was obtained from all adult participants and from parents or legal 
guardians of minors. The study protocol was reviewed and approved by the 
institutional review boards of the US Centers for Disease Control and Prevention 
                                                 
*The Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania 
(IMPACT-Tz) is a multiyear implementation research evaluation project that rests on a 
collaborative platform comprising the US Centers for Disease Control and Prevention, Ifakara 
Health Research and Development Centre, the National Institute for Medical Research, Muhimbili 
University College of Health Sciences, the London School of Hygiene and Tropical Medicine 
(UK), and the Tanzanian Ministry of Health, including its National Malaria Control Programme, the 
Tanzania Essential Health Interventions Project, the Adult Morbidity and Mortality Project, and the 
Council Health Management Teams of Rufiji, Morogoro, Kilombero and Ulanga Districts. 
IMPACT-Tz is primarily supported by funding from the United States Agency for International 
Development. 
  - 50 - 
(CDC) and the Ifakara Health Research and Development Centre (IHRDC). In 
addition, this research has been approved by the National Medical Research 
Coordinating Committee of the Tanzania Commission on Science and 
Technology.  
 
The study was completed in Rufiji District, a rural community in Tanzania’s Coast 
Region. Plasmodium falciparum malaria transmission is intense and perennial 
with some seasonal fluctuation (Mwageni et al. 2002). The district population of 
203,102 (National Bureau of Statistics United Republic of Tanzania 2002) is 
served by 56 hospitals, health centers, and dispensaries operated by the 
government of Tanzania, or officially registered non-governmental organizations. 
One of these, Ikwiriri Health Centre was chosen for this evaluation because of its 
central location and high utilization.  
 
Beginning in January 2003, 2 to 5 senior health workers from each of the 56 
health facilities in the district were invited to participate in one-day training 
workshops conducted by the Rufiji District CHMT. These participatory training 
workshops introduced the principle of ACT and informed health workers to 
prescribe SP+AS as first-line treatment for confirmed or suspected cases of 
uncomplicated malaria in all patients 2 months of age or older. The trainers 
adopted four age-stratified 3-day dosing regimens that had been validated 
elsewhere(International Artemisinin Study Group 2004) and are illustrated in 
table 1.  
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Table 1. Age-specific dosing schedule for sulfadoxine-pyrimethamine (SP) plus 
artesunate (AS), Rufiji District, 2003 
Age group SP tablets§ 
at time 0 
AS tablets† 
At time 0 
AS tablets†  
at 24 hours 
AS tablets† 
at 48 hours 
2 to 11 months 
1 to 5 years 
6 to 13 years 
14 years and older 
0.5 
1 
2 
3 
0.5 
1 
2 
4 
0.5 
1 
2 
4 
0.5 
1 
2 
4 
§SP tablets contain sulfadoxine 500 mg and pyrimethamine 25 mg. 
†AS tablets contain artesunate 50 mg 
 
 
The training employed simple job aids including a dosing guide, wall chart, and 
dispensing envelopes with age-appropriate dosing instructions written in Swahili 
and illustrated for illiterate clients. Participants were trained to administer the first 
dose of SP+AS under direct observation and to counsel patients and their 
caretakers about how to take the remaining 2 days of AS to complete the course 
of therapy. They were also trained to counsel patients and caretakers on how to 
prevent malaria and when to return if treatment failed or the patient developed 
additional symptoms. The training methodology included lecture as well as 
participatory question and answer sessions and clinical case studies. Health 
workers left the training workshops with supplies of drugs and supporting 
materials and were directed to train the remaining workers at their respective 
facilities. This cascade training approach is commonly used to introduce new 
clinical guidelines and other health system innovations.  
 
Following introduction of SP+AS at all health facilities in the district, we enrolled 
patients treated with this combination at Ikwiriri Health Centre between 4 
February and 27 March 2003. Consecutive outpatients diagnosed with 
uncomplicated malaria and prescribed SP+AS were approached for enrollment at 
the under 5 clinic and the general outpatient clinic before arriving at the 
dispensing unit to receive treatment. Patients residing in a catchment area of 9 
census-enumerated villages surrounding the health facility were considered 
eligible and offered consent for enrollment. Patients with severe or complicated 
infections, those requiring inpatient treatments, individuals with known sensitivity 
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to sulfa drugs, pregnant women, and infants less than 2 months of age were 
excluded from receiving the combination and were ineligible for the study. 
 
Two data collectors were recruited from the local community. These data 
collectors observed encounters between dispensing health workers and all study 
patients in the dispensing unit and recorded key health worker behaviors 
(identified in Table 5) on a structured observation checklist. This included noting 
the exact number of tablets delivered under direct observation for the first dose 
and the number dispensed to the patient for follow-up doses on the second and 
third days. In addition they noted what counseling advice dispensing health 
workers provided. Data collectors also recorded demographic data and any 
additional diagnoses other than malaria. Before being discharged home, detailed 
information about the household location was obtained from all enrolled patients.  
 
Enrolled participants were randomly assigned to three study arms:  observation 
of dispensing encounter with no follow-up; observation of dispensing encounter 
with follow-up at home after 24 hours; and observation of dispensing encounter 
with follow-up at home after 48 hours. This design was selected to minimize 2 
sorts of bias that might be expected to affect participants’ behavior. Including a 
no follow-up group introduced some uncertainty, so that patients and caretakers 
may have been less prone to social desirability bias. Including the follow-up at 24 
hours, before the treatment should have been completed, allowed us to 
characterize practices such as completing the entire course ahead of time, which 
might be overlooked by assessing adherence only once, at or beyond 48 hours. 
Data collectors, patients, caretakers, and health workers were blinded to the 
study arm on the day of enrollment.  
 
At the end of each enrollment day, data collectors reviewed the random 
assignment of patients, identified those selected for follow-up visits, and planned 
these visits for the following days. If one of the data collectors observed the 
dispensing encounter with a patient or caretaker the other data collector was 
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assigned to visit that household in follow-up. With the assistance of local leaders, 
they visited patients at home on the selected follow-up day and completed a 
standardized questionnaire. The follow-up questionnaire included questions 
about household education, construction and ownership of specific assets. These 
were included to characterize each household’s relative socioeconomic status. 
Knowledge of the recommended dose was determined by structured interviews 
with patients themselves or their primary caretaker for patients under 12 years of 
age. Adherence with recommended follow-up doses was assessed by self-report 
and corroborated by physically counting the remaining number of tablets 
available at the time of the visit.  
 
Data entry forms were checked in the field by a single investigator (RAK). Forms 
were then sent to the central data processing unit. Data were double-entered 
using MicroSoft FoxPro (Seattle, USA). Data managers developed automated 
routines to identify discrepancies and execute some simple consistency and 
range checks and these were resolved with reference to the original data forms. 
The investigators cleaned and analyzed data using Stata, version 7 (College 
Station, USA).  
 
We defined adherence by self-report as any case where the patient stated they 
had taken all of the tablets as recommended by the time of the follow-up visit at 
either 24 or at 48 hours. Adherence based on tablet counts was defined as any 
case where the expected number of remaining tablets was physically counted. 
Cases in which the health worker dispensed an incorrect number of tablets to 
begin with were excluded. Finally a composite assessment of adherence was 
made using information from both the self-report and tablet counts. Cases where 
tablet counts were correct but where the reported timing of doses was incorrect 
and cases where the reported timing of the doses was correct but did not match 
tablet counts were considered non-adherent using this composite measure. 
Complete adherence was assessed by this composite measure only for patients 
visited at 48 hours. Patients randomized to the 24-hour follow-up arm were not 
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considered in calculating complete adherence, but are presented for comparison 
and were included in the analysis of factors associated with adherence (on the 
basis of the composite measure).    
 
An index of socioeconomic status was derived from a list of 42 household asset 
variables using principal components analysis. This technique has been validated 
in a previous cross-sectional survey in the study area (Armstrong-Schellenberg et 
al. 2003). Statistical comparisons across 2 variables were made using the chi 
square or Fisher exact test as appropriate. The chi square test for linear trend 
was used to examine statistical associations between the asset index and 
outcome variables. Multivariate logistic regression analyses were performed to 
examine the simultaneous influence of multiple potential predictors on patient 
knowledge and adherence outcomes. Findings with P < 0.05 were considered 
statistically significant. 
 
RESULTS 
Figure 1 illustrates the enrollment, randomization and follow-up of study patients. 
A total of 453 consenting patients were enrolled:  222 from the under 5 clinic and 
231 from the general outpatient clinic. Among these 20 (4%) were excluded from 
further analysis because the health worker dispensed an incorrect number of 
tablets. Seventeen of these patients were dispensed too few tablets and only 3 
received more than the recommended number. Table 2 includes information on 
the patients assigned to each of the study groups. There were no statistically 
significant differences observed between the study groups with respect to age, 
gender, or the likelihood of receiving the correct number of tablets. Although 
additional diagnoses other than malaria were rare, participants enrolled in the 48-
hour follow-up arm were significantly more likely than other participants to have 
been diagnosed with a respiratory infection. 
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Figure 1:  Enrollment, assignment and follow-up of patients in SP+AS adherence 
study, Rufiji District, 2003 
222
231
recruited from 
under 5 clinic
recruited from 
general OPD 
453
enrolled and 
observed in 
dispensing unit
randomization
154
136
143
ARM 1:  NO Follow-up
ARM 2:  Follow-up at 24h
ARM 3:  Follow-up at 48h
125
11
assigned
assigned completed
lost to F/U
assigned
128
15
completed
lost to F/U
20
dispensed 
the wrong
dose
 
Two hundred fifty-three (90.7%) of the participants randomized to receive a 
follow-up visit were successfully identified in the community and completed the 
study. There was no statistically significant difference in loss to follow-up 
between the study arms. The 29 patients lost to follow-up did not differ 
significantly from those who completed follow-up visits with respect to age, 
gender, additional diagnoses, nor village of residence. 
 
Household Asset Index. Of the 42 household asset ownership questions asked, 
15 were eliminated from further analysis because they were reported too 
frequently or too infrequently to adequately characterize variation in the sample. 
The analysis retained 27 principal components. The first principal component 
explained 21% of the variability in these variables and gave the greatest weight 
to households constructed with cement walls (0.30), using electric lighting (0.30), 
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having a dirt floor (-0.29) or relying on locally made oil lamps (-0.29). An overall 
index of socioeconomic status was generated using these weights for each of the 
27 principal components. One common way of using this information is to divide 
the participants into wealth quintiles based on their asset index scores. 
Comparing wealth quintiles between participants followed up at 24 hours and at 
48 hours produced a chi-square test for linear trend of 0.02, which demonstrates 
no statistically significant difference in socioeconomic status between participants 
assigned to the 24 and 48 hour follow-up study arms (see Table 2). 
 
 
Table 2. Characteristics of clients enrolled in SP+AS adherence study, by study arm, 
Rufiji District, 2003 
 No visit 
n=162 
24-hour visit 
n=143 
48-hour visit 
n=148 
Point of recruitment 
   Under 5 clinic 
   General OPD 
 
76    (46.9%) 
86    (53.1%) 
 
74    (51.7%) 
69    (48.3%) 
 
81   (54.7%)  
67   (45.3%)  
Gender 
   Male 
   Female 
 
64    (39.5%) 
98    (60.5%) 
 
58    (39.2%) 
90    (60.8%) 
 
57   (39.9%)  
86   (60.1%)  
Additional diagnoses 
   Respiratory Infection 
   Gastroenteritis 
   Skin Infection 
 
9    (  5.6%) 
5    (  3.1%) 
0 
 
10    (  7.0%) 
7    (  4.9%) 
3    (  2.1%)  
 
18*   (12.6%)  
4    (  2.7%)    
4    (  2.7%)  
Dispensed the correct 
number of SP and AS 
tablets for age 
 
 
154    (95.1%) 
 
 
136    (95.1%) 
 
 
143   (96.6%) 
Completed follow-up 
visit 
 
Not applicable 
 
125    (91.9%) 
 
128   (89.5%) 
Socioeconomic status 
by wealth quintile 
   Most poor 
   Very poor 
   Poor 
   Less poor 
   Least poor    
 
 
 
 
 
 
Not applicable§ 
 
 
22 (19.8%) 
20 (18.0%) 
27 (24.3%) 
23 (20.7%) 
19    (17.1%) 
 
 
24   (21.8%) 
23   (20.9%) 
17 (15.5%) 
21   (19.1%) 
25   (22.7%)    
  *Differs significantly from no visit and 24-hour follow-up arms (Ο2df=1=3.92, p=0.05). 
§Socioeconomic data were not collected from patients randomized to the no follow-up study arm. 
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Patient knowledge and adherence. Nearly all patients or caretakers in both 
study groups accurately reported knowledge of the correct dose (Table 3). 
Adherence was measured by self-report, tablet counts, and a composite of the 
two, as defined above. In general adherence was higher among patients visited 
at 24 hours compared with those in the 48-hour follow-up group. This difference 
was statistically significant. The most restrictive measure of complete adherence 
is that from the composite measure in the 48-hour group:  75.0%. Among the 45 
patients who were non-adherent in either study arm, a reason for this could be 
assessed in 42 cases (see Table 4). Finishing all the tablets in fewer than 48 
hours was the most common reason for non-adherence and 12 of the 16 cases 
to which this applied were children. 
  
Table 3. Patient/caretaker knowledge and adherence to SP+AS by self-report, tablet 
counts, and composite measure at 24 and 48 hours, Rufiji District, 2003 (n=253) 
Parameter At 24 hours At 48 hours 
Total number completing follow-up 
Patient/ caretaker knowledge of correct dose 
Adherent by self-report only 
Adherent by tablet count only 
Adherent by composite measure of self-report & count 
125    
118    (94.4%) 
115    (92.0%) 
113    (90.4%) 
112    (89.6%) 
128 
115    (89.8%) 
98∞ (76.6%) 
105    (82.0%) 
  96‡   (75.0%) 
∞Differs significantly from estimate at 24-hour follow-up, (Ο2df=1=11.79=0.001). 
‡Complete adherence. This estimate differs significantly from the comparable estimate at 24-hour 
follow-up, (Ο2df=1=9.48, p=0.002). 
 
 
Table 4. Reasons for non-adherence to SP plus artesunate, Rufiji District, 2003. (n=45) 
Reason for non-adherence Frequency (percent) 
Finished total course of doses in fewer than 48 hours 
Discontinued prematurely because the patient’s condition improved 
Skipped one dose 
Intended to take the dose later in the day 
Took too few tablets with one or more dose 
No reason identified 
16 (35.6%) 
12 (26.7%) 
6 (13.3%) 
5 (11.1%) 
3 (  6.7%) 
3 (  6.7%)  
 
 
Predictors of adherence. In bivariate analyses, adherence was not associated 
with patient’s age, gender, or home village. As noted above, adherence was 
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slightly but significantly higher among patients visited at 24 hours. There was 
also a statistically significant association between adherence and knowledge of 
the correct dose. Adherence was not statistically associated with the education of 
the patient’s head of household or with socioeconomic status as defined by 
household wealth quintiles. All of the patients diagnosed with gastroenteritis were 
adherent, and those patients diagnosed with a skin infection were less likely to 
adhere to the recommended doses. There was no statistical association with 
adherence for those diagnosed with acute respiratory illness or for those with no 
diagnosis other than malaria. 
 
During their training, health workers learned to use simple job aids for prescribing 
and dispensing the SP+AS and for counseling patients and their caretakers on 
how to complete the dose. As part of the study, data collectors observed the 
encounter between each patient and the dispensing health worker and recorded 
key behaviors (see Table 5) in order to examine whether any were associated 
with patient adherence. At one extreme, none of the observed dispensing health 
workers mentioned that the treatment was for malaria, informed the patient about 
possible side effects, or advised the patient to sleep under an insecticide treated 
net. On the other hand, in nearly all interactions, the health worker dispensed the 
correct number of tablets (96.5%), gave the first dose under direct observation 
(98.9%) and correctly advised the patient how to take the remaining AS tablets at 
24 and 48 hours (98.9%). These behaviors occurred either too frequently or too 
infrequently to be evaluated effectively as predictors of adherence. Among the 
behaviors that were observed more intermittently, most were not statistically 
associated with adherence. Paradoxically, only health workers’ advice about 
what to do if the patient vomited was associated with adherence (Ο2df=1 = 5.28, P 
< 0.022), and this association was negative.  
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Table 5:  Potential factors associated with adherence to SP+AS, Rufiji District, 2003 
Potential factor  Adherent 
n=208 
nonadherent 
n=45 
Odds ratio Adjusted OR 
Demograhic factors 
 Patient’s age < 5 years 
 Male patient 
 Assigned to the 48-hour study arm 
 Patient / caretaker knowledge of correct dose 
 
110 (52.8%)   
82 (39.4%) 
96 (46.2%) 
207 (99.5%) 
 
25 (55.6%) 
18 (40.0%) 
32 (71.1%) 
26 (57.8%) 
 
0.90 (0.47, 1.72) 
0.98 (0.50, 1.89) 
0.35 (0.17, 0.70) 
151.27 (11.81, 1937.21) 
 
1.11 (0.54, 2.28) 
dropped 
0.38 (0.18, 0.80) 
not included 
Socioeconomic status 
 Head of household has had formal education 
 Household asset index in the poorest 2 quintiles 
 Household asset index in the least poor 2 quintiles 
 Household asset index as a continuous variable 
 
119 (65.4%) 
73 (35.2%) 
75 (36.1%) 
-- 
 
20 (51.3%) 
16 (35.6%) 
13 (28.9%) 
-- 
 
1.79 (0.89, 3.63) 
0.98 (0.50, 1.92) 
1.39 (0.68, 2.81) 
-- 
  
-- 
-- 
-- 
1.05 (0.92, 1.20) 
Additional diagnoses 
 Acute respiratory illness 
 Gastroenteritis 
 Skin infections 
 None 
 
16 (7.7%) 
11 (5.3%) 
3 (1.4%) 
179 (86.1%) 
 
6 (13.3%) 
0       
4 (8.9%) 
36 (80.0%) 
 
0.54 (0.20, 1.48) 
undefined 
0.15 (0.03, 0.71) 
1.54 (0.67, 3.55) 
 
 dropped 
not included 
dropped 
dropped 
Dispensing health worker behaviors 
 Told the patient the drugs were intended to treat malaria 
 Told the patient about possible side effects 
 Advised the patient to sleep under an insecticide-treated net 
 Told the patient the names of the drugs 
 Advised the patient to return if condition worsened 
 Asked if the patient had questions 
 Told the patient what to do if he/she vomits after a dose 
 Used the wall chart or dosing guide to explain dose 
 Told the patient the drugs were for one person only 
 Told the patient to take the medicines with food or water 
 Dispensed tablets with the age appropriate dosing envelope 
 Told the patient to take 2 daily doses of artesunate at home 
 Gave the first dose under direct observation 
 
0 
0 
0 
1 (0.5%) 
1 (0.5%) 
1 (0.5%) 
9 (4.3%) 
58 (27.8%) 
79 (38.7%) 
88 (42.3%) 
188 (90.4%) 
207 (99.5%) 
207 (99.5%) 
 
0 
0 
0 
0 
3 (6.7%) 
1 (2.2%) 
6 (13.3%) 
13 (29.0%) 
19 (42.2%) 
18 (40.0%) 
39 (86.7%) 
45 (100.0%) 
45 (100.0%) 
 
undefined 
undefined 
undefined 
undefined 
0.07 (0.01, 0.67) 
0.21 (0.01, 3.51) 
0.29 (0.10, 0.87) 
0.95 (0.47, 1.95) 
0.84 (0.43, 1.61) 
1.10 (0.57, 2.12) 
1.45 (0.54, 3.85) 
undefined 
undefined 
 
not included 
not included 
not included 
not included 
dropped 
dropped 
0.29 (0.09, 0.90) 
dropped 
dropped 
dropped 
dropped 
not included 
not included 
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We fitted logistic regression models to examine the influence of various predictive 
factors associated with knowledge of the correct dose and with adherence. 
Because patient knowledge and adherence were closely correlated (Ο2df=1 = 
86.08, P < 0.001), we modeled each outcome individually and did not include 
knowledge as a predictor of adherence. Models developed for patient or 
caretaker knowledge was similar to those developed for adherence outcomes 
and are not presented here. Independent variables included at the start of the 
stepwise logistic regression included demographic characteristics such as age 
and gender; the household asset index as a continuous variable; additional 
diagnoses of acute respiratory illness, skin infections, or none but malaria; and 6 
of the dispensing health worker behaviors that occurred with enough frequency to 
be assessed as predictors of adherence. Diagnosis of acute respiratory infection 
was dropped for colinearity. The health worker behaviors included in the 
modeling process were counseling the patient about what to do if he/she vomited 
a dose, advising them to return if the condition worsened, asking if the patient 
had questions, recommending that the medications be taken with food or water, 
advising that the medications were for one person only, using the dosing wall 
chart, and dispensing the medicines in the age-appropriate dosing envelope. 
Most of these along with gender and the additional diagnosis variables were 
eliminated in fitting the multivariate model.  
 
Because they were related to the study design, variables for age less than 5 
years and study follow-up arm were retained at each step. In the final fitted model 
only being counseled about what to do if the patient vomited was an independent 
risk factor for nonadherence. Being randomized to the 48-hour follow-up arm was 
also statistically associated with nonadherence. Socioeconomic status as 
measured by the household asset index approached statistical significance in the 
multivariate model despite no observable trend in bivariate analysis. Interaction 
terms between socioeconomic status, follow-up arm, age less than 5 years and 
being counseled about vomiting were tested but did not achieve significance nor 
improve the fit of the model. 
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DISCUSSION 
This study provides useful information about how complex multi-dose 
combination therapy regimens for malaria may be delivered in ways that can 
optimize adherence and appropriate drug use. Because patients observed at 24 
hours may not have gone on to complete their third dose, we estimated complete 
adherence only among the patients randomized to the 48-hour follow-up arm.  
Based on a composite of self reports and tablet counts, 75.0% of patients were 
completely adherent to the recommended regimen. This is substantially higher 
than the only other published follow-up study of patients treated with SP+AS, in 
which only 39% of patients were considered adherent based on a similar 
definition combining tablet counts and caretaker’s history.(Depoortere et al. 2004) 
This estimate is also encouraging because it comes immediately after the 
intervention was introduced at health facilities and can be expected to improve as 
health workers and their clients become more familiar with and confident in the 
new treatment. It is equally possible, however, that after the new treatment 
becomes routine, health workers and consumers may eventually feel comfortable 
enough to stray from recommended practices and adherence could decline.  
 
While there is clearly room for improvement, this estimate also compares 
favorably with data from studies examining adherence to 3-day regimens of 
chloroquine monotherapy in Africa. Without interventions to improve complete 
adherence, cross sectional studies have demonstrated that only a small fraction 
of children received adequate doses of chloroquine. Estimates of the proportion 
of children who received complete treatment with chloroquine ranged from 30% 
in Togo, (Deming et al. 1989) to 12% in western Kenya,(Ruebush et al. 1995) 
and 7% in Malawi (Slutsker et al. 1994). These cross-sectional estimates can be 
difficult to compare across studies and are quite dissimilar from the methodology 
employed in our assessment. We found one published study of adherence to 
chloroquine that used a design similar to ours, with observation at the dispensing 
unit and follow-up at home. This study in Uganda showed that among children 
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who were dispensed a correct dose of chloroquine, complete adherence after 3 
days was only 38% (Nshakira et al. 2002).    
 
Intervention studies to improve adherence with chloroquine are more numerous. 
In one Nigerian study complete adherence reached 73.3% after introducing a 
combination of illustrated dosing instructions and health worker counseling 
(Okonkwo et al. 2001). In Ghana, complete adherence reached 91% after an 
intervention promoting prepackaged tablets (Ansah et al. 2001). Also an 
intervention based on training shopkeepers in coastal Kenya improved the 
proportion of children treated with an adequate dose of chloroquine to 65.2% 
(Marsh et al. 1999b). We achieved comparable results after introducing 
counseling and packaging innovations alongside the new SP+AS combination 
therapy. We have no estimate of what complete adherence might have been 
without these additional intervention elements in place.  
 
It is disappointing that few of the observed health worker behaviors could be 
evaluated as independent factors predicting adherence. In general, dispensing 
health workers provided recommended doses very accurately but failed to adopt 
many of the other training elements related to counseling or advising patients. It 
is not possible from this data to say if this is a trend throughout the district or if it 
is limited to the small number of health workers observed at this one health 
facility. The senior health workers who took part in the CHMT’s training 
workshops are primarily responsible for diagnosis and prescribing, and their 
activities were not directly observed. By conducting the study at the dispensing 
unit we were able to observe only the practices of more junior dispensing health 
workers. From their observed behavior, the training cascades appear to have 
been only partially effective at this site. Busy supervisors may have abbreviated 
the training or dispensing health workers may have interpreted their role narrowly 
and opted to leave discussion of diagnosis and potential side effects to their 
senior colleagues. The project team plans to reemphasize these elements in 
future training workshops that will include dispensing health workers as well as 
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prescribers. Additional studies are planned to observe prescribers’ encounters 
with patients and document dispensing health workers’ behavior at other sites in 
the coming months. 
 
The surprising association between counseling about what to do when a patient 
vomits and nonadherence is difficult to explain. Perhaps health workers only 
emphasized this issue to patients who appeared more ill or complained of 
vomiting and who were less likely to complete the follow-up doses for those 
reasons. Alternatively, in the absence of any information about side effects, 
patients and caretakers may have been less likely to complete the follow-up 
doses if they feared the medicine might cause them to vomit. None of the 
participants reported vomiting after taking the SP+AS. More information about 
community perceptions of the SP+AS is needed and qualitative assessments are 
currently underway in Rufiji District to assess these. 
      
One particularly concerning practice was identified in 16 cases, 12 of them 
children. These patients took all their follow-up doses but were considered non-
adherent because they or their caretaker reported having taken the entire course 
of treatment in fewer than 48 hours. In dose-finding studies for artesunate 
monotherapies, the same dose was more effective delivered over 5 days 
compared with 3 days (Li et al. 1994) and still more effective delivered over 7 
days compared to 5.(Bunnag et al. 1991) Indeed, 3 dose artesunate 
monotherapy has been considered insufficiently efficacious to recommend, and 
when used in combination with other antimalarial drugs, a minimum of 2.5 days 
has been demonstrated efficacious.(Barradell and Fitton 1995) This is particularly 
important because the SP+AS combination may be only partially effective if the 
total dose is compressed into fewer than 48 hours. Even if the immediate clinical 
outcome is unaffected, shortening the duration of therapy may increase the 
theoretical potential to select for SP-resistant parasites. 
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Our findings regarding socioeconomic status, as measured by the household 
asset index, as a predictor of adherence, are also equivocal. In a previous study 
that included parts of the same district, Armstrong-Schellenberg, et 
al.(Armstrong-Schellenberg et al. 2003) demonstrated that children from 
relatively poorer households were taken to health facilities less promptly and 
were less likely to receive appropriate care than children from wealthier 
households. However, they also demonstrated that once the children received 
treatment, adherence was not affected by socioeconomic status. 
 
Our study has several other important limitations that should be considered. First 
of all, the study was completed at a single health facility over a relatively brief 
period. It may not be representative of the situation in the rest of the district or at 
other times of year. More importantly, simply enrolling patients in a follow-up 
study may alter their adherence to treatment. We attempted to minimize this by 
including an arm with no follow-up and by blinding the clients, data collectors, 
and health workers to the randomization on the day of enrollment. We also 
visited participants only once, so that a visit at 24 hours would not affect a 
participant’s behavior at or before 48 hours. It is still possible that social 
desirability bias may have led us to overestimate adherence. It is equally possible 
that some patients would have taken their 24- and 48-hour follow-up doses later 
in the day but had not done so by the time the investigators arrived at their 
homes. Indeed 6 of 45 nonadherent patients indicated that they intended to 
complete the recommended dose later that same day. In this way we may have 
underestimated adherence. In the future we plan to assess adherence 
retrospectively through population-based studies that will provide more 
representative data that may be less prone to these biases.  
 
Admittedly, self-report and tablet counts are imperfect measures of adherence. A 
measure based on drug levels in biological samples would be more robust. 
Unfortunately such an approach would be more invasive as well. Because the 
first dose of SP+AS was given under direct observation, there would be little 
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point measuring blood levels of the sulfa component. Furthermore, blood levels 
of the artemisinin compounds would be difficult to interpret without accurate 
information about the timing of the follow-up doses and the samples, which would 
make such a study more difficult to execute in a rural African community where 
timepieces are not commonplace. In addition, such assays require expensive 
equipment and reagents that may be unsuitable for field conditions.(Edwards 
1994) 
 
Nonetheless, these findings were immediately useful to the project team and 
contributed to efforts to improve the coverage and delivery of SP+AS 
combination therapy in Rufiji District. They directly led to development of a health 
communication campaign in the district, which emphasizes the need to take the 
tablets once a day for 3 days in a row, even if patients feel better before then. 
These findings also prompted us to revise our training and supervision plans for 
health workers in facilities throughout the district. As the SP+AS combination 
therapy becomes more widely used in Rufiji District and experience with it 
accumulates, we are hopeful that adherence will improve further. Repeat 
assessments are planned in early 2004. 
 
The findings have relevance beyond our study site as well. At the very least they 
reinforce some of the lessons learned about how to improve malaria treatment 
during the chloroquine era. Interventions such as health worker training, simple 
job aids, patient counseling, directly observed therapy, and unit dose packaging 
with illustrated instructions can be easily adapted to combination therapies for 
malaria. By carefully introducing these elements along with the SP+AS, we were 
able to achieve reasonable levels of adherence right from the first weeks. This 
will be particularly important as other ACTs become more broadly used 
throughout the region. Public health officials, pharmaceutical regulatory bodies, 
and manufacturers should begin now to make sure these simple interventions are 
incorporated as new drugs are deployed in both the public and private sectors.   
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Artemisinin-containing combination therapy has yet to be shown to reduce 
transmission or stall resistance in African settings; it will be an expensive and 
ambitious undertaking to extend this approach where resources and 
infrastructure are badly constrained; but the strategy may represent the best 
hope for confronting the crisis facing malaria treatment in the region. Whether 
this hope has a chance of being realized will depend on optimizing the delivery of 
and adherence to these new treatments. Our findings demonstrate that it is 
possible to achieve reasonably high levels of adherence to a 3 day treatment with 
SP+AS delivered through existing health systems. More experience measuring 
adherence is needed so that practical, standardized approaches that will facilitate 
comparisons across different settings can be devised.         
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Abstract 
Background  
Tanzania has a well-developed network of commercial ITN retailers. In 2004, the 
government introduced a voucher subsidy for pregnant women and, in mid 2005, 
helped distribute free nets to under-fives in small number of districts, including 
Rufiji on the southern coast, during a child health campaign. Contributions of 
these multiple insecticide-treated net delivery strategies existing at the same time 
and place to coverage in a poor rural community were assessed. 
Methods  
Cross-sectional household survey in 6,331 members of randomly selected 1,752 
households of 31 rural villages of Demographic Surveillance System in Rufiji 
district, Southern Tanzania was conducted in 2006. A questionnaire was 
administered to every consenting respondent about net use, treatment status and 
delivery mechanism.  
Findings  
Net use was 62.7% overall, 87.2% amongst infants (0 to1 year), 81.8% amongst 
young children (>1 to 5 years), 54.5% amongst older children (6 to 15 years) and 
59.6% amongst adults (>15 years). 30.2% of all nets had been treated six 
months prior to interview. The biggest source of nets used by infants was 
purchase from the private sector with a voucher subsidy (41.8%). Half of nets 
used by young children (50.0%) and over a third of those used by older children 
(37.2%) were obtained free of charge through the vaccination campaign. The 
largest source of nets amongst the population overall was commercial purchase 
(45.1% use) and was the primary means for protecting adults (60.2% use). All 
delivery mechanisms, especially sale of nets at full market price, under-served 
the poorest but no difference in equity was observed between voucher-
subsidized and freely distributed nets.  
Conclusions  
All three delivery strategies enabled a poor rural community to achieve net 
coverage high enough to yield both personal and community level protection for 
  
 - 73 - 
the entire population. Each of them reached their relevant target group and free 
nets only temporarily suppressed the net market, illustrating that in this setting 
that these are complementary rather than mutually exclusive approaches. 
 
Background 
It is estimated that malaria is responsible for 515 million clinical attacks worldwide, 
70% of these events are concentrated in Africa (Snow et al. 2005). Young African 
children and pregnant women bear brunt of the burden and at least 18% of 
childhood mortality on the continent is due to malaria (WHO/UNICEF 2005). 
More encouragingly, the fact that insecticide-treated nets (ITN) prevent malaria 
has been irrefutably documented (Fegan et al. 2007; Lengeler 2004). The Roll 
Back Malaria Partnership and Millennium Development Goals (MDG), therefore, 
aim to achieve 80% ITN use amongst pregnant women and children below five 
years of age in Africa, while the US President’s Malaria Initiative (PMI) is even 
more ambitious, aiming for 85% use amongst these same population categories 
(2006; MillenniumProject 2005; RollBackMalariaPartnership 2005). However, 
there is growing consensus that this important intervention will only achieve its 
full potential to prevent malaria if at least one third of the entire population sleeps 
under ITN, as well as the vast majority of the most vulnerable groups such as 
pregnant women and young children (Binka et al. 1998; Hawley et al. 2003; 
Killeen et al. 2007b; Maxwell et al. 2002; WHO 2007). This is because residents 
are protected by not only personal use of ITNs but also by the community-wide 
effect that their neighbours nets have on mosquito populations. Much as there is 
increasing call for rapid and sustained achievement of high ITN coverage 
targeting entire populations (Hawley et al. 2003; Howard et al. 2000; Killeen et al. 
2007b; Maxwell et al. 2002), including non-vulnerable adults and older children, 
delivery mechanisms by which this noble goal can be achieved are still actively 
debated [14-16].  Until recently, public debate has largely focussed upon the 
comparative merits of free and market-based strategies for deploying ITNs 
(Magesa 1991; Magesa et al. 2005; Schellenberg et al. 2001b; Skarbinski et al. 
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2007).  While spirited debate over such a potentially important public health issue 
is welcome (Roberts 2007), it carries a risk that policy makers and donors will 
perceive a false dichotomy between free and market-based strategies for 
promoting ITNs. If so, they may overlook an important opportunity to implement 
complementary strategies for rapidly increasing and maintaining high levels of 
ITN ownership and use. 
 
Tanzania has been a front-line country for testing the efficacy (Magesa et al. 
1991) and effectiveness (Schellenberg et al. 2001a) of ITNs , and has developed 
a nationwide implementation strategy based on in-country experience (Magesa et 
al. 2005). Notably, it was also the first country in which a large-scale cost-sharing 
scheme for distributing subsidized ITNs was evaluated and shown to improve 
child survival under programmatic conditions (Schellenberg et al. 2001a). When 
Tanzania first decided to take ITNs to scale, mosquito nets were almost 
exclusively supplied through commercial retailers bundled with insecticide-
treatment kits subsidized by the public sector (Magesa et al. 2005). In 2004, the 
National Malaria Control Programme (NMCP) introduced a voucher subsidy for 
pregnant women as part of a nation-wide programme to prevent malaria by 
enhancing coverage of pregnant women and the young children who share their 
sleeping spaces during and after the pregnancy. In addition to this national 
programme, NMCP also assisted a small number of districts including Rufiji on 
the south-central coast to distribute free bundled nets to under-fives through a 
child health campaign in mid-2005 with support from partner organizations 
including UNICEF and the Tanzanian Red Cross (Skarbinski et al. 2007).  
 
The Interdisciplinary Monitoring Project for Anti-malarial Combination Therapy 
(IMPACT) had been implementing and evaluating effects on drug resistance of 
sulphadoxine-pyrimethamine (SP) combined with artesunate (SP+Art) for routine 
treatment of malaria in Rufiji district southern Tanzania between 2000 – 2006 
(Fuller and Lurry 1977).  Annual household surveys, which included net 
ownership, use and source, were conducted as a routine part of this study. The 
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coincidence of the unsubsidized market, voucher subsidies and free distribution 
happening at the same time and place created an opportunity to evaluate the 
interactions between these major and apparently inconsistent ITN delivery 
strategies – the primary focus of the ongoing debates. This paper presents 
results from this assessment and show that these combined strategies 
complemented rather than competed with each other. 
 
Methods 
 
Study area and population 
Rufiji district lies in southern Tanzania about 178 km south of Dar es Salaam, the 
country’s primary commercial centre and biggest city (Figure 1). The 
Demographic Surveillance System (DSS) site in which this survey was conducted 
is composed of 31 villages with an area of 1,813 km2 and population of about 
85,000 people (Mwageni E 2002). It is low-lying (<500 m above sea level) and 
most of its surface area lies within the fertile flood plain of Rufiji river. Rufiji 
typically experiences a long rainy season between February and May and a 
shorter, less intense one from October to December. The majority of the 
population in this area belongs to Ndengereko tribe. Other important ethnic 
groups include the Matumbi, Nyagatwa, Ngindo, Pogoro and Makonde. Islam is 
the predominant religion in the community and commonest language spoken in 
the area is Kiswahili, consistent with the rest of the country. The main economic 
activity is subsistence farming of crops such as rice, cassava, oranges, mangoes, 
cashews, papayas and coconuts. Farms are often located some distance from 
the family home and rely on periodically flooded alluvial soils. Residents often 
stay in seasonal makeshift dwellings at farms, especially during rice growing 
season of February to July. A significant number of people are also engaged in 
artisanal fishing, charcoal burning, logging, carpentry and small scale trading. All 
study villages are located on the northern side of Rufiji River along Dar-es-
salaam – Kilwa highway (Figure 1). Most of these villages are quite isolated in 
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the interior of the district and are connected to the highway by unpaved roads 
that are often impassable during long rains. Most houses have wood-framed mud 
walls with thatched or corrugated roofs. Common water supplies are communal 
boreholes, natural spring or river water, and hand-dug wells. 
 
Malaria is among the biggest health problem in the area reported by health 
system and perceived by local community (Schellenberg et al. 2004b).  It is 
caused largely by Plasmodium falciparum, primarily transmitted by Anopheles 
gambiae, Anopheles arabiensis and Anopheles funestus vector mosquitoes. 
Transmission in this area is categorized as intense and perennial (Mwageni E 
2002).   Prompt recognition and timely treatment with sulphadoxine-
pyrimethamine (SP) combined with artesunate and the distribution of ITNs to 
young children and pregnant women in particular were the two priority malaria 
control measures in the district at the time.  
  
Nets have been available in most retail shops existing in these villages for more 
than a decade, typically bundled with insecticide. Residents use these retailers to 
buy their nets and insecticide as they do for other household goods. The normal 
retail price for a 6 foot x 6 foot net at the time of the study was 6,000 Tanzanian 
shillings (equivalent to US$ 4.65) and a sachet of insecticide sold at TShs 500 
(equivalent to 40 US cents). A voucher subsidy for nets to be used by pregnant 
women and their newly born babies was introduced under the Tanzania National 
Voucher Scheme (TNVS) in the study area at the end of 2004. The value of the 
voucher was fixed at TShs 3,250 (equivalent to US$ 2.5) and vouchers were 
issued to pregnant mothers attending clinic by Reproductive and Child Health 
staff. The voucher recipient was then entitled to purchase an insecticide treated 
net at reduced cost by presenting the voucher and paying the price difference to 
the contracted retailers.  Distribution of nets free of charge to under-five children 
was implemented through the national child vaccination campaign in July 2005 
lasting for three days. Every child below five years presenting for vaccination 
against measles, treatment of helminths and vitamin A supplementation received 
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a free bed net bundled with an insecticide treatment sachet. Additionally, a small 
number of interviewees received nets at no cost from a variety of sundry sources, 
including small-scale donations, relatives and friends. 
 
 
Figure 1. Location of the study area. 
 
 
Study design and data collection 
A survey on which this paper is based was conducted between June and August 
2006. A total of 2,000 households were randomly selected from DSS Household 
Registration Books (HRB), of which 1,752 were completed with 6,331 
respondents. In each visited household, every registered and consenting 
member who was available on the day of the visit was interviewed using a 
structured questionnaire written in Kiswahili. The questions were pre-tested in 30 
households before being finalized and deployed. Data collectors had been used 
before for similar activities conducted by the project in 2001, 2002, 2004 and 
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2005, but were nevertheless retrained for three days for this particular survey. 
Questions written in the questionnaires included date of interview, sex of the 
respondent, net ownership, whether respondent had slept under net the night 
preceding the interview, how was the net obtained, whether the net had been 
treated before, and when was it last treated together with characteristics of 
houses and households including asset ownership. Dates of birth of household 
members were already available in the DSS data base. Each completed 
questionnaire was inspected by the study supervisor who selected a sample of 
forms from each week’s for authentication in the field. Ethical approval for the 
study was obtained from Centres for Disease Control and Prevention (CDC) of 
the USA and the Ifakara Health Research and Development Centre, the Medical 
Research Coordination Committee of the National Institute for Medical Research 
and Tanzania Commission on Science and Technology of Tanzania. 
 
Data management and analysis 
All completed forms were sent to a central data processing unit and double 
entered using Microsoft (Redmond, WA) FoxPro® software. Data managers 
developed automated routines to identify discrepancies and executed some 
simple consistency and range checks which were resolved by referring to original 
data forms. All data were cleaned and analysed using STATA Version 9.0 
(STATA Corporation). This programme was used in computing frequencies, in 
doing Chi square tests and calculating 95% Confidence Intervals for examining 
the existence of real differences in net use, sources used to get the nets and 
treatment of nets for different population groups described in this paper. A wealth 
index was constructed using principal component analysis for each household 
based on members owned assets and housing characteristics as described in 
detail elsewhere (Fuller and Lurry 1977). Concentration curves were plotted and 
concentration indices calculated by assigning these asset index scores to their 
respective households’ members (Fuller and Lurry 1977; Kakwani et al. 1997; 
Wagstaff 2005) using Microsoft Excel software. 
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Results 
Net use varied across population age groups (Pearson X2 (d.f. =12) = 839.9253; 
P<0.001) with excellent targeting of high coverage to the most vulnerable groups 
(Table 1). Infants (0-12 months) had the highest proportion of net use in the study 
area, with >85% using any net the previous night, exceeding the targets of the 
Millennium Development Goals (MDG), Roll Back Malaria (RBM) and the US 
President’s Malaria Initiative (PMI) for ITN use (2006; MillenniumProject 2005; 
RollBackMalariaPartnership 2005).  It is true that these targets have only been 
exceeded in terms of any net and that approximately half of these were not 
recently treated. However, long-lasting insecticide formulations (Kiszewski et al. 
2007; Teklehaimanot et al. 2007) for factory pre-treatment or bundling with all 
nets made in Tanzania were introduced as of March 2007 so these documented 
levels of coverage with any net should practically translate such achievements 
into  de facto ITN coverage. Coverage of young children exceeded the MDG and 
RBM targets but not the PMI target for protection of under-fives with usage rates 
exceeding 80% (2006; MillenniumProject 2005; RollBackMalariaPartnership 
2005).  While coverage of adults and older children was lower than that of the 
vulnerable groups that were targeted with the bulk of the subsidies, overall 
coverage of the entire population as a whole was more than sufficient to achieve 
major communal reduction of malaria transmission (Hawley et al. 2003; Killeen et 
al. 2007b)  if new long lasting treatments could make most nets insecticidal for 
their lifetime.  Although only short-lived insecticide formulations were available at 
the time, approximately one third of the population used a recently treated net in 
2006 so appreciable communal suppression is likely to have been achieved 
(Killeen and Smith 2007; Killeen et al. 2007b).  It is expected that such invaluable 
community-level benefits to be improved upon by the superior ITN technologies 
which are now available (Bates et al. 2004; Sachs and Malaney 2002) and further 
gains in coverage as these delivery systems become better established.  
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Table 1. Net usage the previous night in Rufiji District during 2006 household survey by age 
group. 
Usage category Infants 
Young 
children 
Older 
children Adults Overall 
N 484 732 2024 3098 6338 
 
 
    
Proportion use (% 
(95% CI)) 
No nets 
12.8  
(10.1, 16.1) 
18.3  
(15.7, 21.3) 
45.6  
(43.4, 47.7) 
40.4  
(38.6, 42.1) 
37.4  
(36.2, 38.6) 
Untreated netsa 
38.2  
(34.0, 42.6) 
42.0  
(38.4, 45.6) 
30.0  
(28.0, 32.0) 
31.0  
(29.4, 32.7) 
32.5 
 (31.3, 33.7) 
Recently treated netsb 
49.0  
(44.5, 53.4) 
39.8 
 (36.3, 43.4) 
24.5  
(22.7, 26.4) 
28.6  
(27.1, 30.3) 
30.2  
(29.0, 31.3) 
Any netc 
87.2  
(83.9, 89.9) 
81.8  
(78.7, 84.3) 
54.5  
(52.3, 56.6) 
59.6  
(57.9, 61.4) 
62.7  
(61.4, 63.8) 
a Untreated nets are defined as nets that were not treated at all or were not treated within six months of the 
interview date 
b Recently treated nets means nets that were treated within the last six months since the day of interview 
c Any net means nets including both untreated and recently treated nets. 
 
It is noteworthy that proportional contribution of various net delivery systems 
varied across age groups (Pearson X2 (d.f. =20) = 844.8122; P<0.001) and each 
delivery system appears to have supported its appropriate target group (Table 2). 
The majority of nets used by infants were obtained through the national voucher 
scheme, indicating this important vulnerable group is effectively targeted by this 
system for delivering heavily subsidized nets through commercial distributors. 
Nets provided at no charge to the user during the child vaccination campaign 
supported half of the net coverage achieved amongst young children and over a 
third of coverage amongst older children. The commercial market, with no 
subsidy other than bundled insecticide, was the biggest source of nets in the 
population as a whole. Nets obtained at full market price accounted for almost 
two thirds of use by older children and adults who must be covered if community-
level suppression of transmission is to be achieved (Killeen et al. 2007b).  Clearly 
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this mix of delivery mechanisms reaching different segments of the population 
demonstrates that all three delivery tactics are complementary rather than 
competitive.  Rapid attainment of high net coverage for the vulnerable population 
was achieved through the combined contributions of the product provision 
campaign and voucher subsidy while broad coverage for the rest of the 
community resulted largely from nets purchased on the open market at full price 
(Magesa et al. 2005). Viewed in this integrated manner, these data provide clear 
evidence that commercial markets, voucher subsidies and free net distribution 
are not mutually exclusive choices and can complement each other effectively to 
make the most of limited subsidy. 
 
 
 
Table 2. Sources of nets used the previous night in Rufiji District during 2006 household survey 
by age group. 
Bed net source Infants Young children Older children Adults Overall 
n 422 598 1102 1848 3970 
      
Proportion use (% (95% CI)) 
Voucher 
41.5  
(36.9, 46.2) 
10.0  
(7.9, 12.7) 
4.0  
(3.0, 5.3) 
14.9  
(13.3, 16.6) 
14.0  
(12.9, 15.1) 
Free-Vaccine 
27.0 
 (23.0, 31.5) 
50.0  
(45.8, 53.8) 
37.3  
(34.5, 40.2) 
15.8  
(14.2, 17.5) 
28.1  
(26.7, 29.5) 
Free-Other 
5.9  
(4.0, 8.6) 
12.7  
(10.3, 15.6) 
19.2  
(16.9, 21.6) 
8.9  
(7.7, 10.3) 
12.0  
(11.0, 13.1) 
Commercial 
market 
24.0  
(20.1, 28.2) 
26.3 
 (22.9, 29.9) 
37.9 
 (35.1, 40.8) 
60.2  
(58.0, 62.4) 
45.1  
(43.5, 46.6) 
Unknown source 
1.7  
(0.8, 3.4) 
1.2  
(0.6, 2.4) 
1.6  
(1.0, 2.6) 
0.2  
(0.1, 0.5) 
0.9 
(0.6, 1.2) 
 
Free-other means all nets that a user obtained it as a gift from a relative or a friend 
Unknown source means all nets that the respondent could not identify its source 
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Figure 2 shows the number of nets in use during the 2006 survey by source and 
time of acquisition.  The distribution of nets at no cost to the recipients through 
the vaccination campaign in the third quarter of 2005 caused a clear surge in net 
acquisition. It is interesting to note that a concomitant surge was observed for 
nets obtained through sundry other sources, suggesting significant redistribution 
within families and communities. Over 16% of all nets reported for this period 
were obtained through this mechanism. It therefore seems likely that under-five 
children who already had a net and received another through free distribution 
from the campaign may have passed on the existing or additional net. This 
suggests that every additional net supplied contributes to both personal and 
communal protection in the population as a whole, regardless of any leakage or 
exchange.  While the number of nets procured on the unsubsidized market or 
through the voucher for pregnant women declined shortly after the free 
distribution in mid-2005, within a year these market-based sources of nets 
appear to have rebounded to levels equal to or in excess of their levels before 
the campaign. Provision of nets at no cost through the public sector did not 
compromise the viability of either the voucher scheme or the commercial market, 
presumably because this limited full subsidy was targeted toward a previously 
unsubsidized population group and was not of sufficient volume to compete with 
established demand for nets in the entire population. Such hybrid approaches 
represent an excellent mix of strategies for catching up and keeping up coverage 
when subsidies are not adequate for mass distribution to entire populations 
(Grabowsky M 2007; Lengeler et al. 2007).  This suggests that a number of 
options are available to NMCPs and that diverse tactics can be astutely 
combined to achieve the RBM, MDG and PMI targets rapidly and sustainably, 
even with only partial subsidies.  
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Figure 2. Reported sources and time of acquisition of nets used in Rufiji District 
at the time of the 2006 household survey. Note that the voucher programme was 
launched in late 2004 and the free distribution occurred at the start of the third 
quarter in 2005.  The household survey did not capture complete data for the 
second quarter of 2006 because this is when the household surveys began.  
 
 
Table 3 demonstrates that contributions of various delivery mechanisms to net 
use vary by socio-economic status (Pearson X2 (d.f. =20) = 844.8122; P<0.001). 
Net coverage was far higher for the least poor with more than four fifths of this 
better off quintile using a net. Over half obtained their net from commercial 
market at full price. The concentration index of inequality was the highest for nets 
obtained from this almost completely unsubsidized distribution mechanism (Table 
3) and the concentration curve for these nets lies below the line of perfect equity 
(Figure 3). This confirms favouritism of the unsubsidized market towards those 
who are better off and can readily pay for nets. Nevertheless, unsubsidized 
commercially sold nets were the most important for net coverage achieved by all 
other socio-economic groups except for the poorest where this source was 
matched but not exceeded by those obtained for free from the child vaccination 
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campaign. Indeed, the contribution of the unsubsidized commercially-obtained 
nets towards net coverage achieved by the poor exceeded that of nets obtained 
with assistance of the voucher subsidy, demonstrating that even the poorest 
invested in nets for non-target groups when no subsidy was available (Table 2). 
Table 3: Sources of nets used the previous night in Rufiji District during 2006 household survey 
by socioeconomic status 
Bed net 
source Most poor Very poor Poor Less poor Least poor 
Concentration 
Index 
N 
(6323 
overall)a 985 1249 1398 1357 1334  
Proportion use (% (95% CI)) 
No net 
66.8  
(63.8, 69.7) 
42.5  
(39.8, 45.3) 
36.6  
(34.1, 39.2) 
30.1 
 (27.8, 32.6) 
19.0 
 (17.0, 21.2) 
-0.214 
 (-0.335,  -0.093) 
Voucher 
5.8  
(4.5, 7.4) 
8.3  
(6.9, 10.0) 
9.4  
(8.0, 11.0) 
10.6  
(9.1, 12.4) 
8.9  
(7.4, 10.5) 
0.067 
 (-0.027,  0.161) 
Free-Vaccine 
11.2  
(9.3, 13.3) 
19.6  
(17.5, 21.9) 
20.7 
(18.7, 23.0) 
20.2  
(18.1, 22.4) 
14.4  
(12.6, 16.4) 
0.015 
 (-0.129,  0.159) 
Free-Other 
6.2 
(4.8, 7.9) 
8.6 
(7.1, 10.3) 
8.1  
(6.8, 9.6) 
7.1  
(5.9, 8.6) 
7.1  
(5.8, 8.6) 
-0.005  
(-0.074,  0.064) 
Commercial 
market 
9.8  
(8.0, 11.8) 
20.4  
(18.3, 22.7) 
24.1  
(21.9, 26.4) 
31.6  
(29.2, 34.1) 
50.3 
 (47.6, 53.0) 
0.254  
(0.119,  0.389) 
Unknown 
source 
0.3 
 (0.1, 0.9) 
0.6  
(0.3, 1.2) 
1.1  
(0.6, 1.8) 
0.3 
(0.1, 0.8) 
0.4  
(0.2, 0.9) 
-0.045  
(-0.295,  0.205) 
Any sourceb 
33.3  
(30.3, 36.1) 
57.5  
(54.7, 60.2) 
63.4  
(60.8, 65.9) 
69.9  
(67.3, 72.1) 
81.1 
 (78.8, 83.0) 
0.127  
(0.021, 0.234) 
 
a Do not add up to 6338 (see tables 1) because data on households’ assets and housing characteristics were collected in 
forms that were separate from those used for other variables. These two sets of forms were merged using household 
registration numbers that were supposed to be identical for forms that were related. Some of these related forms were 
erroneously filled with different numbers that could not be rectified and therefore the study participants had to be 
dropped for this analysis as they could not be assigned their rightful economic status. 
b Proportion of nets obtained from all shown net sources 
 
 
Conventional interpretation of concentration indices, comparing coverage of the 
poorest with that of the least poor, might suggest that all forms of subsidized 
delivery (voucher and free product provision) are completely equitable (Table 3). 
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Similarly, uncritical interpretation of Figure 3 might confirm this observation with 
all these forms of subsidized delivery approximating the line of perfect equity. 
Closer examination of Table 3, however, indicates that the least poor may not be 
a representative group with which to compare the poorest because this group 
appears to underutilize subsidized delivery mechanisms and relies more heavily 
upon the open market, presumably for reasons of choice and convenience. 
Comparing the poorest with the three intermediate wealth quintiles shows that 
the former do suffer substantial inequities relative to the latter, regardless of what 
system is used to deliver subsidized nets. While coverage of the three 
intermediate wealth quintiles is relatively even, coverage of the poorest is 
consistently and substantially lower for both voucher-subsidized and freely 
distributed nets. Nevertheless, population-wide net coverage for the most poor 
approaches the levels at which community level protection may be achieved 
(Killeen et al. 2007b) when the reported long lasting net treatment 
technologies(Yates et al. 2005) will make all the nets insecticidal. It also should 
be noted that the poorest are typically intermingled with neighbours from better 
socioeconomic strata and, therefore, share the communal protection delivered by 
the coverage of these groups which is typically twice as high. 
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Figure 3: Degree of inequality for net distribution strategies for different wealth status. The concentration 
curve below the line of perfect equity indicates that net use obtained from that source is concentrated 
among higher socio-economic groups. The concentration curve above the line of equity indicates that net 
use obtained from that source is concentrated among the poor. When the curve lies along the line of perfect 
equity, then there is no wealth related inequity for that distribution strategy. 
 
 
Discussion and conclusions 
This study has reported how commercial markets, free product distribution 
through mass campaign and voucher subsidy can work together to achieve high 
rapid and sustainable ITN coverage in a poor rural African community exposed to 
intense and perennial malaria transmission. Some recent publications have 
advocated that ITN coverage targets can only be achieved through mass 
distribution at no cost to the end user (Magesa 1991; Magesa et al. 2005; 
Schellenberg et al. 2001b).  While these arguments are based largely on opinion, 
this study provides empirical data showing that direct product distribution through 
mass campaigns can accelerate attainment of coverage in target groups if 
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astutely integrated with market based approaches which similarly target subsides 
to the neediest. Vouchers and free products both clearly succeeded in targeting 
their respective subsidies to different biologically vulnerable population groups 
they were intended to support (Table 2) with insecticide treatment rates being 
highest in the vulnerable groups (Table 1). Not only did both approaches bias 
coverage of nets and insecticide treatment to the young (Table 2), in combination 
they enabled a largely unsubsidized private sector to flourish, resulting in high 
coverage of the non-vulnerable majority of the population. This latter point is 
crucially important for achieving community-wide suppression of transmission 
(Hawley et al. 2003; Killeen et al. 2007b; WHO 2007) and represents a step 
forward relative to recent studies in Kenya and Ghana which focused exclusively 
on coverage of infants and young children (Grabowsky M 2007; Noor et al. 2007).  
When data for infants and young children are pooled, use of any net for under-
fives observed in this study is higher 1020/1216 (83.9%) than that reported from 
Kenya (80.3%) (Noor et al. 2007) and in Ghana (72.6%) (Grabowsky M 2007). 
Use of recently treated nets shown amongst under-fives appears to be lower in 
this study (43.4%; 528/1216) than that achieved in Kenya 67.3% and Ghana 
59.6%. Nevertheless, it is suggested that the issue of net treatment rates will 
become less challenging as NMCPs increasingly prioritize the exclusive 
promotion of long-lasting insecticidal nets and treatments (WHO 2007).  
 
Importantly, largely unsubsidized nets were available to everyone able and willing 
to pay for them through the commercial market which was actively promoted 
through the voucher scheme (Magesa et al. 2005).  Indeed,  the majority of all 
nets used in our study area were obtained at full market price reflecting the 
contribution of the community itself to the cost of high population-wide coverage 
under current circumstances in which global public subsidies for malaria control 
amount to only 20% of the true full cost (Kiszewski et al. 2007).   Although use of 
unsubsidized nets was greater amongst the least poor (Table 3), recently voiced 
concerns about the potential inequities associated with market-based delivery of 
subsidies (Noor et al. 2007; Teklehaimanot et al. 2007) appear to apply just as 
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much to free product delivery, with approximately equivalent inequity resulting 
from both voucher discounts and fully subsidized distribution of nets through 
vaccination campaigns.  
 
Our study has shown that overall net use in Rufiji district was far higher than 
most other parts of Africa. This data provides further definitive evidence that net 
delivery strategies other than fully subsidized mass distribution to entire 
populations can achieve net coverage high enough to provide community level 
benefits. Achieving high ITN coverage for non-pregnant adults and older children 
is just as important as comprehensive personal protection of vulnerable groups 
for three reasons. First, they are the majority in the population and more 
attractive to mosquitoes [36-38] so reasonably high but not necessarily 
comprehensive net coverage is essential to deliver the mass effect of ITNs 
(Hawley et al. 2003; Killeen et al. 2007b; Maxwell et al. 2002).  Second, they are 
the only source of labour for economic productivity required to support  the 
population as a whole and dependent children in particular, so the impacts of 
malaria illness and associated costs trickle down to every one (Sachs and 
Malaney 2002).  Third, many people living with HIV may be biologically 
vulnerable to severe malaria in a manner similarly to small children and pregnant 
women (Bates et al. 2004; French et al. 2001). Here it is demonstrated that high 
net coverage for adults and older children has been achieved in our study area, 
largely through purchase of unsubsidized nets at market prices. This study 
supports the view that high and broad ITN coverage including older children and 
adults is important for effective malaria control (Hawley et al. 2003; Killeen et al. 
2007b; Maxwell et al. 2002) but show here that market-based cost-sharing 
strategies utilizing voucher-targeted subsidies can also help achieve this goal 
(Teklehaimanot et al. 2007).  However, unlike previous reports from other parts of 
Tanzania (Killeen et al. 2007a), this is evidence that such targets can be 
achieved very rapidly by augmenting voucher-stimulated “keep-up” mechanisms 
with complementary “catch up” campaigns directly distributing products at no cost 
to the end user. 
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One limitation of this study is that our survey did not distinguish between 
pregnant and non-pregnant adult females so coverage in this key target group 
could not be directly assessed. Nevertheless, high net usage by infants, largely 
supported by the voucher scheme, presents an informative proxy for net use by 
pregnant women because mothers of newborns tend to share sleeping sites with 
their offspring in this area. All in all, Tanzania may be a uniquely informative site 
for a study of this kind.  It was the site of initial experimental hut trials and ITN 
efficacy studies (Magesa et al. 1991)  and it is where such innovations as do-it-
yourself treatment and social marketing were pioneered (Schellenberg et al. 
1999).  Moreover, the combination of both a socialist past and more recent 
reforms to enable a market-based economy may have elevated many of the 
national and local policy makers above the ideological considerations that have 
too often characterized discussions about how to deliver ITNs. The open market 
and subsidized voucher programme were relatively mature at the time the free 
distribution was undertaken in Rufiji District and this may not be a unique 
situation. Market-based delivery systems for ITNs are operational in many 
countries and present a valid option for attaining high coverage without 
comprehensive subsidies. As donor support for mass distribution of free nets 
become more widely available, and it is sincerely hoped that this will be viewed 
as potentially complementary rather than disruptive to market-based distribution 
and promoted as a means for rapidly expanding coverage, particularly amongst 
vulnerable groups. Unlike the development and implementation of the voucher 
programme (Magesa et al. 2005),  the decision to undertake a mass distribution 
in Rufiji District was not achieved by broad national consensus and was more 
opportunistic in its origins. Instead, the mix of strategies employed in Rufiji 
District represents the pragmatic efforts of local and national health officials to 
sensibly deploy scarce resources offered by partners with competing ideologies. 
In that sense, it is expected that Tanzania and Rufiji District will not remain an 
historic exception.  If, decades after the life-saving value of this intervention has 
been firmly established (Lengeler 2004), ITN advocates, no matter their stripe, 
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can agree that broad community coverage is a priority, then there is promise that 
diverse approaches can be simultaneously applied in an imperfect but 
constructive and complementary manner.  It is time to step away from the 
ideological debates about how to deliver ITNs and engage constructively with the 
local and national authorities to confronting this challenge through whatever 
means are practical. 
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Abstract 
Background: Artemisinine-based combinations have been associated with 
reduced malaria transmission in areas with low to moderate transmission. To 
investigate whether this effect is also measurable in highly endemic areas, we 
performed a longitudinal study based on repeated cross-sectional surveys in 
two communities of Tanzania, one where ACT was deployed (Rufiji) and one 
where standard treatment with conventional monotherapy was maintained 
(Kilombero/Ulanga).   
Methods: Community-based cross-sectional surveys were performed 
regularly from 2001-2006 in two highly endemic areas under continuous 
demographic surveillance system. Households were randomly selected and a 
finger prick blood sample was taken from every available person for 
parasitological assessment by blood slide microscopy and from every child 
less than 5 years for parasitaemia and haemoglobin measurement. A 
questionnaire was also administered to these households for documenting 
households’ characteristics, asset ownership and individual net use. The 
combination of sulfadoxine/pyrimethamine (SP)+artesunate(AS) was 
deployed in 2003 in Rufiji concurrently with the national roll out of insecticide 
treated nets (ITNs). ITNs had been introduced earlier in Kilombero/Ulanga 
where SP treatment continued to be used throughout the study period. 
Findings: In 2001, parasite prevalence was 26% in the general population of 
Rufiji versus 18% in Kilombero/Ulanga. Following the deployment of ACT, 
there was a sharp decline of malaria prevalence from 29% in 2002 to 19% in 
2004 in Rufiji. Then the level decreased to 15% in 2006. The respective 
estimates for Kilombero/Ulanga were 22% in 2002, 25% in 2004, 11% in 2005 
and 14% in 2006. The anaemia prevalence (Hb<8g/dl) measured from 2004 
to 2006 showed a drop from 23% in 2004 to 16% in 2005 and 2006 in Rufiji. 
Respective values for Kilombero/Ulanga were 12%, 18% and 10%. Use of 
any nets increased from 18% in 2001 to 63% in 2006 in Rufiji and from 69% 
to 86% in Kilombero/Ulanga 
Conclusion: The findings show that malaria transmission and prevalence of 
anaemia were generally decreasing overtime in both study sites, although 
there were fluctuations that may be the result of moving from stable to 
unstable malaria transmission. The sharp decline observed in Rufiji one year 
after deployment for ACT suggests that the introduction of the new 
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combination may have contributed to the decrease in malaria transmission. 
However, a well conducted ITN program reached similar effects in 
Kilombero/Ulanga without introduction of an ACT. While it was not possible to 
distinguish a direct contribution of one intervention over the other- or from 
climatic trends- our findings support current efforts to scale up effective case 
management and vector control interventions in highly endemic communities. 
 
Background 
Malaria is still one of the biggest public health concerns in Africa and its 
control has become an issue of international urgency. As a result of this 
increasing global interest, health and development resources invested for 
malaria have been sharply increased. However, community-based information 
highlighting evidence of progress arising from this investment is still limited.  
 
Between 2003 and 2006, the Interdisciplinary Monitoring Project for Anti-
malarial Combination Therapy in Tanzania (IMPACT-Tz)1 implemented 
sulfadoxine-pyrimethamine (SP) + artesunate (AS) combination treatment at 
all health facilities in Rufiji District as the routine treatment for uncomplicated 
malaria. This separately formulated combination was a precursor to co-
formulated products such as artemether + lumefantrine (Arlu) combination 
whose implementation is currently under way nationwide in Tanzania.  At that 
time, official first line treatment for malaria in other parts of the country was 
SP mono-therapy. IMPACT’s primary objective was to evaluate the potential 
of SP+AS combination in reducing emergence and spread of malaria parasite 
resistance and transmission of malaria (Kachur et al. 2004; Njau et al. 2006) . 
The project conducted annual cross-sectional household surveys over this 
period to assess several endpoints in Rufiji, as an intervention district, and 
Kilombero and Ulanga Districts (Kilombero valley), as comparators. The 
collection of blood samples to screen for parasitaemia and to measure 
                                                 
1
 The Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania 
(IMPACT-Tz) is a collaborative implementation research platform resting on: Ifakara Health 
Institute, U.S. Centers for Disease Control and Prevention, London School of Hygiene and 
Tropical Medicine, and the Ministry of Health and Social Welfare including its National Malaria 
Control Programme, the Tanzania Essential Health Interventions Project and the Council 
Health Management Teams of Kilombero, Rufiji, and Ulanga Districts.  Financial support for 
IMPACT-Tz comes primarily from CDC, the U.S. Agency for International Development and 
Wellcome Trust. 
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hemoglobin concentration in children less than five years provided an 
opportunity to look at trends and patterns of malaria indicators by age and 
socio-economic status over this period between these two study sites.  
 
Approaches & Methods 
Study area and population 
Data were collected in villages lying along the flood plains of the Rufiji and 
Kilombero rivers in southern Tanzania whose detailed description is available 
elsewhere (Kachur et al. 2004; Njau et al. 2006; Schellenberg et al. 1999). In 
this paper, we have used Rufiji District to refer to the area of study located in 
the Valley of Rufiji River and Kilombero valley for villages lying in the Valley of 
Kilombero River which are spread in Kilombero and Ulanga Districts. The last 
census conducted in 2002 shows that these three districts have a total 
population of 706,892. The inhabitants belong to several ethnic groups but the 
biggest are Ndengereko, Matumbi, Nyagatwa, Ngindo, Pogoro, Ndamba and 
Hehe. More than four fifths of the population is either Muslims or Christians. 
Major economic activities in the area are small holder farming, fishing and 
carpentry. The main crops grown are rice, maize, cassava, fruits and 
plantains. Most local houses have mud walls and thatched roofs. The health 
services in the area is composed of network of hospitals, health centres and 
dispensaries operated by the government of Tanzania and religious non-
governmental organizations.  
 
Malaria is still a major health problem recorded at the health facilities. Its 
transmission is intense and stable. All health facilities in all areas of the study 
currently manage malaria episodes based on the national malaria treatment 
policy that require the use of Arlu as the first line treatment for uncomplicated 
malaria. As we stated at the beginning, at the time of our surveys malaria 
patients attending the health facilities in Rufiji were treated with SP+AS 
combination while those from Kilombero received SP monotherapy consistent 
with the nation-wide policy at the time. As a policy, all pregnant women 
attending ante-natal clinics during their second and third trimesters were 
required to be administered SP as Intermittent Preventive Treatment (IPT). It 
was and is still applied in both study sites much as it is the policy for the rest 
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of the country. Kilombero Valley was the site where a social marketing 
program of treated nets and net treatment for malaria control was 
implemented and evaluated in the late 1990s (Schellenberg et al. 1999). This 
and other ITN delivery strategies that were subsequently implemented as part 
of the national plans for taking ITN to scale (Khatib et al. 2008; Skarbinski et 
al. 2007; Smithson 2009) were able to increase net use in Kilombero to more 
than 80% for under-fives by 2006 (Table 1). Concentrated efforts to roll out 
ITN to vulnerable groups in Rufiji started in 2005 with the introduction of 
pregnant women vouchers that enabled pregnant women to buy nets and 
insecticide sachets at a substantially subsidized price for their protection and 
their newly born babies (Hanson et al. 2008). That initiative was 
complemented by free distribution of ITN to under-fives during the measles 
vaccine campaign introduced the same year. By 2006 net use for under-fives 
in Rufiji had also been pushed up to more than 80% (Table 1).  
 
We have shown data on rainfall in the study sites in figure 1. It is indicated 
that Kilombero/Ulanga experienced average higher rainfall for all years than 
Rufiji. However, it reached its highest point in 2002 and the lowest 
measurement in 2003. The highest rainfall reading to be recorded in Rufiji 
was in 2004 and the smallest one was measured in 2003. In the months 
between June and September, the period that our surveys were conducted, 
average rainfall was generally very low compared to the rest of the year. The 
situation between the study sites during this season was quite the same.  
However, the first two surveys were conducted during times periods that were 
wetter than the last three.  
 
Study design and procedures 
Households were randomly selected from demographic surveillance 
databases of the two study sites. Repeated cross-sectional household 
surveys were conducted over 5 years (2001 – 2006).  Separate samples from 
the same population were selected for each of the survey years. All surveys 
were conducted immediately after the long rainy season in the study areas, 
between June and September where malaria is reported to be at its peak. A 
questionnaire was administered to the head of the households that provided 
information on household asset ownership and their characteristics. A 
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composite index of socioeconomic status was generated using this 
questionnaire as outlined below and in (Kachur et al. 2004). Study participants 
were visited at home and they signed written consent on their own. For 
children less than 12 years it was obtained from their parents or guardians. A 
finger prick blood sample was taken from every member of the household 
available on the day of the visit. Haemoglobin concentration for under-five 
children was measured on site by trained field workers using HemoCue 
system (HemoCue, Angelholm, Sweden). A child was classified anaemic if 
his/her hemoglobin concentration (hb) was <8g/dl as this is the level that has 
been associated with mortality (Stoltzfus 1997) and is consistent with earlier 
study in Tanzania (Skarbinski et al. 2007; Smithson 2009) and is 
recommended as an indicator of effective malaria control (MERG 2003). 
Blood slides were being sent to reference laboratory where the smears were 
stained with Giemsa and read using standard procedures by trained 
microscopists.  Only P. falciparum asexual stage infections were considered 
positive for the analysis of parasitaemia prevalence as they were found to 
consist of more than 98% of malaria parasite infections in the study area. 
Parasites were shown whether present and their densities were quantified by 
counting number of asexual forms per number of leucocytes. Five per cent of 
slides read by each microscopist were read again by senior laboratory 
technician for ensuring the reliability of results and it was found out that the 
disagreement was consistently less than 14%.  
 
Ethical approval 
We obtained ethical approval for the study from the institutional review boards 
of Ifakara Health Research and Development Centre (IHRDC), now Ifakara 
Health Institute (IHI), the US Centres for Disease Control and Prevention 
(CDC), and from the National Tanzanian Medical Research Co-ordinating 
Committee.  
 
Data analysis 
Data were entered using Microsoft FoxPro software (Redmond, WA). We then 
transferred them into STATA version 10 software (Stata Corp., college station, 
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TX) for merging, cleaning and performing analyses. An index of socio-
economic status was generated using Principal Component Analysis for 
household characteristics and asset ownership as described in detail 
elsewhere (Kachur et al. 2004). Statistical comparisons between outcome of 
interest and the assumed explanatory variables were made using Chi-square 
test. All statistical tests presented are based on the STATA.svy commands to 
control for clustering of findings at the household level. 
 
Results  
Table 1 shows the frequency distribution of study participants for all survey 
years in both study sites by age group, net use pattern and health facility use 
for febrile illnesses. Age group distribution was similar for all survey years for 
both Rufiji and Kilombero/Ulanga. Adults constituted the majority of the 
sample for each year and site. Children aged 1-5 years comprised 
approximately 20% of the sampled persons.  
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Table1: Characteristics of study population in both Rufiji and 
Kilombero/Ulanga study sites 
 
Rufiji      
 2001 2002 2004 2005 2006 
      
Households, n 1036 996 1380 1724 1739 
Infants (< 1y), n(%) 46 (1.2%) 91 (2.5%) 124 (2.5%) 148 (2.3%) 237 (3.7%) 
Young children (1-5 y), n(%) 285 (7.4%) 532 (14.7%) 808 (16.2%) 1107 (16.9%) 993 (15.5%) 
School age children (5-15 y), n(%) 602 (15.6%) 1099 (30.3%) 1581 (31.7%) 2026 (31%) 2044 (31.9%) 
Adults (>15 y), n(%) 2938 (75.9%) 1902 (52.5%) 2477 (49.6%) 3252 (49.8%) 3252 (48.8%) 
      
No net use 1563 (82.5%) 2974 (82.3%) 3985 (79.9%) 4035 (61.8%) 2387 (37.3%) 
use of untreated net* 278 (14.7%) 545 (15.1%) 506 (10.1%) 1068 (16.4%) 2090 (32.7%) 
use of treated net* 53 (2.8%) 96 (2.7%) 499 (10%) 1428 (21.9%) 1923 (30.1%) 
use of any net* 331 (17.5%) 641 (17.8%) 1005 (20.1%) 2496 (38.9%) 4013 (62.8%) 
use of medicine from health facility for recent fever/malaria** 680 (28.7%) 375 (34.9%) 456 (45.2%) 857 (41%) 691 (30%) 
      
Kilombero/Ulanga      
Households, n 1155 1380 1483 1626 1774 
Infants (<1 y), n(%) 51 (0.5%) 118 (2.5%) 185 (3.6%) 261 (4.4%) 203 (3.2%) 
Young children (1-5 y), n(%) 240 (2.6%) 742 (15.7%) 778 (15.1%) 944 (16%) 960(15.2%) 
School age children (5-15 y), n(%) 555 (5.9%) 1378 (29.2%) 1626 (31.5%) 1838(31.1%) 1989 (31.5%) 
Adults (>15 y), n(%) 8564 (91%) 2486 (52.7%) 2574 (49.9%) 2860(48.5%) 3172 (50.2%) 
      
No net use 579 (31.2%) 1420 (30.1%) 1213 (23.5%) 1112 (18.9%) 903 (14.3%) 
use of untreated net* 1095 (59%) 2809 (59.5%) 2587 (50.2%) 2751 (46.7%) 3165 (50.1%) 
use of treated net* 181 (9.8%) 491 (10.4%) 1357 (26.3%) 2034 (34.5%) 2253 (35.6%) 
use of any net* 1276 (68.8%) 3300 (69.9%) 3944 (76.5%) 4785 (81.2%) 5418 (85.7%) 
use of medicine from health facility for recent fever/malaria** 553 (26%) 657 (33.3%) 507 (28.2%) 560 (35%) 545 (34.5%) 
* During the previous night 
** The demonstrated denominator is all people who were interviewed 
  
 - 102 - 
Table 1 also summarizes the contextual factors that could influence trend for 
malaria parasitaemia and anaemia in the implementation and comparison sites. 
Kilombero/Ulanga participants reported higher use of any net than did Rufiji 
participants during each survey period. Bed net use in Rufiji increased from 18% 
in 2001 to 63% in 2006 (insecticide-treated use rose from 3% to 30%). 
Respective estimates for Kilombero/Ulanga were from 69% to 86% (ITNs 
from10% to 36%). The increase over the entire period was therefore more 
striking for Rufiji which was able to bridge the difference with Kilombero/Ulanga in 
the last survey year. The data suggest that about a third of the population slept 
under insecticide treated nets in 2006 in both Rufiji and Kilombero/Ulanga. 
Getting medicines for fever or malaria from formal health facilities was low but 
equal in both sites during the first two years. Not more than a third of the 
respondents reported obtaining health facility treatments for their recent febrile 
illnesses. In 2004, after the introduction of SP+AS in Rufiji, health facility use 
increased significantly. Almost half of the respondents reported utilizing health 
facilities when getting sick with malaria. The rate remained flat in 2005 and 
declined to 30% in 2006. In Kilombero/Ulanga the trend dipped in 2004, then 
moved up in 2005 and leveled out during the last survey period.  
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Figure 1: Rainfall pattern between Rufiji and Kilombero/Ulanga during the study period. 
 
 
Figure 2 compares annual trends for malaria parasite prevalence between the 
two study sites for all survey years and highlights the interrelated dynamics. In 
the first two surveys (2001-2002) Rufiji was characterized by higher parasitaemia 
than Kilombero/Ulanga. A quarter of the Rufiji population was infected with 
malaria parasites compared to a fifth of that in Kilombero/Ulanga. However, a 
sharp decline was observed in Rufiji from 2004 onwards. Compared to 2002, 
parasite prevalence in Rufiji dropped by about 46% in 2006. In contrast, in 
Kilombero/Ulanga, malaria prevalence only declined in 2005 where it reached its 
lowest point, with a 56% decrease when compared to 2004. Prevalence were 
almost equivalent (15 and 14%) in both districts in 2006. 
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Figure 2: Trend in malaria parasitaemia in Rufiji and Kilombero/Ulanga (Ifakara) and their respective ITN coverage 
 from 2001 to 2006, as established by repeated cross-sectional household surveys  
 
 
Table 2 presents the distribution of parasitaemia prevalence by age groups and 
socio-economic status. Parasite prevalence is shown to be significantly higher for 
young and school aged children than infants and adults in both Rufiji and 
Kilombero/Ulanga. According to results shown in table 2, infants and adults had 
equal rates of parasitaemia in Kilombero/Ulanga but in Rufiji the former had more 
than double of the parasitaemia prevalence of the latter (p<0.001). This study 
confirms that poverty increases vulnerability to malaria as parasite prevalence 
was much more common among the poorest group compared to the least poor in 
both study sites. In both sites malaria parasitaemia prevalence among the 
poorest was almost twice as that among the least poor.  
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Table 2: Parasite and anaemia prevalence between Rufiji and Kilombero/Ulanga by age and asset index 
                                                                                 Rufiji Kilombero/Ulanga 
Parasitaemia by age Proportion %(95% CI) Proportion %(95% CI) 
Infants (<I year) 116/512 22.81(19.4-26.66) 77/665 11.53(9.3-14.2) 
Young childre (1-5 years) 1076/3007 35.9(34.2-37.6) 835/3124 26.6(25.08-28.2) 
School age children (5-15 years) 1736/5754 30.2(29.1-31.4) 1736/5982 28.9(27.74-30.0) 
Adults (>15 years) 1117/10000 10.7(10.1-11.3) 1947/16000 11.9(11.37-12.4) 
Parasitaemia by asset index      
Most poor 458/2127 21.6(19.9-23.4) 536/2620 20.4(18.85-21.9) 
second poor 476/2599 18.3(16.9-19.8) 464/2752 16.8(15.5-18.2) 
third poor 501/2856 19(17.6-20.5) 501/2856 17.5(16.1-18.9) 
fourth poor 520/2943 17.7(16.4-19.1) 451/3002 15(13.7-16.3) 
Least poor 357/2864 12.5(11.3-13.8) 345/3051 11.3(10.2-12.4) 
Anemia by age      
Infants 97/364 26.7(22.4-31.4) 80/490 16.4(13.3-19.9) 
Young children  353/2091 16.9(15.4-18.6) 269/2115 12.7(11.4-14.2) 
Anaemia by asset index      
Most poor 83/343 24.2(20.0-29.0) 86/448 19.2(15.8-23.1) 
Second poor 90/477 18.9(15.7-22.7) 71/539 13.2(10.6-16.3) 
third poor 117/569 20.6(17.5-24.1) 68/549 12.4(9.9-15.4) 
fourth poor 106/578 18.4(15.4-21.7) 60/545 11(8.7-14.0) 
Least poor 54/480 11.3(8.8-14.5) 62/516 12.1(9.5-15.2) 
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Figure 3 similarly shows trends for anaemia for children younger than five 
years in the study sites for 2004-2006. In 2004, anaemia prevalence in Rufiji 
was twice that of Kilombero/Ulanga (23% vs 12%). It dropped steeply in 2005 
and remained the same in 2006 (16%). In Kilombero/Ulanga the prevalence 
increased considerably from 2004 to 2005 (12% to 18%) and dropped to its 
lowest level in 2006 (10%), significantly lower than in Rufiji. When anaemia 
was compared between infants and young children as shown in table 2 the 
former were more anaemic than the latter in Rufiji. Little more than one 
quarter of infants were anaemic compared to a sixth of young children. The 
difference was statistically significant (p=0.027).  In the Kilombero Valley on 
the other hand, anaemia prevalence was not much different between both 
categories of children. In terms of socio-economic status as measured by 
household wealth index demonstrated in table 2, anaemia prevalence 
observed in Rufiji was highest for children from poorest households and 
lowest for the least poor. Almost a quarter of poorest children were anaemic in 
Rufiji but less than one sixth of the least poor qualified for that status 
(p<0.057). In Kilombero/Ulanga there was no statistically significant difference 
in anaemia prevalence between different socio-economic categories but again 
the poorest had the highest level of anaemia when compared to the other 
groups.  
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Figure 3: Trend in anaemia prevalence in Rufiji and Kilombero/Ulanga  from  
2004 to 2006, as established by repeated cross-sectional population based surveys 
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Discussion 
Our findings demonstrate that malaria parasitaemia prevalence in the 
community dropped significantly over a period of five years both in Rufiji 
District and Kilombero Valley in the South Eastern Tanzania. The decline 
presents evidence of progress towards achieving targets defined by 
international health initiatives (Anonymous; MillenniumProject 2005; 
RollBackMalariaPartnership 2005). It brightens hope for those involved in 
implementing malaria control interventions in Africa. Our findings have 
included coverage achieved for health facility utilization in malaria treatment 
and use of bed nets. ACT implementation in Rufiji district from 2003 increased 
health facility utilization for malaria from 17% in 2001 to 45% in 2004. The 
trend slightly declined thereafter. Anti-malarial treatment combining SP+AS 
was theoretically expected to reduce both asexual parasitaemia and also 
partly  gametocytaemia (Bloland et al. 2000).  
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Hence increasing use of medicines containing artemisinin derivatives for 
febrile episodes may have played an important role in the sharp decline in 
malaria parasitaemia prevalence observed in Rufiji District especially between 
2002 and 2004 when coverage of ITNs remained low. Indeed, we report 
elsewhere the high levels of health facility workers’ and patients’ adherence 
with recommended usage requirements with SP+AS combination (JI Thwing 
et al. 2009; Kachur et al. 2004). Also, during the same period parasitaemia 
prevalence actually increased in the adjacent Districts Kilombero/Ulanga 
where SP alone continued to be used as first line treatment for uncomplicated 
malaria. The potential beneficial effect of ACT on malaria transmission in 
Rufiji cannot be readily separated from the possible impact of increased use 
of insecticide-impregnated bed nets (from 3 to 10%) during the period 2001-
2004. However, this slight increase in bednet use is unlikely to be the major 
contributor to the 46% decrease of parasitaemia observed during this period.  
 
The lower overall parasitaemia prevalence in Kilombero/Ulanga is likely to be 
due to the long-term impact of the social marketing program for insecticide 
treated nets that had been ongoing since 1997 (MillenniumProject 2005). This 
intervention and later schemes of voucher subsidies for insecticidal nets 
carried out in the area led to a much higher overall coverage in 
Kilombero/Ulanga than in Rufiji. The initial increasing trend in parasitaemia 
prevalence from 2001 to 2004 in Kilombero/Ulanga in spite of increasing use 
of bed nets illustrates possible fluctuations of malaria transmission to be 
expected in the transition from stable to unstable malaria. ITN has long been 
demonstrated to substantially reduce exposure to malaria transmission. 
Based on this evidence it is widely recommended as life saving intervention 
for reaching global public health goals and the overall lower malaria 
parasitaemia in the community reported for Kilombero/Ulanga in this study 
can partly be a result of this achievement. The increased use of every status 
of nets in Rufiji in the final years of our surveys may be similarly responsible 
for the additional fall of parasitaemia in this site shown for this period. Overall 
trend of decreasing malaria burden in sub-Saharan Africa in recent years is 
not unique to our study.  Similar trends have been reported for overall 
Tanzania (Smithson 2009)  and particularly for the Ifakara town area, where 
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the infection rate for infants fell from 9.1% in 1996 to 3.5% in 2001, and 
similarly dropped from 17% in 1996 for older children to 8.5% in 
2001(Schellenberg et al. 2004a). An even more dramatic fall of malaria 
parasitaemia and malaria related mortality was also observed in Zanzibar 
(Bhattarai et al. 2007). At the African level, WHO reported a 64% decline of 
malaria cases and 66% decrease of mortality among small children between 
2005 and 2007 in Rwanda (Chambers et al. 2008). In Ethiopia malaria related 
deaths went down by 51% and cases fell by 60% over the same period 
(Chambers et al. 2008).  It is reasonable to assume that this progress could 
be achieved thanks to wide availability and integrated use of the common 
malaria control interventions; particularly the promotion of ITNs and the early 
diagnosis and treatment with ACTs.  
 
The fact that the level of anaemia also declined supports earlier studies 
associating anaemia in children in malaria endemic areas with malaria 
parasitaemia (Bhattarai et al. 2007; Bloland et al. 2000; Schellenberg et al. 
2004a; Thwing et al. 2009). It suggets the validity of anaemia as a measure of 
malaria burden in Africa and/or of impact of malaria control interventions. The 
study has shown that children in Rufiji were generally more anaemic than in 
Kilombero/Ulanga (table 1), which corresponds to the overall higher 
parastaemia rates. The difference was statistically significant only in 2004 and 
2006 probably as the decline in anaemia prevalence that was achieved in 
Rufiji in 2005 compared to 2004 was maintained well up to 2006. In contrast, 
the anaemia prevalence worsened in Kilombero/Ulanga in 2005 compared to 
2004 and then improved to 2004 levels when it reached 2006. The reason for 
a higher prevalence of anaemia in Kilombero/Ulanga in 2005 when compared 
to 2004, in spite of a sharp decrease of parasitaemia is not fully understood 
as we could not investigate possible other interrelated causes in the area.  
 
The malaria burden observed in our study matches the well-know pattern of 
high endemic areas with prevalence highest among young and school aged 
children reflecting the development of semi-immunity  (Perlmann and Troye-
Blomberg 2002) and a short protection after birth owing to the transfer of 
maternal antibodies (Hviid and Staalsoe 2004).  
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Variation in parasite prevalence between the most poor and the least poor in 
our study reflects similar variation in the use of malaria control interventions 
between different socio-economic categories. Many studies seeking to 
evaluate the effectiveness of delivery strategies for these interventions in sub-
Saharan Africa have shown that coverage is influenced by socio-economic 
status (Bloland 1999a; Hviid and Staalsoe 2004; Njau et al. 2006; Skarbinski 
et al. 2007). The least poor tend to benefit most from these malaria control 
tools vis-à-vis the most poor.  So, the benefits of malaria control interventions 
are not equally shared between different socio-economic categories.  
 
This study has shown that infants were more anaemic than older children. 
Similar observations have been reported elsewhere (Breman et al. 2001; 
Kitua et al. 1997; Menendez et al. 1997; Schellenberg et al. 2004a)  and 
reflect  pattern of anaemia prevalence in areas of intense malaria 
transmission where higher parasite density prevail in infants compared to 
older children (Bloland 1999a; Kitua et al. 1997). In addition, infants tend to be 
more anaemic owing to maternal iron deficiency and anaemia that can lead to 
impaired fetal development and iron deficient and anaemic babies (Sweet et 
al 2001; Singla et al 1996; Singla et al 1997; Jaime-Prez et al 2000). Our 
surveys were conducted during the main farming season in the study areas. 
As an overwhelming majority of adults including lactating mothers spend the 
whole day on their fields often far from the villages, it is possible that most 
infants are also not sufficiently breastfed during this time. Finally, we could not 
investigate to what extent the dynamics of the HIV epidemic might also have 
contributed to the anaemia pattern, maybe would have affected it differently in 
the two sites. 
 
Our study was conducted during the peak of malaria transmission in the study 
area. Hence, the levels of parasite infections and anaemia are probably the 
highest during the year in the study area. The fact the last survey year was 
least parasitaemic and anaemic in both study sites gives hopes for malaria 
control and elimination efforts in Africa.  It may demonstrate evidence that this 
progress was not based on a single intervention. It shows the effect of an 
integrated use of curative, early diagnosis and treatment with ACTs, and 
preventive, the promotion of ITNs, approaches. Besides achieving the 
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effectiveness of integrated control approaches, these data also indicate that 
more needs to be done with regards to equity effectiveness. There is still a 
higher malaria burden among the poorest segments in the study populations.  
Adding active mass treatment strategies to the existing measures in place 
may help address the problem through increasing access for all population 
groups (Menendez et al. 1997).  
 
Finally the study highlights the burden of malaria profile at community level in 
rural districts in Tanzania (Breman et al. 2001) and underlines the importance 
of combining the routine data collection with community-based data to design  
public health strategies that, certainly for the case of malaria, need to be of 
integrated nature  when one aims at achieving the elimination of malaria as 
public health burden or, eventually, elimination of malaria from certain areas 
at all.  
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Abstract 
 
Background: Appropriate use of antimalarial drugs within 24 hours on the 
onset of illness has for a long time been an important component of malaria 
control. Implementation of home management is seen as integral for 
achieving this goal in Africa where access to health services is limited. 
Concerns for inappropriate treatment associated with this strategy prompted a 
call for its reconsideration when the continent moved towards artemisinin 
based combination therapy. This factor and other important challenges 
encouraged provision of combined sulfadoxine-pyrimethamine (SP) + 
artesunate (AS) only in health facilities at the time when the Interdisciplinary 
Monitoring Project of Anti-malaria Combination Therapy (IMPACT) 
implemented and evaluated the drugs in rural Tanzania. This approach of 
implementation created an environment to evaluate changes in health facility 
utilization for malaria treatment in our study. 
 
 Methods: Population-based cross-sectional surveys were performed 
annually from 2001-2006 in Rufiji and Kilombero/Ulanga demographic 
surveillance system sites. In Rufiji, official malaria treatment was available in 
health facilities only and in Kilombero/Ulanga the medicine had broader 
unrestricted access also through private providers. Households were 
randomly selected and their members were interviewed about recent febrile 
episodes, sources of treatment, medicine use and socio-economic 
characteristics 
 
Findings: Treatment seeking for people reporting recent febrile episodes was 
31% and 35% in 2001 and 2002 respectively in Rufiji site before the 
implementation of combination treatment in health facilities. The use 
increased to 45% in 2004, one year after the implementation of combination 
treatment in health facilities only. It declined slightly to 41% in 2005 and 
dropped further to 30% in 2006. In the Kilombero/Ulanga site, 27% and 33% 
of febrile respondents obtained their treatment from the health facilities in 
2001 and 2002 respectively. The trend declined to 29 % in 2004, picking up to 
36% in 2005 and levelled out at 35% in 2006.  In relation to age, under-fives 
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had been consistently more likely than other age categories to get treatment 
from health facilities in both study sites. In addition, the least poor had higher 
facility use by at least 50% than the poorest in both study areas. 
 
Conclusion: Implementation of combination treatment in health facilities 
increased treatment seeking from this source of care in Rufiji District. 
However, as the years extended, the difference between prior and after 
implementation periods were not significant. This scenario raises concerns 
that limiting ACT to health facilities will not achieve the level of treatment 
access that is enough for better public health outcome. 
 
 
Introduction 
Prompt recognition and appropriate treatment with effective drugs is a key 
component of any malaria control strategy. The Roll Back Malaria Initiative 
(RBM) has set a target of achieving 80% treatment of malaria patients with 
effective medicines within twenty four hours of the onset of illness in sub-
Saharan Africa. Home-based management of malaria has been identified as 
an important strategy for achieving this target (Pagnoni et al. 2005; Were 
2004). It involves the use of drugs available at community level without 
prescription. The strategy to provide malaria treatment early and at the 
periphery, eg households, is conceptually simple but is associated with a 
series of problems in a real health system setting such as inapropriate advise 
and poor compliance with dose regimens for drugs requiring more than one 
single dose (Bloland et al. 2003a). There is also the risk of over-dispensing of 
antimalarials, as often all fevers are treated without differential diagnosis and 
the quality of antimalarials on the market is poor or doubtful in many areas 
(D'Alessandro et al. 2005; Marsh et al. 1999a). These problems not only 
prevent effective treatment of those suffering but also - alone or in 
combination – contribute to the development of drug resistance owing to the 
highly prevalent levels of sub-therapeutic drug levels in the population. This is 
of particular relevance in the light of reports of lower sensitivity to ACTs in SE-
Asia (Hyde 2005; Wongsrichanalai and Meshnick 2008) . Consequently, any 
national policy must take these factors into account for all health service 
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providers and must also aim at gaining the involvement of the informal sector 
(Were 2004).  
 
It is within this context that the Interdisciplinary Monitoring Project for Anti-
malarial Combination Therapy, Tanzania (IMPACT-Tz) piloted in Rufiji District 
in southern Tanzania the co-administration of SP+AS for the treatment of 
uncomplicated malaria  (Bloland et al. 2000). This treatment was made 
available only in the health facilities to avoid the potential complexities 
associated with the informal drug outlets. Here we report trend in health 
facility utilization for malaria treatment after the introduction of ACT in rural 
Tanzania. 
 
METHODS 
Study area and population 
This study was conducted as part of the Interdisciplinary Monitoring Project 
for Antimalarial Combination Therapy in southern Tanzania (IMPACT-Tz)∗. 
The study area took place in two Demographic Surveillance System (DSS) 
sites. One site is located in Rufiji District, Coast Region, covering 31 villages 
with 73,839 people and another one is in Kilombero and Ulanga Districts, 
Morogoro Region comprising 25 villages with 66,503 people. Common ethnic 
groups in Rufiji are Ndengereko, Matumbi, Pogoro and Makonde. Dominant 
tribes in Kilombero and Ulanga are Ndamba, Pogoro, Hehe and Bena. Swahili, 
the national language in Tanzania, is lingua franca in these multi-tribal 
communities. The main religions in the area are Islam and Christianity. Major 
economic activities are subsistence farming, artesnal fishing, animal 
husbandry, carpentry, charcoal making and small-scale informal trading. Main 
crops grown are rice, maize, cassava, plantains, cashews and fruits. Short 
rains are normally between October and December and the long rains span 
between February and May. A detailed description of the study areas is found 
elsewhere (de Savigny et al. 2004; Schellenberg et al. 1999)  
 
Malaria is the leading public health problem in the area. The infection is 
commonly caused by Plasmodium falciparum. Transmission is intense and 
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perennial with some seasonal fluctuation. It is most frequent between April 
and September (Smithson 2009; Tanner et al. 1991). The health care system 
in these districts is based on a network of hospitals, health centres, 
dispensaries, pharmacies and drug stores both government, private not for 
profit and private for profit. Getting medicines for febrile episodes from general 
retail outlets is also common like other places in the country. A cost sharing 
scheme is already in place in public health facilities in Kilombero and Ulanga 
Districts while its implementation has not yet started in Rufiji. In August 2001 
malaria treatment policy shifted from Chloroquine to salfudoxine-
pyremethamine (SP) which continued to December 2006. However, IMPACT 
introduced combination treatment with SP and Artesunate (AS) for treatment 
of uncomplicated malaria in Rufiji District in 2003. The combination was made 
available only in hospitals, health centres and dispensaries. Since January 
2007 the new, national first malaria treatment policy has changed to 
combination of Artesunate and Lumefantrine (Arlu) (2007)  
 
Study design and data collection 
This paper is based on five household surveys that were conducted between 
May and September in 2001, 2002, 2004, 2005 and 2006. Between 1300 and 
2000 households were selected at random from the DSS databases for each 
survey. Each member who was available and willing on the day of the 
interview from every selected household was asked questions on whether 
they were sick with fever or malaria two weeks prior to the interview, whether 
they sought treatment from any source and what medicines they obtained 
from every source of medicines they visited. Questionnaires for young 
children were administered to their caretakers. There were also questions 
addressing household characteristics and asset ownership that were directed 
to heads of households.   
 
Interviewers were recruited from people who were familiar with study 
communities. More individuals had been invited for the training than those 
who were finally selected for the assignment. The questionnaires were 
prepared in English and translated to Swahili and back translated. The 
interviewers were rigorously acquainted with these questionnaires and pre-
tested them among themselves and in the field. All questionnaires were 
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administered in Kiswahili. Each selected household was visited not more than 
three times in case some of its members had not been available during the 
first and second visits. The interviewers were given consent forms to read 
them to the study participants and only when these participants were satisfied 
and had agreed to take part then the interview could start. The interviewers 
submitted the completed forms each week to one of the study investigators 
who undertook a standardized quality control for completeness, consistency 
and coherence. Problems that interviewers could not clarify were solved 
through an additional field visit in the following days. In addition, the principal 
investigator randomly selected a sample of 5 forms from each 30 forms that 
were returned during the week’s rounds and took them back to the field to 
verify whether the households had actually been visited and interviewed.  
 
Data management and analysis 
All completed forms were brought to the central data processing unit. Data 
were double entered using Microsoft (Redmond, WA) FoxPro® software. Data 
managers developed automated routines to identify discrepancies and 
executed some simple consistency and range checks and these were 
resolved with reference to original data forms. The study investigators moved 
all data into Stata Version 8 software using Stata Transfer (Stata Corp., 
College station, TX). Data were cleaned again, all modules linked and finally 
analysed in the same Stata version. Analyses have been corrected for 
clustering both between individuals in the same household and within study 
sites and weighted to adjust for population sampling fractions. 
 
Results 
Table 1 shows that there was no statistically significant difference in health 
facility use for malaria treatment at baseline years, 2001 and 2002, between 
Rufiji and Kilombero/Ulanga DSS sites. In 2004, one year after the 
introduction of ACT in all health facilities in Rufiji District and SP monotherapy 
remained the same in Kilombero/Ulanga; health facility visits for febrile 
episodes were higher at 45.2% in Rufiji compared to Kilombero/Ulanga where 
the visits were 28.5%. The difference was statistically significant different (X2 
= 28.94; p<0.005). In 2005, the visits between the two study sites were still 
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statistically different between the two DSS sites. More people obtained their 
treatment from health facilities in Rufiji than in Kilombero/Ulanga (X=3.91, 
p=0.048). There was no difference that was observed between the two sites in 
2006.  
 
Table 1:  Health facility use for malaria treatment by district and survey years 
Rufiji  Kilombero/Ulanga  
  n % 95% CI   n % 95% CI p  
2001 341 30.5 25.6:35.4  268 26.9 21.6:32.2 0.33  
2002 375 34.9 30.1:39.8  657 33.3 29.7:36.9 0.6  
2004 456 45.2 40.6:49.7  509 28.5 24.6:32.4 <0.005  
2005 859 41 37.7:44.3  573 35.8 31.9:39.7 0.048  
2006 691 30 26.5:33.4  545 34.5 30.5:38.5 0.089  
 
 
 
In a next step, 2002 was taken as the baseline and subsequent health facility 
visits for fever and/or malaria were compared in the two study sites between 
2004, 2005 and 2006 (table 2). As table 2 reveals, there was an increase of 
53% for febrile episodes that were treated with drugs from the health facilities 
in Rufiji DSS site in 2004 compared to a survey that was conducted one year 
before the implementation of ACT in the site (95%CI: 1.16; 2.03). The 
increase slowed to 29% in 2005 (95%CI: 1.01; 1.66). The upward trend 
reverted to nil in 2006.  
 
Table 2:  Change in health facility use before and after implementing ACT in health facilities in Rufiji 
using 2002 as baseline 
Rufiji   Kilombero/Ulanga 
  OR 95% CI p   OR 95% CI p 
2002 comparison 
2004 1.53 1.16:2.03 0.003  0.8 0.62:1.02 0.08 
2005 1.29 1.01:166 0.05  1.11 0.88:1.41 0.37 
2006 0.8 0.61:10 0.1  1.05 0.83:1.34 0.67 
 
 
Table 3 suggests that under-five children used health facility for medicines 
meant for febrile episodes more frequently than school aged children or adults 
from both study sites. From Rufiji DSS site, under-fives were more likely by 
40% than school aged children to get medicines from health facilities (95%CI: 
0.48; 0.75). They were more likely by 62% than adults to get medicines from 
health facilities (95%CI: 0.4:0.57). The pattern was the same for 
Kilombero/Ulanga. Under-fives were similarly more likely than both school 
aged children and adults to get treatment from health facilities. The odds were 
higher against adults by 73% than by school aged children at 68%.  
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Table 3: Association between health facility use and age groups for malaria treatment in the study sites 
using under-fives as baseline 
Rufiji   Kilombero/Ulanga 
  OR 95% CI p   OR 95% CI p 
under fives comparison 
4-15 years 0.6 0.48:0.75 <0.005  0.42 0.34:0.53 <0.005 
over15 0.48 0.4:0.57 <0.005  0.37 0.30:0.44 <0.005 
 
 
Table 4 demonstrated that socio-economic status is an important factor in the 
choice of health facilities for fever treatment in both sites. Febrile study 
participants from the least poor socio-economic category were 50% more 
likely than the poorest to get treatment from health facilities from Rufiji (95%CI: 
1.11; 2.03). From Kilombero/Ulanga DSS site, this relatively better off group 
was more likely by 99% than the poorest to use medicines from health 
facilities (95%CI: 1.43; 2.77). Gender was a risk for health facility utilization 
only in Rufiji where males were more likely by 55% than females to get 
medicines from the health facilities. However, this was not observed in the 
Kilombero/Ulanga area.  
 
 
Table 4: Association between health facility use and socio-economic status in the study sites using most poor as baseline 
Rufiji Kilombero/Ulanga  
  OR 95% CI p   OR 95% CI p  
most poor comparison  
more poor 0.7 0.51:0.96 0.025  1.11 0.77:1.6 0.588  
poor 1 0.74:1.35 0.998  1.26 0.88:1.79 0.211  
Least poor 1.33 0.987:1.79 0.061  1.23 0.88:1.72 0.232  
Least poor 1.5 1.11:2.03 0.008  1.99 1.43:2.77 <0.005  
 
 
 
 
 
Discussion 
Health facility use for malaria investigated in this study is based on individuals 
who reported febrile episodes in the previous fourteen days. This is the 
standard procedure for identifying fever prevalence at household level (Njau 
et al. 2006) . Fever is an important component of clinical diagnosis of malaria 
but is confounded by the large body of non-malaria fevers which is also 
prevalent. For this study, we did not apply additional methods to distinguish 
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malaria-related fevers at health facility level from fevers due to other illnesses. 
Hence, health facility use for malaria observed in this study may have been 
overstated.  Despite this potential limitation, the study is helpful for next steps 
of the introduction of ACTs.  
 
Our study did not reveal any difference in the frequency of visits to health 
facilities for treatment of fever and/or malaria between the two DSS sites 
during survey years before the implementation of SP+AS combination in Rufiji 
district in 2003. The pattern changed significantly in 2004 and 2005. Rufiji 
experienced more health facility visits than Kilombero/Ulanga during the 
period. This difference can be associated with the introduction of the ACTs as 
it was the only relevant intervention that distinguished the two sites.  It is also 
true that health facility use showed important improvement in Rufiji during the 
implementation period compared to pre-implementation phase. Again, this 
development was not observed in Ifakara.  These differences in treatment 
seeking between the two sites suggest that availability of effective anti-
malarial medicines in only health facilities can strengthen dependence on 
formal sources for malaria treatment. This is a desirable outcome as it is true 
that health facility delivery of therapeutic intervention against malaria is more 
conducive to optimal use. Some studies have demonstrated that  parasite 
resistance to ACT was not seen in South East Asia because it has been 
administered under professional supervision in the formal health sector 
(Bloland et al. 2000). There were concerns that this benefit could not be 
replicated in Africa because of widespread use of drugs at community level 
(Ajayi et al. 2008). Many countries in Africa had already adopted SP as the 
first line malaria treatment. Unlike SP which was a single oral dose, ACT, 
particularly artemether-lumefantrine, entails six doses over three days. Hence, 
home management of malaria with insufficient information could be a potential 
risk for incomplete treatment. ACT is more expensive than SP, so tight 
household budgets could prevent purchasing the full course in case of getting 
the medicines from the informal sector. All these are potential risks associated 
with treatment available from sources other than health facilities which in turn 
can undermine ACT effectiveness in Africa. And these are some of the 
arguments raised in favour of adopting ACT as a prescription only medicine.   
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The highest health facility use for all survey years was observed in Rufiji in 
2004, even so we could discovered  that only 45% of febrile patients obtained 
their medicines from the health facilities. Consequently, more than half of the 
patients still obtained their treatment from informal sources. Hence, the 
availability of ACT at health facility level did not prevent / reduce the use of 
other sources of treatment. We have also observed that, health facility use in 
Rufiji sharply increased at the beginning but decreased as the years went on. 
These trends must be followed and studied carefully in order to understand 
the underlying reasons, particularly to what extent  ACTs “lost their role” as 
incentive to seek treatment at health facility level owing to the broad offer of 
ACTs and/or artemisinin monotherapies in the private and informal sector. 
The careful study of the factors that govern access and use in different health 
systems settings are of crucial importance for the broad introduction and 
promotion of ACTs in other endemic areas (Greenwood 2008).  
 
The experience from the present study suggests that informal sources have 
and will have a role in implementing ACT in Africa. In addition, more efforts 
need to be made to define the diagnostic strategy for the different endemic 
areas in order to assure the appropriate use of the ACTs at the different levels 
of care (D'Acremont et al. 2009; Whitty et al. 2008). While  in an areas of high 
malaria endemnicity, malaria treatment is based on a clinical diagnosis 
(Pagnoni et al. 2005) and is encouraged by the adoption of Integrated 
Management of Childhood Illnesses strategies, the diagnostic strategies for 
areas of lower endemicity and areas where successful control leads to a 
decline of malaria need to be adapted to prevent mis- and overuse of precious 
drugs potentially resulting in early drug resistance (D'Acremont et al. 2009; 
Reyburn et al. 2004)   Finally, the re-thinking of the diagnosis and treatment 
strategies should also take into account that studies showed that specificity of 
diagnosis of malaria in children performed at home by their caretakers is 
comparable with that at the health facilities (D'Acremont et al. 2009; Dunyo et 
al. 2000; Whitty et al. 2008).   
 
The fact that health facility use for malaria treatment was significantly more 
common by under-fives than for other age groups is consistent with the 
situation of a highly endemic area (Bloland et al. 2000). Since young children 
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are more likely to seek treatment increased health facility use therefore 
favoured under-fives much more than other ages in the population. 
Consequently, efforts to develop ACT formulations that are appropriate and 
acceptable for young children are of crucial importance for any introduction of 
ACTs. Recently, progress was made by the development of infant and 
children formulations for artemether-lumefantrine (Abdulla et al. 2008). 
 
Our findings may also have implications for policy discussion intent on 
addressing the issue of equity for ACT access through health facilities.  The 
study has demonstrated that the least poor were more likely than the poorest 
to obtain their malaria treatment from the health facilities from both study sites. 
It should be noted that ACT implemented in health facilities in Rufiji district 
was provided to patients for free consistent with the operating government 
policy in the area. Hence, the user fee problems which have long been shown 
to be important barrier to access to malaria treatment for the poor had been 
resolved. Hence, there are still additional challenges to health facility 
utilization in malaria treatment for the poor other than direct financial 
payments and availability of effective medicines. Some studies have shown 
that people from wealthier households have higher chances to seek 
appropriate malaria treatment when getting sick compared to the poorest 
families because better off individuals appear more informed and/or 
knowledgeable of danger signs of the disease and their access to a health 
facility is more likely to be shorter (Schellenberg et al. 2003).  Our study did 
not explore population knowledge of danger signs of the disease in question, 
but could establish that wealthier families lived in areas with easier physical 
access to health care facilities. Understanding these factors helps us to 
become more cost- and equity-effective in introducing ACTs in Africa.   
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CHAPTER 7: Discussion and conclusions 
This section synthetically discusses the major findings presented in different 
chapters of this thesis. It also highlights the methodological issues of the 
different studies/approaches pursued. Finally it aims at defining the further 
research needed in the area of artemisinin based combination therapy (ACT) 
as well as the evidence established and the lessons learnt that could be 
directly translated into public health action.   
 
Methodological issues 
The studies presented in this thesis are based on data collected from a series 
of repeated annual cross sectional surveys at household and health facility 
level; conducted by the Interdisciplinary Monitoring Project for Anti-malaria 
Combination Therapy (IMPACT) in Tanzania between 2001 and 2006. The 
samples for the surveys were selected from the databases of Household 
Registration Books (HRB) compiled and updated four months a year by the 
demographic surveillance systems (DSS) of Rufiji and Kilombero/Ulanga 
(Mwageni E 2002; Schellenberg 2001). The choice of study sites was linked 
to the availability of DSS infrastructures and did not have to rely on the civil 
registration system that still lacks completeness in Tanzania. Thanks to the 
availability of HRBs, it was not necessary for the project to conduct a full 
census in the study site. Selected households had DSS numbers that guided 
our interviewers to their locations. Households’ members had been listed 
according to their respective households, their dates of birth, sex and 
education together with their members’ numbers called permanent 
identification numbers (permanent ID). The permanent IDs were crucial for 
merging individual information collected in separate data collection tools. It 
was easy for our study to use dates of births to determine individual’s age, 
something that could be very difficult to figure out in communities that lack 
useful birth registration. This basic approach firmly grounded on the DSS 
ensured high quality and completeness of the data collected. Problems arising 
such as missing households or for those that were no longer occupied, wrong 
sex or odd dates of birth could usually be resolved with the DSS teams. This 
was further facilitated by the fact that the DSS sites started to equip their field 
interviewers with tablet PCs based on experiences from southern Tanzania 
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(Shirima et al. 2007).  Data collection for this study was conducted using the 
same tools in all survey years; hence the questions remained the same in all 
surveys. This feature, and the fact that we sampled our study subjects from 
the same population, further strengthened the quality and validity of the data. 
The field interviewers remained largely the same during the entire study 
period and this also reduced the possibility of between-observer biases.  
Having the same team in the field doing interviews to largely the same people 
for so many years in the community that had been overstudied might, of 
course, expose our study to a high risk of unresponsiveness and “data 
cooking”. However, the implementation of several public health interventions 
in these communities played a very important role in reducing these concerns 
(de Savigny et al. 2004; Schellenberg et al. 2004b; Schellenberg 2001). Our 
research centre’s policy of recruiting the interviewers and intervention 
implementers from these communities has also created a perception that that 
these studies are important for their livelihood. As part of our responsibility as 
researchers to the community and as a component of our formal  ethical 
responsibility for our study we also used to ask every study participant found, 
who was ill, to seek treatment from the facility of their choice with full 
expenses paid by the project. There was also a concern that interviewers’ 
over familiarity might encourage “cooking of data”. We introduced a control for 
this justified concern of repeat follow-up visits to a random sample of 
households that had been interviewed. This was a routine practice in our 
study every week on the basis of the forms returned by the interviewers. 
Concluding the methodological considerations, we feel that the data collected 
is of a very high quality, i.e. does not entail major systematic errors/biases 
that might seriously affect the evidence generated and our conclusions drawn.  
 
Malaria parasitaemia before and after the introduction of ACT 
ACT for malaria is highly efficacious and is the current policy for first-line 
treatment in Africa (Hallett et al. 2004; NMCP 2006; Omari et al. 2004; PMI 
2007; White 2004). This development is the only strategy to overcome the 
ever-growing and intensifying parasite resistance to drugs that had once been 
efficacious, affordable, and acceptable and had long been used in most 
malaria endemic settings. ACTs had already had a great impact when 
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adopted for large-scale use in South-East Asia where treatment failure 
against falciparum malaria had previously been alarming (Bloland et al. 2000). 
The issue that dominated policy discussion for sub-Saharan Africa following 
intolerable parasite resistance to chloroquine and sulfadoxine-pyrimethamine 
was whether the success from South-East Asia could be replicated in Africa; 
i.e. the transmission dynamics in Asia and Africa are different – Africa having 
large areas of intense perennial transmission – and also with marked 
differences in the public health approaches to malaria and in the health 
system's characteristics (Bloland et al. 2000). 
 
In highly endemic areas of Africa, the older children and adults who constitute 
the majority of the population at any time are less likely to fall sick when 
infected with malaria (White and Pongtavornpinyo 2003). Infants, young 
children and pregnant mothers form the population groups at highest risk. 
This age-pattern of malaria is reflected in the health seeking behaviour 
reported in our study (chapter 6). This observation raises concerns for malaria 
control initiatives that shift from control to elimination (AfricanUnion 2007; 
Feachem and Sabot 2008). It means that small children fall sick quickly when 
they are infected and the severity of symptoms encourage their caretakers to 
seek treatment for them, mostly from health facilities (chapter 6). Hence it is 
critical for the health care facilities to sustain continuous availability of ACTs in 
order to make sure that the lives of these young children are saved. But 
because these children are similarly vulnerable to common illnesses other 
than malaria, but with overlapping symptoms, it is important that the treatment 
is guided by parasitological examination.  This is especially important during 
the period of lower parasitaemia when fevers may not be due to malaria and 
malaria fevers are non-specific (D'Acremont et al. 2009; Rafael et al. 2006). It 
is why the current discussions on the introduction of rapid diagnostic tests at 
peripheral health facility levels in many areas of Africa are a welcome 
development for improved treatment outcome for these children, and 
especially when malaria control debates are moving towards elimination 
(AfricanUnion 2007; D'Acremont et al. 2009; English et al. 2009; Feachem 
and Sabot 2008; Greenwood 2008; Rafael et al. 2006). However, innovative 
approaches need to be developed to ensure that the existing effective drugs 
have an impact on the parasitaemia carried by adults in those endemic 
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settings. This is despite it being increasingly likely that as malaria loses further 
ground, many more adults will lose their existing semi-immunity to malaria 
and thus, their risk of disease will be no different than that of small children.  
 
The strategy and efficiency of early diagnosis followed by treatment has 
important implications on the rational use of ACTs, and the prevention of the 
development of resistance, besides the economic considerations (Bloland et 
al. 2000; Bloland et al. 2003c). In addition, poor access to health care facilities 
and/or the poor quality of services offered encourages care seeking practices 
outside the formal health care system (McCombie 1996a). In addition, it has 
invariably been reported that informal drug outlets in sub-Saharan Africa form 
an important risk for poor drug use and the consequent emergence and 
spread of parasite resistance (Bloland et al. 2000).   On the basis of these 
facts IMPACT was designed and implemented in Tanzania. The project was 
actually one of the first two large scale ACT effectiveness evaluations in Africa 
(chapter 3). It responded to arguments raised in the discussions that 
preceded final decisions to recommend ACT as a malaria treatment in Africa 
(Bloland et al. 2000). The evidence generated and experience obtained from 
IMPACT can certainly contribute to the effective use of ACTs in many other 
parts of Africa. The data shows a substantial decline of malaria parasitaemia 
in the community after the introduction of ACTs as a routine first line treatment 
in the health facilities (chapter 3). The decline also observed in the 
comparison site where patients continued to be treated with the failing SP 
treatment, appears, however, clearly linked to the high and widespread ITN 
coverage as expected from the experience on ITN effectiveness in the 
specific comparison area and other places in Africa (Lengeler 2004).  Use of 
insecticide treated nets in Ifakara had consistently been higher, throughout 
the study years, than Rufiji (chapter 5). Our study highlights that were it not for 
the use of ACT for malaria treatment parasite prevalence would always have 
been higher in Rufiji than in Kilombero/Ulanga. This fact is supported by 
another study conducted in Zanzibar and KwaZulu-Natal, South Africa, where 
multiple implementations of several malaria control interventions, including 
treatment of malaria patients with ACTs, achieved substantial achievements 
in the area of malaria control (Barnes et al. 2005; Bhattarai et al. 2007).   
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Moreover, benefits arising from parasitaemic patients' use of ACTs have been 
demonstrated to extend beyond the direct users (Garner and Graves 2005). 
Artemisinins and thus also ACTs have been shown to be gametocytocidal. 
Hence, gametocyte free individuals are an impediment to the spread of 
malaria parasites in the population. Consequently, it is reasonable to assume 
that the introduction of ACTs has - besides reducing parasitaemia - also had 
an impact on transmission. However, our findings should not conclude that 
these developments from our study and their impact on malaria are unique, as 
significant progress has been reported in other several places in Tanzania 
and elsewhere in sub-Saharan Africa (Hommel 2008; Smithson 2009). The 
distribution of parasitaemia among the different age-groups largely 
represented the pattern of highly endemic areas. Interestingly, the pattern of 
parasitaemia and its decline was not reflected in the levels of anemia 
observed which can partly be explained by the multifactorial nature of 
anaemia in these rural African areas (Menendez et al. 2000).  
 
Treatment seeking practices for malaria episodes before and 
after the introduction of ACT  
ACT was only delivered through health facilities in this study. A 
comprehensive program ought to, in general, include home management 
strategies, an area in which much development is still required, particularly for 
the effective use of ACT (Pagnoni et al. 2005; RBMAMFm 2008). Despite this 
limitation, our program provided an opportunity to evaluate to what extent the 
availability of effective drugs in health facilities governs treatment seeking 
practices; The data shows that getting malaria treatment from health facilities 
increased significantly after the introduction of ACT (Chapter 6) and should be 
considered when one discusses a possible restriction of ACT to health 
facilities only, i.e. without home management practices that include ACT 
(D'Alessandro et al. 2005). Based on our data we cannot disentangle to what 
extent the increased use of health facilities was due to the availability and/or 
perceived effectiveness of the new drugs. In this respect it is noteworthy that 
another study in Tanzania documented the influence of sufficient drug supply 
(de Savigny et al. 2004).  Although this has played a role in our study, the 
results from the focused group discussions conducted by another team of our 
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study revealed that members of the community perceived the ACT to be 
superior in alleviating their febrile illness problems (unpublished results from 
IMPAC-Tz).  Our project provided the medicines at no cost to the patients, 
compared to charges of around USD 5 when they obtained them from 
commercial drug outlets. Assuming that a higher price reflects the superiority 
of the commodity might also have swinged the public opinion in favour of 
combination treatment and has also contributed to the increased use of health 
facilities following the introduction of ACT.   
 
Several studies have associated the majority of inappropriate use of anti-
malarial drugs in Africa to informal care providers (Bloland 2003; 
D'Alessandro et al. 2005).  Like the patients, the informal sector is not well 
informed on the correct use of the drugs. In addition there is an economic 
motive. The guiding principle of the informal sector is also maximization of the 
highest margin for every cent invested. The risks could be higher for 
separately formulated and packaged SP and Artesunate which was the ACT 
used for our study (RBMAMFm 2008). Naturally, they would also serve 
customers who would not buy both drugs (RBMAMFm 2008). While these 
factors played a role in the present study, they are now overcome with the 
particularly unique use of co-formulated ACT and the fact that most national 
control programmes are run as integrated programmes (Pagnoni et al. 2005; 
Sirima et al. 2003) that include the informal sector as an important provider of 
care (NMCP 2006; PMI 2007). 
 
Besides the distribution of the risk of infection and disease explained by the 
transmission pattern, the perceived importance and risks of spells of illness 
that also show age-differentials have also contributed to the observed health 
seeking behaviours (Bloland et al. 2000). As stated in chapter 6, illness 
perceptions and the perception of the quality of care provided are the main 
drivers of health seeking dynamics. Finally, and as also documented in other 
studies (Barat et al. 2004; de Savigny et al. 2004; Njau et al. 2006; 
Schellenberg et al. 2003; Uzochukwu et al. 2008), we have observed that 
higher health facility utilization was most beneficial to higher socio-economic 
groups. This apparent inequality might partly have been contributed to by the 
existing standards used to measure socio-economic status in epidemiological 
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studies in poor rural communities. The Principal Component analysis 
generates scores for household asset ownership which gives bigger weight to 
assets that are more common in the population centres. Health facilities are 
predominantly concentrated in these settlements which give an access 
advantage to their inhabitants. This emphasizes the importance of community 
based approaches that will expand ACT access to remote settlements and will 
therefore help to overcome inequities in access to treatment and general 
health care. Once one shift from control to elimination particular importance 
should be paid to marginal areas and populations, as inadequacy in service 
provision could leave remaining foci/pockets of transmission.  Accredited drug 
dispensing outlets (ADDOs) have shown a good potential for addressing 
some of these important issues in Tanzania, but this strategy needs additional 
evaluation and larger-scale validation when it is scaled up in the country 
(Mbwasi and Mlaki 2008; Samarasekera 2008). 
 
Malaria patients’ adherence to ACT provided at the health 
facilities 
In studying care-seeking patterns for fatal malaria in Tanzania, de Savigny et 
al (de Savigny et al. 2004) found out that treatment seeking practices for 
malaria has shifted to “modern”/Western health care. The majority of children 
who died of malaria and whose families they followed up for verbal autopsy 
had used medicines from modern health care facilities. The previous studies 
that had predominantly associated treatment seeking for malaria with cultural 
beliefs and practices that encouraged the choice of traditional treatments in 
Africa seem largely to have no more relevance in Tanzania (Hausmann-Muela 
and Ribera 2003; Makemba et al. 1996; McCombie 1996a; Minja et al. 2001; 
Mwenesi et al. 1995; Tarimo et al. 2000; Winch et al. 1997). Consequently, 
demand creation for ACTs should not be overwhelming, but we should still be 
sensitive by such concerns. The new challenge for malaria case management 
strategies is to identify issues related to health systems factors that 
encompass both patient adherence and providers’ appropriate practices. This 
challenge is more important for treatments that are more expensive and their 
dosing regimen is more complex than the previously used single treatments.  
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Thus, the real challenge is, besides knowing the efficacy of a drug established 
through randomized control trials, to learn how under specific health and 
social systems factors, a given efficacy of an intervention will be translated 
into community effectiveness, say the cure rate of a drug provided through the 
different layers of the health system (Tanner 1990; Tanner and Vlassoff 1992). 
Finally it is of primary interest to know to what extent social, ethnic and gender 
strata have equal access and are equally covered by the intervention and 
what is captured in the term “equity effectiveness of an intervention” that has 
recently  been introduced (Tanner 2005a; Tanner 2005b). It is therefore 
important to understand qualitatively and quantitatively as many elements of 
the complex pathways of health interventions in a given health and social 
systems context to identify why and where they can lose traction (Tanner 
2005a; Tugwell et al. 2006)  Provider compliance and patient adherence have 
been singled out as key determinants for effectiveness in ACT programs. 
Chapter 3 shows that patients who had been treated with the combination 
treatment and followed up at home achieved 75% complete adherence. This 
was an encouraging observation for an assessment that was carried out not 
more than three months since the treatment had been introduced. This very 
satisfactory level of patient adherence has certainly been translated into the 
decreasing levels of overall parasitaemia observed in the community (chapter 
5). When infected individuals obtained an efficacious treatment from the 
appropriate source of care and are adherent to treatment which is also 
gametocytocidal, their risk to contribute to ongoing transmission is 
substantially reduced. The decline of parasitaemia in the study area after the 
introduction of ACTs is a good indicator of the success of our programme in 
particular and sort of the proof of concept for ACT introduction in general.   
 
Scaling up the intervention, i.e. nationwide deployment remains the next 
challenge to overcome. The Tanzanian malaria control programme with 
support of the Global Fund to fight AIDS, TB and Malaria (GFATM), the World 
Bank and United States President’s Malaria Initiative (PMI) is currently on its 
way towards the sustainable use of ACTs (Na et al. 2003; NMCP 2006; PMI 
2007; Smithson 2009; Turell et al. 2002).  However, it should be noticed that 
this progress was achieved following massive investments in developing and 
deploying information, education and communication tools and training health 
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workers before and after the drugs had been brought to the forefront of health 
workers desks.  
 
Factors other than ACT that could influence malaria 
transmission 
Our study had been comparing public health outcome in the Rufiji DSS site 
where District-wide ACT deployment was introduced and the 
Kilombero/Ulanga DSS site where health care facilities continued with the 
then ongoing policy of SP use for first line treatments. As described above, 
the decrease in the Rufiji area appears mainly due to the introduction of ACT 
while the reduction of parasitaemia prevalence in Kilombero/Ulanga is clearly 
related to the very successful introduction of ITNs.   
 
It is against this background that our project investigated ITN use throughout 
the study period and a particularly good other opportunity came with the Red 
Cross distributing free insecticide treated nets to under-fives in the middle of 
our study in Rufiji District.  There was a big difference in ITN use between 
Rufiji and Kilombero/Ulanga at the beginning of the study which was no longer 
seen by the end of the study (see chapter 5). The experience from Tanzania 
on ITN promotion and use shows that it is no longer relevant to discuss which 
should be the single effective strategy (Curtis et al. 2003; Lengeler and 
desavigny 2007; Teklehaimanot et al. 2007). Best results are obtained when a 
combined strategy is based on the local realities, i.e. campaigns with long-
term promotion and social marketing with free-distribution linked to a local 
private sector committed to producing the ITNs (Curtis et al. 2003; Lengeler 
and desavigny 2007; Teklehaimanot et al. 2007). Rufiji's experience 
documents this, as the implementation of free distribution of ITNs to children 
under five within Rufiji's DSS site went in parallel with the continued presence 
of ITNs sold in the retail commercial outlets and - additionally - vouchers that 
subsidized the price for pregnant women and their infants were able to 
equitably achieve high ITN coverage that could bridge its substantial gap with 
Kilombero/Ulanga.  
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The way forward for malaria control in Tanzania and 
elsewhere 
Our study was started during the time when ACT had not yet been generally 
promoted as a malaria control policy for Africa and when co-formulated 
products were only about to be introduced. The debates at the start of 
IMPACT entailed with the primary aim to prevent early resistance to ACTs: 
Which combination therapy (non-fixed/co-blistering, [chloroquine+artesunate; 
SP+artesunate; amodiaquine+artesunate; mefloquine+artesunate) versus 
fixed co-formulation, fixed [artesunate+lumefantrine)], type of delivery 
strategies, costs, outlets and compliance etc.  
 
Our experience with the co-blistered SP and artesunate, although we have 
now moved towards co-formulated ACTs – anyhow inspired - and can still (do 
so) other countries in Africa on the strategies for wide-scale first-line use of 
ACT. The dispensing envelopes with age-appropriate dosing instructions 
written in Swahili and illustrated for illiterate patients were adopted by malaria 
control programmes in Zaire and Zanzibar when they introduced ACT and the 
current large-scale use of artesunate-lumefantrine carefully considered during 
the IMPACT experience (Leonard et al. 2003; Na et al. 2003; NMCP 2006; 
PMI 2007; Smithson 2009). Particular emphasis was placed on the 
information and communication strategies to allow smooth transitions in order 
not to repeat the problems and confusions caused when SP was first 
introduced as the first-line treatment (Leonard et al. 2003; Na et al. 2003; 
NMCP 2006; PMI 2007).  
 
The decline of malaria parasitaemia at the community level demonstrated in 
our study (chapter 5) echoes the general trend observed for the rest of the 
country (Smithson 2009). Of late there has been encouraging reports of 
malaria decline in several countries in sub-Saharan Africa (Bhattarai et al. 
2007; Nyarango et al. 2006; Okiro et al. 2007; Otten et al. 2009). Many 
important factors including secular trend may have a role for this decline. But 
it is important to note that all these countries have experienced expanded and 
sustained coverage of a package of malaria control interventions, thanks to 
availability of unprecedented funding for malaria control (Feachem and Sabot 
2008; Grabowsky 2008; Hommel 2008). This progress brings hope to debates 
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dominating malaria elimination in Africa (Feachem and Sabot 2008; 
Grabowsky 2008; Hommel 2008).  
 
 However, while acknowledging these positive developments, it is equally 
important to reflect on important challenges brought by the observed 
development related to malaria control in Tanzania. The study demonstrated 
that the majority of malaria patients who use health care facilities are small 
children (chapter 6). The majority of older children and adults are getting their 
treatment from the retail and informal sector. The malaria control program 
needs to expand the availability of ACTs to this important source of treatment. 
It is true that drugs need to be dispensed and used appropriately. There are 
concerns that the private sector can encourage continued use of single drugs 
in contrast to the official policy of ACT use (RBMAMFm 2008). The 
introduction of ADDOs in some areas of Tanzania has shown the potential to 
improve access and effective treatments so long as official regulatory 
oversight is in place (Mbwasi and Mlaki 2008; Samarasekera 2008). It is also 
encouraging that the Global Fund is to introduce Affordable Medicines Facility 
for malaria (AMFm), the strategy that will likely reduce the costs for ACTs in 
the private sector. The high price of ACTs in the private sector has often been 
blamed as a main reason why artemisinin monotherapies are still wide-spread 
in Africa (Laxminarayan and Gelband 2009).  
 
Even the highest net coverage we have observed in our study (chapter 6) is 
still below the latest declared targets.  The African Ministers of Health who 
met in Johannesburg in 2007 replaced the Abuja target with universal access 
to every malaria control intervention including ITNs (AfricanUnion 2007). They 
agreed on a 50% reduction of malaria morbidity and mortality by 2010 
(AfricanUnion 2007). It has been demonstrated that if coverage for these 
interventions reaches a reasonable level (as it has been resolved by the 
ministers), mortality could be reduced by 60% (Tanner 2005b). Since 2008 
the Tanzania National ITN program (NATNETS) coordinated by the ITN cell of 
the National Malaria Control Program with a technical support from the Swiss 
Tropical Institute has been conducting the under-fives Long Lasting 
Insecticidal Nets (LLIN) coverage campaign throughout Tanzania (Mwita 
2009). This campaign will be followed by the universal coverage campaign 
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targeting every population group. It is likely that these programs will expand 
ITN coverage to more sleeping sites and replace worn-out nets, hence 
making all untreated nets insecticidal. Similar campaigns had substantial 
impact on ITN coverage in Zanzibar and in Kenya (Bhattarai et al. 2007; 
Lengeler and desavigny 2007). A new push is needed to ensure that the nets 
are used at all times as it has been shown that in some parts of Africa they 
are only used during the cold season (Gunasekaran et al. 2009; ter Kuile et al. 
2003; Toé et al. 2009) . Anopheles mosquitoes can become infected with 
malaria parasites all year round and thus transmission is perennial (Beier et al. 
1999). The risks posed by changing the feeding habits of mosquitoes in 
response to increasing levels of ITN coverage is real and could be countered 
by programs to spray all households with IRS or larvicidal interventions at the 
potential breeding sites of mosquitoes (Killeen et al. 2006). The present 
project, as well as previous work, has emphasized that only integrated 
approaches to malaria control and elimination will have substantial effects and 
long-term success (Utzinger et al. 2002). 
 
Further key research areas 
It has been demonstrated in chapter 5 that additional decline of the 
community based malaria burden was observed in Rufiji after expanded ITN 
coverage. In Zanzibar, it was reported that the introduction of ACTs after 
extended use of ITNs accelerated the decline of malaria (Bhattarai et al. 
2007). These results from two study areas with similar levels of malaria 
endemicity can generate a hypothesis that integrated implementation of 
combined malaria interventions can have synergistic effectiveness. This 
important finding will have great significance for malaria control if different 
combinations of malaria control interventions will be compared to find out 
which one of these combinations is the best one for achieving the most 
substantial results. For example, a research study could select a study area A 
with a high coverage of ITNs and ACTs and compare it with study area B 
using IRS and ACTs and area C using a larviciding program, high ITN 
coverage and ACT and follow them up over a period of time to document 
some important outcome measures.  
 
  
 - 140 - 
As discussed earlier, the potential efficacy of drugs demonstrated in clinical 
trials is often lost when introduced in a large scale operation (Whitty et al. 
2008). This is an important concern, especially for malaria control in which a 
substantial amount of money is continuously invested in R&D of new drugs 
while far too little is invested in understanding the determinants of 
effectiveness in different health system settings. Poor access to drugs, 
especially for the poorest people in remote corners of areas with endemic 
malaria transmission, is reported to be an important factor in this problem 
(chapter 6) (Whitty et al. 2008). Drugs are often delivered through modern and 
public health care facilities, which in sub-Saharan Africa are normally 
concentrated in the demographic centres overwhelmed by people who are 
relatively well-off (chapter 6). This health care delivery strategy not only bears 
the risk of creating health inequities but also stifles the promise of the drugs. A 
comprehensive approach would entail inclusion of all providers in the strategy 
for delivery of treatments.  In Tanzania, one important response has been the 
introduction of ADDOs which have demonstrated promising results at the 
beginning (Samarasekera 2008). Yet, because ADDOs  can only be sustained 
if run by individuals with basic business skills and knowledge of rules and 
bureaucratic procedures, it is difficult to envision how they would be 
maintained in areas predominantly inhabited by illiterate poor peasants.  In 
this case, it is important to design and implement a research study that will 
evaluate different strategies of ACT delivery involving all types and levels of 
providers, particularly the public, private and NGO/charity sectors. A carefully 
defined set of such operational research will help us to better understand the 
determinants for access to and sustainability of ACTs, particularly also for the 
most disadvantaged segments of the population (Hopkins et al. 2007).  
 
Conclusion 
 The present thesis has presented the dynamics of malaria in rural Tanzania 
following the introduction of artemisinin based antimalarial combination 
therapy. The delivery of ACT through modern health facilities contributed to 
substantial decline in the malaria burden on the community. Multiple ITN 
distribution strategies were shown not only to be complementary (and not 
mutually exclusive) in the rural endemic setting of Africa but to have achieved 
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significant coverage, resulting in an accelerated decline of malaria 
transmission. The effective treatment available only at health facilities 
achieved a high level of patient adherence and increased treatment-seeking 
within the public health facilities. However, if ACTs will continue to be 
available in public health facilities only, a substantial number of malaria 
patients will not have optimal access to new and effective approaches for 
malaria control. A broader approach that includes the design of ACT 
[deployment?] strategies in all types and levels of health care providers is 
necessary to sustain the success of malaria control and possibly eventual 
elimination of malaria in Tanzania (Feachem 2009). 
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